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Preface 
This thesis describes the candidate’s full-time (three years, 2007-2009) work on the Blue 
Mountains Eye Study. The Blue Mountains Eye Study (BMES) is a population based cohort 
study of older Australians. The baseline examination (BMES 1) was conducted from 1992 to 
1994 and included baseline visual acuity, collection of comprehensive lifestyle and health 
data and a complete eye examination including retinal photography. The five year follow up 
examination (BMES 2) was conducted from 1997 to 1999 and repeated previous data 
collection with the addition of hearing assessment. The ten year follow up (BMES 3) was 
conducted from 2002 to 2004 and repeated the previous data collection with the addition of 
olfactory assessment. The fifteen-year follow (BMES 4) was conducted from 2007 to 2009 
and repeated the previous data collection. Professor Paul Mitchell (candidate’s supervisor) is 
the Principal Investigator, Professor Robert Cumming (candidate’s co-supervisor), Professor 
Stephen Leeder and Wayne Smith are the three Chief Investigators of the Study. 
 
This thesis examined the associations of olfactory, auditory and visual impairments, 
individually and combined, with morbidity and mortality by both direct and indirect 
pathways in a representative older Australian population.  
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Abstract 
Purpose: To estimate the prevalence and examine the clustering patterns of visual, auditory 
and olfactory impairments; to estimate the associations of olfactory impairment with 
neurodegenerative and other morbidities; to estimate the associations of visual and auditory 
impairments with morbidity and mortality using Cox regression; and to examine the 
associations of visual and auditory impairments with morbidity and mortality using structural 
equation modelling to identify potential indirect pathways and assess whether Cox regression 
underestimated the associations between VI, AI and mortality in a representative sample of 
older Australians. 
 
Methods: The Blue Mountains Eye Study (BMES) examined 3,654 persons aged 49+ during 
1992-1994, and after 5 and 10 years. The Blue Mountains Hearing Study (BMHS) invited 
participants who attended the second cross-sectional survey of the Blue Mountains Eye Study 
(BMES 2). Persons who moved into the study area or study age group, identified from a 
repeat door-to door census in 1999, were also invited to participate. The Blue Mountains 
Hearing Study (BMHS) examined 2956 persons aged 49+ years (75.5% response) during 
1997-2000. Vision, hearing and olfaction were assessed in BMES 3. Assessment was by 
interviewer administered structured questionnaire, clinical examination, audiometry, blood 
testing and the San Diego Odor Identification Test. A total of 1,497 (74.3% of all 
participants) had complete vision, auditory and olfactory data after BMES 3. 
 
Visual impairment (VI) was categorized as either: presenting visual impairment (PVI), VA 
less than 6/12 Snellen equivalent (<39 letters read correctly) in the better eye using current 
glasses; or correctable visual impairment (CVI), PVI less than 6/12 Snellen equivalent 
correctable to 6/12 or better after subjective refraction; or non-correctable visual impairment 
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(NCVI), PVI correctable to less than 6/12 Snellen equivalent in the better eye, after 
subjective refraction.  
 
Olfactory impairment (OI) was defined by San Diego Odour Identification Test score with 
subjects classified as having no impairment (score 6, 7 or 8), mild impairment (4 or 5), 
moderate impairment (≤3), or any impairment (<6). Auditory impairment (AI) was defined as 
the pure-tone average (0.5-4kHz) of air-conduction hearing thresholds >25 decibels hearing 
level (dBHL). Cognitive impairment was defined as mini mental state exam (MMSE) scores 
<24. 
 
Log-linear models were used to assess the concomitant presence of the three sensory 
impairments (visual, auditory and olfactory). Observed frequencies of concomitant sensory 
impairments were compared to the expected frequencies estimated assuming they occurred 
independently (no clustering tendency). Multivariable adjusted logistic regression models 
were constructed to estimate associations between olfactory impairment and morbidities, 
including neurodegenerative conditions. Associations between visual impairment and 
mortality risk, and between hearing loss and mortality risk, were estimated using Cox 
regression and structural equation modelling (SEM). Odds ratios (OR), hazard ratios (HR) 
and 95% confidence intervals (CI) are presented. A p-value of less than 0.05 was considered 
statistically significant. Australian National Death Index data confirmed deaths until 2005. 
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Results: After13 years from baseline, 1273 participants had died. After 5 years from BMES 2 
(BMHS), 403 participants had died. 
 
At BMES 3, the prevalence of PVI, CVI and NCVI was 11%, 8% and 3% respectively. The 
prevalence of any OI was 27.0% and the prevalence of AI was 43%. The observed prevalence 
of having all three sensory impairments in persons with PVI (or NCVI) was 2.6 (or 3.0) times 
greater than predicted if they clustered independently. VI, AI and OI clustered differently in 
women compared to men.  
 
Inverse associations were observed between OI and body mass index (OR per 5 kg/m2 
increase, 0.8, CI 0.7-0.9) and between moderate impairment and hypertension (OR 0.6, CI 
0.4-0.9). There was no significant relationship with angina, previous myocardial infarction or 
diabetes. Persons with Parkinson disease had an increased likelihood of both mild (OR 9.8, 
CI 2.0-47.5) and moderate OI (OR 16.1, CI 3.8-68.2), as did persons with impaired cognitive 
function (OR 3.3, CI 1.3-8.6 and OR 3.7, CI 1.5-9.6, respectively).  
 
After adjusting for mortality risk markers using Cox regression, higher mortality was 
associated with NCVI (HR 1.35, CI 1.04-1.75). This association was stronger for ages <75 
years (HR 2.58, CI 1.42-4.69). Structural equation modelling revealed greater effects of 
NCVI on mortality risk (HR 5.25, CI 1.97-14.01 for baseline ages <75), with both direct (HR 
2.16, CI 1.11-4.23) and indirect effects (HR 2.43, CI 1.17-5.03). Of the mortality risk 
markers examined, only disability in walking demonstrated a significant indirect pathway for 
the link between VI and mortality. Disability in walking acted both directly on mortality and 
via an association with self-rated health. 
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Using Cox regression, hearing loss was associated with increased risk of both cardiovascular 
(HR 1.36, CI 1.08-1.84) and all-cause mortality (HR 1.39, CI 1.11-1.79) after adjustment for 
age and sex, but not after multivariable adjustment. Structural equation modelling pathway 
analysis, however, revealed a higher all-cause mortality risk (HR 2.58, CI 1.64-4.05) in 
persons with hearing loss, which was mediated by two variables: cognitive impairment (HR 
1.45, CI 1.08-1.94) and disability in walking (HR 1.63, CI 1.24-2.15). These variables 
increased mortality both directly and indirectly through effects on self-rated health.  
 
Conclusions: In this representative population of older Australians, over one in ten persons 
had VI, over one in four persons had OI and almost one in two persons had AI. The 
prevalence of VI, AI and OI increased with increasing age. The prevalence of AI and OI was 
higher in males. The prevalence of VI was higher in females. Visual, auditory and olfactory 
impairments aggregated mutually and dependently.  
 
Visual impairment and AI were significantly associated with morbidity and mortality. Visual 
impairment predicted mortality by both direct and indirect pathways. Auditory impairment 
predicted mortality via indirect pathways. Disability in walking, which can substantially 
influence general health, represented a major indirect pathway for both VI and AI. Auditory 
impairment was also associated with increased all-cause mortality via cognitive impairment 
and self-rated health. Adjustment for these co-variables using Cox regression underestimated 
the associations between VI and AI and mortality. 
 
Olfactory impairment was inversely associated with BMI and hypertension. Olfactory 
impairment was significantly higher among persons with Parkinson disease and cognitive 
impairment. 
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It is important to recognise that persons with sensory impairments are at increased risk of 
important comorbidities and mortality. Dependent clustering of sensory impairments suggest 
the possibility of a common underlying mechanism and that separate hearing and vision 
services may not adequately support older persons.  
12 
 
Summary 
Visual, auditory and olfactory impairments were frequent in this representative older 
Australian population. The prevalence of VI (11%), AI (43%) and OI (27%) increased with 
increasing age in both sexes. The prevalence of AI and OI was higher in males. The 
prevalence of VI was higher in females.  
 
Visual, auditory and olfactory impairments aggregated mutually and dependently. Common 
mechanisms may underlie these sensory impairments. Persons with this combination of 
disabilities are at increased risk of social isolation, depression, low self-rated health and 
quality of life, functional difficulties, mobility problems, falls, fractures and mortality. 
Separate hearing and vision services may not adequately support older persons with multiple 
impairments. 
 
Our data support a role for olfactory function in maintaining nutritional status and body 
weight and provide additional support to the link between impaired olfaction and 
neurodegenerative disorders. 
 
These data reaffirm reports that visual impairment is associated with increased risk of all-
cause mortality and suggest the association may be greater than previously reported with 
traditional regression modelling. Disability in walking was an indirect pathway to mortality 
for persons with visual impairment. 
 
This study supports the contention that hearing loss is associated with an increased risk of 
mortality through the mediating variables disability in walking and SRH and identifies 
cognitive impairment as another potential mediating variable.  
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Chapter One: Literature Review of the Prevalence and 
Associations of Visual, Auditory and Olfactory Impairment 
with Morbidity and Mortality in Older Persons 
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Visual, auditory and olfactory impairments are prevalent disabilities that are reportedly 
significantly and negatively associated with morbidity and mortality. The following review 
summarises representative examples from the literature that report the prevalence of visual, 
auditory and olfactory impairments and their associations with morbidity and mortality. The 
results of studies that report associations with morbidities examined in this thesis are included 
as background. This permits comparison of the results reported in this thesis with the 
literature current at the time of writing.  
 
One of the difficulties in objectively scrutinizing these studies is that each differs in 
population demographics, particularly in age range and mean population. Each study also 
differs by the specific covariates used for adjustment in the multivariate models, and many 
differ in the definition of baseline visual impairment, by the methods of olfactory and 
auditory assessment. Some studies lacked objective measures of sensory function, using self 
and by proxy reporting of sensory impairments. 
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1.1 Visual Impairment 
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Prevalence 
The visual impairment prevalence data presented in this review are derived from studies 
representative of the findings in the literature and that are similar in design and timing of data 
collection, when compared to the Blue Mountains Eye Study (BMES).1-8 Previous results 
from the BMES are also included. These studies were chosen to provide suitable background 
for the findings of this thesis and to illustrate the addition this thesis makes to the literature.  
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The Prevalence of Visual Impairment 
The World Health Organisation estimated the global burden of visual impairment (best 
corrected visual acuity (BCVA) of <6/18 in the better eye) to be 161 million, including 37 
million with blindness (BCVA of <3/60).9,10 If this definition is expanded to include persons 
with uncorrected refractive error then an estimated 259 million persons were visually 
impaired in 2002, including 42 million persons with blindness.11 
 
 The burden of visual impairment in Australia (BCVA <6/12) was estimated to be 297,800 
persons, including 48,600 with blindness (BCVA 6/60) in 2004.12 If this definition is 
expanded to include persons with uncorrected refractive error, then this estimate increases to 
480,300 with visual impairment, including 50,600 persons with blindness.12 The number of 
persons in Australia with low vision is projected to increase to 800,000 by 2020.12 These 
estimates were based on the combined results of the BMES and the Melbourne Visual 
Impairment Project (MVIP).12  
 
The BMES is a population-based cohort study of common eye diseases and other health 
outcomes in a suburban Australian population located west of Sydney.2 The BMES baseline 
visual acuity data were collected during the years 1992-1994 and included persons aged from 
49-97 years old. The baseline participation rate was 82%. The MVIP was a random cluster 
sample population based study of eye disease in urban and rural residents of Victoria.1 The 
MVIP baseline visual acuity data was collected during the years 1993-1995 and included 
persons aged 40-98 years old. The participation rate was 83%.  
 
These studies defined levels of visual impairment differently. The BMES defined visual 
impairment as: blindness (BCVA <6/60); moderate visual impairment (BCVA ≤6/24->6/60) 
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and mild visual impairment (BCVA ≤6/12->6/24).2 The MVIP definitions were : blindness 
(BCVI <3/60); visual impairment (BCVA <6/18); and visual impairment excluding blind 
persons (BCVA <6/18-≥3/60).1   
 
The BMES reported prevalence rates for bilateral mild, moderate and severe best corrected 
visual impairment (BCVI) of 3.4 %, 0.6% and 0.5% respectively.2 In the MVIP cohort, the 
prevalence of visual impairment (BCVI<6/18- ≥3/60) was 0.58% and the prevalence of 
blindness (BCVI <3/60) was 0.12%.1 
 
The Beaver Dam Eye Study (BDES) is a population based cohort study of common eye 
diseases and other health outcomes in an urban United States population located in Beaver 
Dam, Wisconsin.3 The BDES baseline visual acuity data were collected during the years 
1988-1990 and included persons aged 43-84 years old. The baseline participation rate was 
83%. The BDES utilised the same visual acuity limits as the BMES (mild (BCVA ≤6/12-
>6/24), moderate (BCVA ≤6/24->6/60) and severe (BCVA <6/60) and reported a similar 
prevalence of bilateral mild, moderate and severe BCVI of 3.9%, 0.8% and 0.5% 
respectively.3 
 
The Los Angeles Latino Eye Study (LALES) is a population based cohort study of eye 
disease in the predominately Latino population of Mexican ancestry in and around the city of 
La Puente, Los Angeles County.4 The LALES baseline data was collected during the years 
2000-2003 and included persons aged 40 years or older. The baseline participation rate was 
82%. The LALES reported the same visual acuity limits as the BMES and BDES (mild 
(BCVA ≤6/12->6/24), moderate (BCVA ≤6/24->6/60) and blindness (BCVA <6/60). The 
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reported prevalence of BCVI in this population was 3% for any VI, 2.1% for mild and 0.5% 
for moderate and 0.4% for blindness.4  
 
The Rotterdam Elderly Study (RES) is a population based cohort study of neurogeriatric, 
cardiovascular, locomotor and ophthalmologic diseases in an urban Dutch population in 
Ommord, Rotterdam.5 The RES baseline visual acuity data were collected during the years 
1990-1993 and included persons aged 55 and older. The baseline participation rate was 78% 
(66% participated in the ophthalmologic examination). The RES reported the same visual 
acuity limits as the MVIP and observed a higher prevalence of bilateral visual impairment 
(BCVA <6/18-≥3/60) and blindness (BCVA<3/60) of 1.4% and 0.47% respectively.13  
 
The Salisbury Eye Evaluation (SEE) project is a population based cohort study of age-related 
eye diseases in an urban United States population located in Salisbury, Maryland.8 The 
baseline visual acuity data were collected during 1993-1995 and included persons aged 65-
84. The eligible sample included 100% of the identified black residents and an age-stratified 
random sample of 58% of the identified white residents. The baseline participation rate was 
65%. The SEE study reported the same visual acuity limits as the MVIP and RES and 
observed a higher prevalence of bilateral visual impairment (BCVA <6/18-≥3/60) and 
blindness (BCVA<3/60) of 3.7% and 0.83% respectively.8 
 
The Prevalence of Visual Impairment and Age  
The prevalence of visual impairment was found to increase significantly with increasing age 
in these population based studies.1-4 In addition, population based studies with older cohorts 
consistently report higher prevalence rates of visual impairment compared to the BDES, 
BMES, MVIP and the LALES including the RES5 and the SEE Project.8  
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The Prevalence of Visual Impairment and Gender 
With the exception of the Baltimore Eye Study (BES)14 and SEE8 study, the studies presented 
reported significantly higher prevalence of visual impairment in women compared to men 
after adjustment for age.1-3,5,8 The WHO reported women are more likely to have a visual 
impairment than men in every region of the world, with ratios ranging from 1.5 to 2.2.9 
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The Prevalence of Visual Impairment, Race and Socioeconomic Status 
The BMES, BDES, MVIP, LALES and the BES reported visual impairment to have higher 
prevalence in persons from lower socioeconomic backgrounds.4,6,15-17  
 
The SEE study examined racial differences in the prevalence of visual impairment and 
blindness, but not socioeconomic status. The SEE study reported African Americans had two 
times higher likelihood of being visually impaired and more than three times higher 
likelihood of being blind when compared to white persons.18  
 
The Baltimore Eye Study (BES) reported a higher prevalence of visual impairment and 
blindness in African Americans when compared to whites and that this increase was largely 
attributable to lower socioeconomic status rather than racial differences.6 Significantly, the 
increased prevalence of visual impairment found in African American or persons of lower 
socioeconomic status in this population was due to surgically treatable or potentially 
preventable causes such as cataract, diabetic retinopathy, glaucoma and refractive 
error.15,16,18,19  
 
Comparing age specific rates of VI, the LALES authors reported the prevalence of VI to be 
higher in this population of predominately Latino persons of Mexican ancestry when 
compared to non-Hispanic whites in the BDES, BMES, Baltimore Eye Study (BES), 
Rotterdam Eye Study (RES) and the Salisbury Eye Evaluation (SEE) Project, but not as high 
as in African Americans.4 
 
Socioeconomic status is a significant predictor of an increased prevalence of visual 
impairment worldwide. Studies of visual impairment in developing countries consistently 
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report higher rates of visual impairment compared to developed countries. In 2002, the WHO 
estimated prevalence of blindness was 9.0% in Africa compared to 0.4-0.6% in the United 
States, Western Europe and Australia, mostly due to cataract.9  
 
The Beijing Eye Study (BJES) is a population based study of eye diseases in urban and rural 
areas of Northern China. It was carried out in seven communities, four from the Haidian 
urban district and three from the rural village area of Yufa.7 The baseline visual acuity data 
was collected during 2001 and included persons aged older than 40 years. The baseline 
participation rate was 83%.  The Beijing Eye Study examined the same age group and 
reported the same visual acuity limits as the MVIP of bilateral visual impairment (BCVA 
<6/18-≥3/60) and blindness (BCVA<3/60).7  
 
The BJES reported a higher prevalence compared to the MVIP of visual impairment (1.1% 
vs.. 0.58%) and blindness (0.3% vs.. 0.12%).1,7 The Beijing Eye Study also reported a 
significant inverse association with education level and that the largest cause of visual 
impairment was cataract.7 In contrast to western countries, age related macular degeneration 
and diabetic retinopathy played minor roles in causing visual impairment.7 
 
Tables 1.1 and 1.2 summarise the prevalence of visual impairment these studies reported by 
category of visual impairment. 
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 Study Participation 
Rate  
(%) 
Mild  
 
(%) 
Moderate  
 
(%)    
Severe/ 
Blindness  
(%) 
BMES a 82 3.4 0.6 0.5 
BDES b 83 3.9 0.8 0.5 
LALES c 82 2.1 0.5 0.4 
† Visual impairment limits defined as mild (BCVAd ≤6/12->6/24); moderate (BCVAd ≤6/24-
>6/60); and severe/blindness (BCVAd <6/60) 
a Blue Mountains Eye Study2 
b Beaver Dam Eye Study3 
c Los Angeles Latino Eye Study4 
d Best corrected visual acuity 
 
 Study Participation 
Rate 
(%) 
Visual 
Impairment 
(%) 
Blindness 
 
(%) 
MVIP a 83 0.58 0.12 
RES b 66 1.4 0.47 
SEE c 65 3.7 0.83 
BJES d 83 1.1 0.3 
† Visual acuity limits defined as visual impairment BCVA (<6/18-≥3/60); and blindness 
(BCVI <3/60) 
a Melbourne Visual Impairment Project1 
b Rotterdam Elderly Study5 
c Salisbury Eye Evaluation project 8 
d Beijing Eye Study 7 
 
 
  
1 Table 1.1 Summary of the prevalence of visual impairment in studies using the same 
categories of visual impairment† compared to the Blue Mountain Eye Study (BMES). 
2 Table 1.2 Summary of prevalence of visual impairment in studies using different categories 
of visual impairment† compared to the Blue Mountains Eye Study (BMES). 
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The Associations between Visual Impairment and Morbidity 
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Visual Impairment and Self-rated-health 
Few studies have examined the associations of visual impairment with low self-rated health 
(SRH). The association has been estimated in the BMES population.20 During the baseline 
data collection, participants were asked: For someone of your age, how would you rate your 
overall health? Excellent, good, fair or poor. Self-rated health was dichotomised into 
excellent and good versus fair or poor. The answers fair or poor were scored as low SRH. 
Presenting and best corrected visual acuity were modelled as continuous independent 
variables using multivariable regression modelling. The model included all other co-variables 
found significantly associated with low SRH in this population and included socioeconomic 
variables, physical limitations, chronic diseases, risky health behaviours and hearing loss (17 
co-variables in total).20  
 
After multivariable adjustment, there was a significantly increased likelihood of low SRH for 
both presenting and BCVI in persons younger than age 80 years.20 The association was not 
significant in persons older than 80 years. The likelihood of low SRH was greater when VI 
was modelled using best corrected visual acuity. For each one line (5 letters) decrease in 
visual acuity, there was a 10% increased likelihood of low SRH (odds ratio (OR) 1.1, 95% 
confidence interval (CI) 1.1-1.3) for PVA compared to a 20% increase (OR 1.2, CI 1.1-1.3) 
when visual acuity was modelled as BCVA.20 
 
The Jerusalem Seventy Year Old’s Longitudinal Study (JLS) also reported a significant 
association between visual impairment and poorer self-reported health.21 The JLS is a 
population-based cohort study of social and medical conditions of persons living in West 
Jerusalem born between June 1920 and May 1921. Baseline visual acuity data were collected 
from May 1990 to June 1991. Baseline participation rate was 61%. Visual impairment was 
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defined as BCVA in the better eye of ≤ 6/18. Self-rated health was measured in both absolute 
terms and in relation to others of the same age. Of the persons examined at baseline, 68% 
were re-examined in 1997 (Age = 77). A second cohort of persons aged 77 were also 
examined to maintain study numbers for future follow up.21  
 
The JLS reported that persons with visual impairment at age seventy (baseline examination) 
were significantly more likely to report poor SRH both in relative and absolute terms 
compared to persons with normal vision.21 The effect was significant in both sexes but 
stronger in women. Persons with visual impairment at age 70 were significantly more likely 
to subsequently report poor relative SRH at seven years follow up (OR 2.36, CI 1.09-5.10). In 
persons with visual impairment at age 77 (baseline participants plus additional cohort), only 
women were significantly more likely to report relative poor SRH.21 
 
Two studies have reported significant associations between self or by proxy-reported VI and 
SRH.22,23 Lee et al, used pooled results from the American National Health Interview Survey 
collected over the years 1986 to 1996.22 In total, 140366 non-institutionalised civilian adults 
aged 18 years or older living in the United States were included in the study. Visual 
impairment was assessed by asking if participants were blind or had difficulty seeing in one 
or both eyes, even when wearing glasses. Visual impairment was defined as severe VI (self or 
by proxy-reported blindness in both eyes), some visual impairment (self or by proxy-reported 
visual impairment reported in one or both eyes or blindness in one eye with or without visual 
impairment in the other eye) and no visual impairment (no self or by proxy-reported 
difficulty with vision in either eye). Persons reporting excellent or good SRH were compared 
to persons reporting fair or poor SRH.22 
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After adjusting for survey design, race, educational status and number of reported nonocular 
conditions, persons reporting some or severe VI had a greater likelihood of reporting low 
SRH compared to persons who reported no VI.22 Severe VI was associated with greater 
likelihood of low SRH compared to persons reporting some VI. Younger persons with VI 
were more likely to report low self-rated health compared to older persons. Women reporting 
VI had a greater likelihood of low SRH compared to men. For women reporting severe VI, 
the greater likelihood of low SRH was; OR 7.24, CI 2.91-18.07 for 18-44 year olds; OR 6.72, 
CI 2.90-15.55 for 45-64 year olds; and OR 2.14, CI 1.35-3.40 for 65+ year olds. For men 
reporting severe VI, the greater likelihood of low SRH was; OR 4.48, CI 2.22-9.03 for 18-44 
year olds; OR 2.54, CI 1.20-5.39 for 45-64 year olds; and OR 2.50, CI 1.44-4.32 for 65+ year 
olds.22 
 
Wallhagen et al studied two thousand four hundred forty-two community-dwelling persons 
aged 50 to 102 from the Alameda County Study (California).23 The aim of the study was to 
compare independent impacts of two levels of self-reported hearing impairment (HI) and VI 
on subsequent disability, mental health, physical and social functioning. Baseline data 
including self-reported VA was collected in 1994, with the one-year outcomes measured in 
1995. Three questions were used to assess VI. Participants were asked how much difficulty 
they had (even with glasses) reading street signs at night, recognising a friend across the 
street and reading a newspaper. The possible responses (score) were: “a great deal” (3), 
“some” (2), “a little” (1), or “none” (0). Scores were summed and the resulting scale divided 
into three categories: no VI (score = 0), mild VI (score = 1-3), and moderate or more VI 
(score ≥ 4). Those reporting SRH as fair or poor were compared with those reporting good or 
excellent SRH.23 
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The study reported no significant association between mild VI and low SRH, however, a 
significant association was reported between ≥ moderate VI and Low SRH (OR 1.63, CI 
1.07-2.48).23 
 
Table 1.3 summarises the findings of the studies that did not separate results by sex.  
 
3 Table 1.3 Summary of odds ratios (OR) and 95% confidence intervals (CI) of reporting low 
self-rated health in persons with visual impairment by study and age. 
Study Participant Age 
(Years) 
Odds Ratio 95% Confidence 
Interval 
BMES a, c ≥49 1.20 1.10 – 1.30 
JLS a, d ≥70 2.36 1.09 – 5.10 
ACS b, e ≥50 1.63 1.07 – 2.48 
a Best corrected visual impairment <6/12 BMES; ≤ 6/18 JLS 
b Self-reported visual impairment  
c Blue Mountains Eye Study20 
d The Jerusalem Seventy-year old’s Longitudinal Study21 
e Alameda County study23  
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Visual Impairment, Measures of Function and Health Related Quality of Life 
In comparison to SRH, more data has been reported for standardised measures of Health 
Related Quality of Life including the generic Medical Outcomes Study 36 item Short-Form 
(SF-36) and the vision specific National Eye Institute Visual Function Questionnaire (NEI-
VFQ25). Both have been validated across a range of populations.24-28 These assess different 
dimensions of the same outcome measures and are reported to be valid and reliable measures 
of quality of life.24,29  
 
The SF-36 includes eight subscales: limitations in physical activities due to health problems; 
limitations in social activities because of physical or emotional problems; limitations in usual 
role activities because of physical health problems; bodily pain; general mental health; 
limitations in usual role activities because of emotional problems; vitality; and general health 
perceptions.26  
 
The NEI-VFQ25 includes twelve subscales: general health; general vision; near vision; 
distance vision; driving; peripheral vision; colour vision; ocular pain; role limitations; 
dependency; limitations in social functioning; and mental health.25  
 
Associations between visual impairment and health related quality of life measured by the 
SF-36 and the NEI-VFQ25 are reported for the BMES population. 27,29,30  The SF-36 
questionnaire was completed and visual acuity re-assessed in the BMES 2 data collection 
period in 1997 to 1999 in 2335 participants (75.1% of the original cohort). A repeat door to 
door census found 1378 more persons had become eligible for inclusion into the study (age 
50 years or older). Of these, 1174 persons (85%) were interviewed and examined in the 
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BMES extension study (BMES 2B). The HRQOL of the BMES 2B cohort was assessed 
using both the SF-36 and the NEI-VFQ-25.27,29,30  
 
Complete SF-36 and VA data were available from 3153 (90%) participants and complete 
NEI-VFQ-25 and VA data were available from 892 (76%) of the BMES 2B cohort.27,29,30 The 
impact of unilateral and bilateral visual impairment was examined. Presenting visual 
impairment was defined as VA <6/12. Correctable visual impairment was defined as PVI 
improving to ≥6/12 after subjective refraction and NCVI was defined as VI that persisted 
after subjective refraction. Levels of VI were defined as mild (<6/12 - ≥6/24), moderate 
(<6/24 - ≥6/60) and severe (<6/60).27,29,30  
 
For unilateral VI, after age and sex adjustment, there were no statistically significant 
differences in SF-36 scores for unilateral VI, mild unilateral or correctable unilateral VI 
compared to persons without VI.29 Persons with moderate to severe unilateral NCVI had 
statistically significant lower SF-36 scores in three of the eight dimensions compared to 
persons without VI after age and sex adjustment; role limitations due to physical problems 
(15%), social functioning (7%), role limitations due to emotional problems (13%) and in the 
mental component score.29  
 
There were no statistically significant decreases in any NEI-VFQ-25 scores for persons with 
unilateral CVI.28 Unilateral PVI was associated with statistically significant decreases in NEI-
VFQ-25 scores in four dimensions compared to persons without PVI; general vision (6%); 
mental health (4%); dependency (2%); and driving (3%) and composite score (2%).28 
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Unilateral NCVI was associated with statistically significant lower NEI-VFQ-25 scores in 
eight dimensions after age and sex adjustment; general vision (11%); near vision (6%); 
distance vision (4%); social function (2%); mental health (10%); role difficulty (6%); 
dependency (2%); and peripheral vision (7%) and composite score (5%).28 
 
The following associations reported between bilateral VI and NEI-VFQ-25 were age and sex 
adjusted.28 The associations reported between bilateral VI and SF-36 scores were 
multivariable adjusted for age, sex, home ownership, current employment, marital status, 
tertiary education, receipt of a government pension, hospital admission in the preceding year, 
current smoking, and history of angina, stroke, hypertension, diabetes, arthritis, thyroid 
disease and cognitive impairment.30 
   
Bilateral CVI was associated with statistically significant lower SF-36 scores in two of the 
eight dimensions; physical functioning (8%); social functioning (6%); and the physical 
component score (5%) after multivariable adjustment.30 Bilateral CVI was also associated 
with statistically significant lower scores in seven of twelve dimensions of the NEI-VFQ-25; 
general vision (12%); near vision (9%); distance vision (5%); mental health (8%); role 
difficulty (8%); dependency (5%); peripheral vision (6%) and with the composite score (5%) 
after age and sex adjustment.28  
 
In comparison, bilateral NCVI was associated with statistically significant lower SF-36 
scores in five of the eight dimensions; physical functioning (8%); general health (13%); 
vitality (18%); social functioning (9%); and mental health (9%) and the mental component 
score (8%) after multivariable adjustment. Bilateral NCVI was also associated with 
statistically significant lower scores in all dimensions of the NEI-VFQ-25; general health 
49 
 
(24%) general vision (61%); ocular pain (16%); near vision (55%); distance vision (59%); 
social function (44%); mental health (49%); role difficulty (50%); dependency (33%); 
driving (74%); colour vision (33%); peripheral vision (47%) and composite score (45%) after 
age and sex adjustment.28,30 In addition, increasing severity of NCVI was associated with 
statistically significant decreases in SF-36 and NEI-VFQ-25 scores.28,30 
 
The 1958 British birth cohort assessed vision related quality of life (VRQOL) using the 
vision-related Quality of Life Core Measure 1 (VCM1).31 The cohort comprised everyone 
born in Britain during one week in 1958. The VCM1 is a validated 10 item self-completed 
VRQOL measure 32 with a scoring range from 0 to 5. Higher scores represent lower VRQOL. 
Visual acuity and VCM1 data were obtained from 9324 of 11971 (78%) invited persons aged 
44/45 years during 2002 to 2003.31 A score of greater than two was defined as impaired 
VRQOL. Visual acuity was defined as; normal (≥6/9.5 in both eyes); unilateral visual loss 
(normal VA one eye and ≤6/12 other eye); socially significant visual loss (≤6/12-≥6/18 better 
eye VA); visual impairment (≤6/19-≥6/60 in the better eye); severe visual impairment (<6/60-
≥3/60 better eye VA); and blindness (<3/60 better eye VA).31  
 
In the 1958 British birth cohort study, the combined prevalence of VI and severe VI was 
1.2%.31 After adjustment for age, sex, socio-economic, employment and marital status, all 
levels of presenting visual impairment were associated with significantly increased likelihood 
of impaired VRQOL. The likelihood of impaired VRQOL increased with increasing visual 
impairment (unilateral OR 2.94, CI 1.66-5.20; socially significant OR 3.49, CI 1.50-8.08; 
visual impairment OR 8.15, CI 3.00-22.40; and severe VI or blindness OR 10.03, CI 1.69-
59.50).31 
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The LALES examined associations between presenting visual impairment and NEI VFQ-25 
and SF-12 scores.33 Complete data for the NEI VFQ-25 and SF-12 were available from 5377 
(85%) of the LALES participants. Presenting visual impairment was categorised as unilateral 
or bilateral; no VI (>6/12); mild VI (≥6/12->6/24); and moderates/severe VI (≤6/24). Mean 
SF-12 and NEI VFQ-25 scores were adjusted for age, sex, education, employment status, 
income, acculturation, co-morbidities, health insurance status, vision insurance status, and 
visual field impairment.33  
 
In the LALES study, no significant differences were reported between persons with and 
without PVI for any SF-12 score33 and the NEI VFQ-25 item scores for general health and 
ocular pain.33 The remaining NEI VFQ-25 item mean scores were significantly lower in 
persons with any category of PVI compared with no VI, except for the item colour vision in 
persons with unilateral PVI. Compared to persons without VI, persons with moderate/severe 
PVI had the lowest mean NEI VFQ-25 scores in all items and the composite score; general 
vision (21%); near vision (28%); distance vision (30%); social function (20%); mental health 
(31%); role difficulty (23%); dependency (32%); driving (49%); colour vision (12%); 
peripheral vision (17%) and composite score (23%).33 
 
The MVIP examined the association of VI with performance of visually dependent functional 
tasks using the VF-1434 and two vision related functional tasks.35 The VF-14 is a valid 
instrument for measuring difficulties with vision related activities. It is a 14-item 
questionnaire scored on a 100-point scale. Lower scores represent increasing difficulty 
performing vision related tasks.34 The two vision related tasks were identifying a ten cent 
coin from a group of three and reading a telephone number correctly from a telephone book.35  
Participants from two test sites and with presenting visual acuity (PVA) of less the 6/18 (508 
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participants) completed the VF-14 and the two vision related functional tasks.35 Results for 
each VF-14 item were categorised dichotomously as moderate/great deal of 
difficulty/inability to perform task and little/no difficulty (control). Odds ratios were 
estimated using logistic regression.35 
 
Persons with PVI <6/12 had significantly higher odds of VF-14 total score < 90 and having ≥ 
moderate inability to perform tasks in all items except driving during the day when compared 
to persons with ≥6/12 VA.35 Participants with a VA of <6/12 were significantly more likely 
to be unable to recognise a 10 cent coin (OR 7.0, CI 2.6-19.3) or correctly read a telephone 
number (OR 10.1, CI 5.6-18.1). The mean VF-14 score was 59 for persons who could not 
identify a ten-cent coin compared to 95 for those who could. Similarly, the mean VF-14 score 
was 79 for those who could not read a telephone number correctly compared to 96 for those 
who could. The proportion of persons unable to correctly perform the functional tasks 
increased with decreasing VA.35 
 
The MVIP five-year follow-up study examined the impacts of unilateral and bilateral VI on 
various functional impairments.36 Of the 3040 surviving participants in the MVIP baseline 
study, 2594 (85%) participated in the 5-year follow-up study. For this study, VI was defined 
as unilateral correctable (PVI <6/12 correctable to ≥6/12), non-correctable (BCVI <6/12) and 
moderate to severe non-correctable VI (BCVI <6/24) and bilateral correctable and non-
correctable VI.36 
 
After age and sex adjustment, unilateral CVI was associated with increased likelihood of 
problems watching television.36 Unilateral NCVI was associated with increased odds of 
falling away from home, needing help with chores, dependency, difficulties seeing faces, 
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reading the telephone book and newspaper and watching television. Similar associations were 
found for persons with moderate to severe unilateral NCVI except that watching television 
and falling away from home became non-significant.36 
 
Bilateral VI was associated with a greater number and likelihood of functional difficulties.36 
Bilateral CVI was associated with increased likelihood of difficulties reading the telephone 
book and newspaper, watching television and seeing faces. Bilateral NCVI was associated 
with the greatest number and magnitude of increased likelihood of functional difficulties. 
Affected participants had increased likelihood of being in a nursing home, using supplied 
meals, needing help with chores, dependency, health/emotional problems, not feeling full of 
life, difficulties reading the telephone book and newspaper, watching television, seeing faces 
and doing other activities.36 There were no associations found between any form of VI and 
falling at home and hip replacement surgery.36 Multivariate adjustment for other outcome risk 
factors did not significantly attenuate the associations.36 
 
The SEE study reported associations between self-reported functional status and PVA 
<6/12.37 Physical function was assessed using two standardised questionnaires; the Activities 
of Daily Living (ADL),38 which measures difficulties in basic areas of self-care such as 
dressing, bathing, toileting, mobility and feeding; and the Instrumental Activities of Daily 
Living (IADL),39 which measures difficulty in more complex tasks necessary for independent 
living such as house work, paying bills and shopping. Vision specific function was measured 
using the activities of daily vision scale (ADVS.) questionnaire.40  
 
The SEE study reported that after adjusting for age, sex and race, visual impairment was 
significantly associated with functional limitation in all measures of functional status and 
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with a decline in ADVS. score (-6.73).37 The likelihood of reporting a lot of difficulty with 
ADL and IADL compared to no difficulties was greater in persons with PVI compared to 
persons without PVI (OR 1.82, CI 1.18-2.83 and OR 2.45 CI 1.77-3.40 respectively).37 
 
Lee et al, using pooled results from the American National Health Interview Survey (NHIS) 
collected over the years 1986 to 1996, estimated the associations between self or by proxy 
reported visual impairment and restricted activity days, bed days, doctor’s visits and hospital 
stays.22 They reported males with severe bilateral VI were significantly more likely to have 
one or more days of restricted activity or bed rest in the preceding two weeks or to have been 
admitted to hospital in the previous twelve months. They were also less likely to have seen a 
doctor in the previous 12 months.22 Females with some VI were significantly more likely to 
have one or more days of restricted activity or bed rest in the preceding two weeks or to have 
been admitted to hospital in the previous twelve months. There were no significant 
associations in females with severe bilateral VI.22 
 
Swanson et al, using the American 1995 NHIS and its supplement on Disability (NHIS-D) 
estimated the impacts of self-reported serious difficulty with vision (SDV) on ADLs and 
IADLS.41 For those who reported a serious difficulty with vision, 94% had a perfect or 
probable condition match consistent with their reported vision difficulty. The data used were 
for persons 18 years and older. In total 67570 persons were included in the study. The age 
range was 18-99 years old (mean = 44.6). The supplement included detailed questions on six 
ADLs; bathing; dressing; eating; toileting; getting in and out of chairs and getting around the 
house; and six IADLs; shopping; preparing meals; managing money; using the telephone; 
doing light house work and doing heavy house work. The results were dichotomised as no 
difficulty and any degree of difficulty.41  
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After adjusting for age, gender, race, poverty, self-rated health, living arrangements, 
depression and mental status, SDV was significantly associated with difficulty in each of the 
ADLs and IADLs.41 For persons reporting difficulty in the following ADLs, the increased 
odds of reporting SDV were; bathing OR 3.64, CI 1.85-7.19; dressing OR 1.79, CI 1.40-2.29; 
eating OR 2.02, CI 1.32-3.07; toileting OR 1.70, CI 1.29-2.23; transfer OR 1.53, CI 1.20-1.96 
and getting around OR 1.75, CI 1.36-2.25. For persons reporting difficulty in the following 
IADLs, the increased odds of reporting SDV were; shopping OR 2.53, CI 2.09-3.05; meals 
OR 1.92, CI 1.51-2.43; money OR 2.56, CI 1.98-3.33; telephone OR 2.65, CI 1.75-4.01; light 
housework OR 1.88, CI 1.53-2.31 and heavy housework OR 1.76, CI 1.51-2.05.41 
 
Laitinen et al conducted a cross sectional survey of a representative Finnish population 
examining the associations between PVI with ADLs and IADLs.42 The data were obtained 
from the Health 2000 survey, a nationwide population based survey of health and functional 
capacity carried out in Finland in 2000-2001. The data used were from persons living on the 
mainland of Finland aged 55 years and older. Visual impairment was defined as VA ≤6/24 
and good vision was defined as ≥6/7.5. Of 3392 eligible persons, 3185 were interviewed 
(93.9%) and 2781 (82.0%) had distance visual acuity assessed.42  
 
This study reported that compared to persons with good vision, persons with VI had a 
statistically significant increased likelihood of reporting difficulties with ADL’s (OR 4.36, CI 
2.44-7.78) and IADLs (OR 4.82, CI 2.38-9.76) after adjustment for socio-demographic and 
behavioural factors and chronic conditions.42 
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Visual Impairment, Mobility, Falls and Fractures 
The association between distance vision and mobility in a population of 5143 older adults 
was examined by Salive et al in a cross sectional cohort study of three communities 
(Established Populations for the Epidemiologic Studies of the Elderly).43 Participants were 
interviewed in 1988-89 and residents of two communities were reinterviewed 15 months later 
(n = 3133, 97% of those eligible). After adjustment for age, sex, race, site, income, diabetes 
and a history of stroke, the relative odds of limitations in mobility was 3.1, CI 2.3-4.3 in 
persons with VA <6/60; 1.7, CI 1.4-2.0 for persons with VA ≥6/60 but <6/18 and 1.5, CI 1.3-
1.8 for persons with VA ≥6/18 but <6/12 compared to persons with VA ≥6/12.43 In 
prospective analyses controlling for potential confounders, participants with severe visual 
impairment had 3-fold higher odds of incident mobility and activity of daily living limitations 
than those with acuity of 6/12 or better (P < 0.001). In prospective analyses investigating the 
relationship of VA with improvement in mobility, those with poor vision were about half as 
likely to improve as those with better acuity.43  
 
The association between VI and falls in the elderly has been examined in the BMES 1. After 
adjustment for confounding variables the prevalence ratio for two or more reported falls in 
the 12 months prior to the examination was 1.9 in persons with VI <6/9.44 Visual impairment 
was also associated with an increased risk of hip fracture in this population.45  Ivers et al 
reported an increased risk of fracture in the first two years after the initial eye examination in 
the BMES 1 cohort, but not after a longer period of time. The risk of hip fracture in those 
with BCVA worse than 6/18 was HR 8.4, CI 1.5-48.5 after adjustment for age, sex, health 
status, BMI, and Parkinson’s disease. In persons aged 75 and older, visual acuity worse than 
6/18 gave an adjusted HR of 40.6, CI 5.6-292.5.45  
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The BDES prospectively examined the associations of visual function with physical 
outcomes and limitations.46 Visual acuity and physical outcomes were measured at the five 
year follow up and again at the ten year BDES follow up. The outcomes measured were; 
change in 3m walk time (time at ten year minus time at five year examination); incidence of 
the use of walking aids; incidence of nursing home/assisted living facility placement; 
incidence of not driving at night; incidence of fracture; incidence of 2 or more falls in the 12 
months preceding the ten year follow up; and the incidence of fear of falling.46 
 
After adjusting for confounding variables, there was no statistically significant association 
between measured walk time and visual impairment.46 The likelihood of the incidence of the 
use of walking aids and not driving at night was associated with decreasing PVA (p for trend 
0.03 and 0.001 respectively) but not BCVA (p for trend = 0.17 and 0.11 respectively). The 
likelihood of the incidence of any fracture, nursing home placement and two or more falls 
increased with decreasing VA for both PVI (p for trend = 0.05, <0.0001 and 0.01 
respectively) and BCVI (p for trend = 0.04, <0.0001 and 0.03 respectively).  In persons with 
VA≤6/12 in the better eye, the likelihood of any fracture was 1.75, CI 1.02-2.99 for PVI and 
2.00, CI 1.10-3.62 for BCVI. The likelihood of two or more falls over the five-year periods 
was 2.02, CI 1.13-3.63 for PVI ≤6/12 and 1.55, CI 0.77-3.10 for BCVI ≤6/12. Change in time 
to walk the measured course was not significantly associated with any of the visual 
functions.46 
 
Dargent-Molina et al 47 examined the risk factors associated with hip fractures in 7575 
women aged 75 years or older from the areas of Amiens, Lyon, Montpellier, Paris and 
Toulouse in France. They excluded women with previous hip fractures, previous bilateral hip 
replacement or women who were unable to walk independently.47 Visual impairment was 
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defined using best corrected binocular VA. The authors reported the relative risk of hip 
fracture increased with decreasing VA. Visual acuity of ≤6/30 was associated with a 2 fold 
increased risk of hip fracture (RR 2.0, CI 1.1-3.7) after adjustment for age, centre, bone 
mineral density, calf circumference, gait speed and tandem walk score.47 
 
Felson et al reported the 10 year risk of hip fracture associated with visual impairment in 
those members of the Framingham Study Cohort who took part in the Framingham Eye Study 
(FES) in 1973-75.48The authors reported that poor vision in one or both eyes was associated 
with an elevated fracture risk. The fracture rates in those with moderately impaired (6/9 to 
6/24) vision (8.5%) and poor (6/60 or worse) vision (11.3%) were higher than in those with 
good (6/7.5 or better) vision (3.0%). After adjustment for age, sex, weight, alcohol 
consumption, and (in women) oestrogen use, the relative risk of fracture in those with 
moderate impairment was 1.54 (CI 0.95-2.49), while for those with poor vision, the relative 
risk was 2.17 (CI 1.24-3.80). In addition, persons with moderately impaired vision in one eye 
and good vision in the other remained at higher risk of fracture (RR=1.94) than those with a 
similar degree of binocular impairment (RR = 1.11). The risk of fracture with poor and 
moderately impaired vision combined was increased in women (RR 1.96, CI 1.23-3.11) but 
not in men (RR 0.79, CI 0.23-2.72).48 
 
Cox et al reported that the prevalence of VI is significantly higher in a population of persons 
admitted to hospital for hip fractures compared to that estimated in the general community.49 
This Scottish multicentre study examined all persons (537) admitted with hip fracture in four 
hospitals (Ayr, Dunfermline, Glasgow and Dundee) aged 65 years or older. They found a 
significantly higher prevalence of visual impairment (46%) in this population compared to 
that estimated to be present in the general community (15-30%) for the same age group. The 
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principal causes for visual impairment were preventable or potentially modifiable causes 
(untreated cataract (49%), macular degeneration (21%), uncorrected refractive error (17%), 
and glaucoma (3%)) and higher proportion of persons with visual impairment lived in areas 
of social deprivation (40 vs.. 26%).49 
 
Table 1.4 summarises the reported risk of hip fracture in persons with visual impairment by 
study. 
 
4 Table 1.4 Summary of risk (odds ratios (OR) or risk ratios (RR) and 95% confidence 
intervals (CI) of risk of hip fracture in persons with visual impairment by study. 
Study Visual Acuity Risk 95% Confidence 
Interval 
BMES a <6/18 8.40 b 1.50 – 48.50 
ALMPT d ≤6/30 2.00 c 1.10 – 3.70 
FES e ≥6/9-≤6/24 1.54 c 0.95 – 2.49 
FES e ≤6/60 2.17 c 1.24 – 3.80 
a Blue Mountains Eye Study45 
b OR  
c RR 
d Amiens, Lyon, Montpellier, Paris and Toulouse study in France47 
e Framingham Eye Study48  
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Visual Impairment and Depression 
A population-based cross-sectional study of 13,900 people aged 75 years or older in 49 
family practices examined the associations of visual impairment with depression and anxiety 
in older people living in Britain.50 Visual impairment was defined as VA ≤6/18 and 
depression was defined using the Geriatric Depression Scale Short Form (GDS-SF), a set of 
15 short questions with yes-or-no answers about feelings over the previous week.50-52.  
 
Evans et al reported that 13.5% of visually impaired persons were depressed (GDS-15 score 
of 6 or more) compared with 4.6% of people with good vision (age and gender adjusted OR 
2.69, CI 2.03-3.56).50 This association was attenuated by adjusting for activities of daily 
living (OR 1.26, CI, 0.94-1.70).50  
 
Hayman et al 53 estimated the prevalence of depression in a sample of older adults with 
impaired vision and associations between visual impairment and depression. The authors 
used cross-sectional baseline data from 391 participants aged ≥75 years with visual acuity of 
≤6/24, recruited for the Visually Impaired Person’s (VIP) trial.54 Using the geriatric 
depression scale (GDS-SF) the authors reported that visual function was significantly worse 
for those with depression, independent of the effect of physical disability.53 
 
Tsia et al examined the associations between visual impairment and depression in persons 
aged ≥65 years in a population based survey of eye diseases in a metropolitan Taipei 
community using the Geriatric Depression Scale-Short Form (GDS-15).55 Visual impairment 
was defined as a BCVA of <6/12 in the better eye. Impaired vision was significantly 
associated with depression and was a significant predictor of four items of the GDS-S after 
multivariable adjustment. These were; feel unhappy most of the time (OR 1.73, CI 1.01-
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2.88); do not think it is wonderful to be alive now (OR 2.13, CI 1.21-3.64); feel worthless the 
way they are now (OR 2.23, CI 1.24-3.90); and feel their situation is hopeless (OR 1.95, CI 
1.03- 3.52).55 
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The Associations Between Visual Impairment and Mortality 
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The Association Between All-Cause Visual Impairment and All-Cause Mortality 
Wang et al reported the association between VI and all-cause mortality in the Blue Mountains 
Eye Study at seven years from baseline.56 Visual impairment was defined as BCVI < 6/12. 
Australian National Death Index data were used to confirm persons who had died since 
baseline. Associations between mortality and presence of visual impairment at baseline were 
assessed using the Cox proportional hazards regression model, controlling for age, sex, 
demographic and socioeconomic status, medical history, and health risk behaviours.56 
 
Of the 3654 participants included at baseline, 604 participants (16.5%) had died before seven 
years.56 The age- and sex- standardized 7-year cumulative mortality rate from baseline was 
26% among persons with any visual impairment and 16% in persons without visual 
impairment. After adjusting for factors found significantly associated with mortality, 
including age, male sex, low self-rated health, low socioeconomic status, systemic medical 
conditions, and negative health risk behaviours, the presence at baseline of any VI was 
independently associated with increased mortality risk (risk ratio (RR), 1.7, CI 1.2-2.3).56 
 
Cugati et al reported the eleven-year data for the association between VI and mortality in the 
Blue Mountains Eye Study population.57 Mortality occurring between baseline and December 
31, 2003, were again obtained via data linkage with the Australian National Death Index. 
Age-standardized mortality rates were calculated, and hazard ratios (HRs) and 95% 
confidence intervals (CIs) were determined using Cox models. Similar to the seven-year data, 
age-standardised mortality was higher in persons with vs. without visual impairment (54.0% 
vs. 34.0%). At eleven years however, after adjusting for factors that predict mortality in this 
population, visual impairment (HR 1.3, CI 0.98-1.7) was no longer significantly associated 
with all-cause mortality in this cohort. However, among persons younger than 75 years, VI 
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remained associated with higher all-cause mortality (HR 2.9, CI 1.6-5.5). This association 
became non-significant after further adjustment for triglyceride level, fibrinogen level, 
educational level, and walking disability (HR 1.97, CI 0.8-4.8).57 
 
Kuang et al examined the association between visual impairment and 3-year risk of mortality 
in a cohort of urban Chinese elderly individuals in the Shihpai Eye Study.58 Participants were 
aged ≥65 years at baseline. Baseline examinations were conducted between July 1, 1999 and 
December 31, 2000. Visual impairment was defined as PVI < 6/12. Of 2045 eligible persons 
randomly selected to participate in the study, 1361 (66.6%) participated in both the 
questionnaire and eye examination. A follow-up of a fixed cohort was also conducted after 3 
years. Deaths were confirmed through the household registration system.58 
 
During the three years before the follow-up, 54 (3.97%) had died. After adjustments were 
made for age, sex, education, marital status, lifestyle factors, depression symptoms, fall 
history, and history of systemic diseases, visual impairment was not a significant predictor of 
3-year mortality in elderly persons.58 
 
Lee et al examined the associations between self-reported visual impairment (SRVI) and 
mortality in adults 18 years and older using data from the American National Health 
Interview Survey (NHIS).59 The NHIS is conducted annually by the National Center for 
Health Statistics (NCHS) and is a continuous, multipurpose and multistage probability survey 
of the US civilian non-institutionalised population. Approximately 50000 households are 
selected to participate with a response rate of 95-98%. The study used data from 116796 adult 
participants for the years 1986-1994. Adults within households were administered questions 
about VI and selected eye diseases. Mortality linkage data with more than 96% of the survey 
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participants were available. To determine the association of visual impairment with mortality, 
the study controlled for survey design, age, race, marital status, educational level, reported 
health status, glaucoma, cataract, and retinopathy. Statistical analyses used Cox proportional 
hazards regression analysis.59 
 
There were 8949 deaths in the study population from baseline before December 31 1997.59 In 
persons with severe bilateral visual impairment (SRVI), women, but not men, were at a 
significantly increased risk of death relative to their counterparts without VI (HR 2.21, CI 
1.61-3.02 and HR 1.33, CI 0.96-1.84, respectively). In persons with some SRVI compared to 
those reporting no VI, the risk of mortality was significantly elevated in women and men (HR 
1.35, CI 1.20-1.52 and HR 1.14, CI 1.01-1.29 respectively).59   
 
The association of visual impairment with all-cause mortality has been reported for the 
Beaver Dam Eye Study (BDES) population at 5 and 14 years from baseline.60 61 Baseline 
examinations took place between 1988 and 1990. Participants were aged 43 through 84 years 
at baseline. Visual impairment was defined as BCVA of 6/12 or worse. Deaths were 
ascertained by contacting family members, daily review of obituaries, and use of vital status 
records. Data were analysed using Cox Proportional Hazards Model.60 
The association of visual impairment with five-year survival from baseline in the BDES 
population was reported by Klein et al.60 At five years from baseline 9.5% (467/4926) of the 
BDES population had died. After correcting for age and sex, poorer survival was associated 
with visual impairment (HR 1.57, CI, 1.18-2.08) however, after controlling for systemic 
factors, the association became non-significant (HR 1.08, CI 0.77-1.51).60 
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The association of visual impairment with 14-year survival from baseline in the BDES 
population was reported by Knudtson et al.61 At fourteen years from baseline, 32% of the 
baseline population had died. After multivariate adjustment for age, sex, and systemic and 
lifestyle factors, poorer survival remained significantly associated with visual impairment 
(HR 1.24, CI 1.04-1.48).61  
 
In contrast to Lee et al,59 the associations tended to be stronger in males in the BDES cohort. 
The associations were also stronger in younger persons. By restricting the cohort to persons 
younger than 65years, the relationship between visual impairment and decreased survival 
after multivariable adjustment increased (HR 2.18, CI 1.02-4.67).61 
 
McCarty et al reported the association of visual impairment with mortality in the 5 year 
follow up of the Melbourne Visual Impairment Project (MVIP) cohort.62 This population 
based study examined the distribution and determinants of age related eye disease in a cluster 
random sample of Melbourne residents. The participants were aged 40 years and older at 
baseline. The baseline examinations were conducted between 1992 and 1994. Causes of death 
were obtained from the National Death Index for all reported deaths. Visual impairment was 
defined as BCVA <6/12. Survival analyses were conducted with the Wilcoxon test for 
statistical significance of the survival curves. Before five years, 231 (7.1%) of the original 
3271 participants had died. Visual impairment was associated with a significantly increased 
risk of mortality (OR 2.34, CI 1.03-5.32) after multivariable adjustment.62 
 
The Age-Related Eye Disease Study (AREDS) is a major clinical trial sponsored by the 
American National Eye Institute examining the natural history and risk factors of age-related 
macular degeneration (AMD) and cataract.63 The study also evaluated the effect of 
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antioxidant, vitamin and mineral supplements on the progression of AMD and cataract.63 A 
total of 4757 persons were enrolled. The baseline examinations were conducted between 
November 13, 1992, and January 15, 1998. Participants were aged 55 to 81 years at baseline. 
Visual impairment was defined as <6/12 BCVA. At baseline, participants had to be free of 
any condition that would make long-term follow-up unlikely or difficult. Persons with a 
history of cancer with a poor prognosis for 7-year survival or a major cardiovascular or 
cerebrovascular event within the year before enrollment were ineligible. Persons with more 
than minimal diabetic retinopathy or any other eye disease that could complicate assessment 
of the progression of lens opacities or AMD, or that could affect visual acuity (e.g. optic 
atrophy and acute uveitis) were also ineligible. All AREDS participants had at least 1 eye 
with 6/9 or better visual acuity at baseline.63 
 
Clemons et al reported the association of VI at baseline with all-cause mortality in the Age-
Related Eye Disease Study population within 6.5 years from baseline.64 When mortality was 
reported, death was confirmed from hospital records and from death certificates. Associations 
between mortality and presence of VI in one eye at baseline were assessed using the Cox 
proportional hazards regression model controlling for statistically significant covariates in 
this population. During median follow-up of 6.5 years, 534(11%) of 4753 AREDS 
participants died. In the multivariable adjusted model, participants with VI to less than 6/12 
in 1 eye had an increased risk of mortality (relative risk (RR) 1.36, CI 1.12-1.65).64 However, 
ninety-one percent of participants who had < 6/12 in 1 eye were in AMD Category 4. Thus, 
the association between all-cause visual impairment and mortality could not be distinguished 
from the association between AMD and mortality in this study.64 
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Freeman et al reported the association of VI and 8-year mortality in the Salisbury Eye 
Evaluation (SEE) project.65 The authors also examined whether depressive symptoms acted 
as a mediator between visual impairment and mortality in this population. The Salisbury Eye 
Evaluation was a population-based cohort study of 2520 (65% of those approached) older 
adult residents of Salisbury, Maryland. Participants were reexamined two years later, and of 
these, 1991 were eligible for the assessment of the association between VI, mortality and 
depression. Baseline examinations were conducted between September 1993 and September 
1995. Participants were aged 65 to 84 years at baseline. Baseline presenting visual acuity 
(PVA) was examined categorically but then used as a continuous variable, as PVA was found 
to have a linear relationship with mortality in this population. Information on mortality was 
obtained by a report from family members, by the local newspapers, and by staff follow-up. 
All deaths reported by July 2003 were used in the analysis. Statistical analyses were 
performed with the Cox proportional hazards regression.65 
 
In the SEE, worse baseline acuity was associated with a higher mortality rate (HR 1.05, CI 
1.01-1.09 per 0.1 logMAR (1 line) change in acuity) after multivariable adjustment.65 Change 
in PVA within two years from baseline was also significantly associated with mortality at 
eight years. Participants who gained two or more lines of visual acuity within two years from 
baseline had a lower multivariable adjusted risk of dying at eight years (HR 0.47, CI 0.23-
0.95). Also, women, but not men, who lost three or more lines of visual acuity over a 2-year 
period, had a higher adjusted risk of dying (HR 3.97, CI, 2.21-7.15 vs.. HR 1.32, CI 0.66-2.63 
respectively). Depressive symptoms did not mediate the relationship between visual 
impairment and mortality in this population.65  
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The Medical Research Council (MRC) trial of assessment and management of older people in 
the community is a cluster randomised trial comparing different methods of population-based 
multidimensional screening in 106 general practices (family practices) from the United 
Kingdom MRC General Practice Research Framework.66 Of these, 53 general practices were 
randomly allocated to the universal screening arm of the trial. Participants at these practices 
were given a visual acuity test as part of a detailed health assessment at baseline.67 The 
number of participants with baseline visual acuity measurements was 13569. Baseline 
examinations were performed between 1995 and 1999. Participants were aged 75 years and 
older at baseline. Visual impairment was stratified into three groups: binocular PVI <6/18; 
binocular PVI >6/9 but ≤ 618; and binocular PVI <6/6 but ≥ 6/9. Poisson regression 
modelling was performed with all-cause, cardiovascular disease, and cancer mortality rates as 
the outcomes of interest. All-cause mortality rates by level of visual acuity were modelled. 
Participants with a baseline PVA of 6/6 or better were used as the baseline reference group.67  
 
Thiagarajan et al reported the associations of visual impairment with mortality after 6 years 
from baseline in the MRC trial of assessment and management of older people in the 
community population.67 Rate Ratios of mortality for visually impaired participants after 
adjustment for confounding factors were determined. The incidence of mortality was 
significantly higher in participants with PVA <6/18 and in participants with PVI <6/9 but ≥ 
6/18 when compared to participants with PVA of 6/6 at baseline after adjustment for all 
confounding variables in this population (RR 1.17, CI 1.07-1.27 and RR 1.10, CI 1.01-1.19 
respectively). The association of mortality incidence with PVI <6/6 but ≥ 6/9 was not 
significant after multivariable adjustment (RR 1.01, CI 0.93-1.10).67 
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The Copenhagen City Eye Study was a prospective population based cohort study of 946 
persons. The study examined vision and common eye diseases in an urban population 
residing in the Østerbro district of Copenhagen, Denmark.68 The baseline examinations were 
conducted from 1986 to 1988. Participants were aged 60-80 years old at baseline. Mortality 
data was reported 14 years from baseline. Participants were followed until death or until May 
1, 2002, whichever came first. At baseline, participants underwent an extensive 
ophthalmologic examination, including fundus photography, at Rigs Hospitalet, the National 
University Hospital of Copenhagen. Visual impairment was defined as ≤ 6/12. Data from the 
National Central Person Register, the National Death Register, and the National Patient 
Register were used, and information on the causes of death was obtained from the Danish 
National Death Register. The independent contribution of ARM, cataract, and visual loss to 
death, was estimated using Cox’s proportional hazards regression analysis.68 
 
In the Copenhagen Eye Study the presence of visual loss at baseline was not associated with 
increased mortality risk after adjustment for age and gender (RR 1.17, CI, 0.78-1.75).68  
 
The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) is a population 
based study of 996 persons (83% of all persons with type 1 diabetes who were receiving care 
in 11 counties in Wisconsin).69 Baseline examinations were conducted during the period 
1980-1982. Follow up examinations were conducted 4, 10, 14 and 20 years later. Participants 
were aged > 0 years at baseline. Levels of visual impairment were defined as: BCVA > 6/12, 
none; 6/12 – 6/19, mild; 6/24 - 6/48, moderate; ≤ 6/60, severe. Mortality was determined 
yearly by telephone contact with study subjects or a contact person and monitoring of local 
newspapers for obituaries of study subjects. When unable determine subject vital status or 
last known address or death, the subjects name was submitted to the National Death Index. 
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Death certificates were obtained for those known to have died. Kaplan-Meier survival 
procedures were used for cardiovascular deaths. Cox proportional hazards regression analysis 
was used for multivariable models.69,70 
 
After multivariable adjustment, visual impairment was associated with 16 year all-cause 
mortality in the younger-onset (Mild: HR 1.78, CI 1.02-3.11, Moderate: HR 1.41, CI 0.56-
3.52, Severe: HR 1.94, CI 1.19-3.17) and the older-onset diabetes groups (mild: HR 1.48, CI 
1.16-1.90, moderate HR 1.77, CI 1.25-2.51, severe: HR 2.14, CI 1.42-3.22).70 Table 1.5 
summarises the results of these studies. 
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5 Table 1.5 Summary of mortality risk (risk ratios (RR), hazard ratios (HR) or odds ratios 
(OR) and 95% confidence intervals (CI) in persons with objectively measured visual 
impairment after multivariable adjustment. 
Study Visual Acuity Mortality 
Risk 
95% Confidence 
Interval 
BMES a <6/12 1.70 k 1.50 – 48.50 
BMES b <6/12 1.30 l 0.98 – 1.7 
SES c <6/12 Not Significant Not Significant 
BDES d ≤6/12 1.08 l 0.77 – 1.51 
BDES e ≤6/12 1.24 l 1.02 – 4.67 
MVIP f < 6/12 2.34 m 1.03 – 5.32 
AREDS g <6/12 in one eye 
≥6/9 fellow eye 
 
1.36 k 1.12 – 1.65 
MRC h >6/9 
<6/9-≥6/18 
<6/18 
 
1.01 k 
1.10 k 
1.17 k 
0.93 – 1.10 
1.01 – 1.19 
1.07 – 1.27 
WESDR i 6/12-6/19 
6/24-6/48 
≤6/60 
 
1.78 l 
1.41 l 
1.94 l 
1.02 – 3.11 
0.56 – 3.52 
1.19 – 3.17 
WESDR j 6/12-6/19 
6/24-6/48 
≤6/60 
1.48 l 
1.77 l 
2.14 l 
1.16 – 1.90 
1.25 – 2.51 
1.42 – 3.22 
a Blue Mountains Eye Study 7-year follow-up56 
b Blue Mountains Eye Study 11-year follow-up57 
c Shihpai Eye Study 3-year follow-up58 
d Beaver Dam Eye Study at 5-year follow up60 
e Beaver Dam Eye Study 14-year follow-up61 
f Melbourne visual impairment project 5-year follow-up62 
g Age Related Eye Disease Study 7-year follow-up64 
h Medical Research Council trial of assessment and management of older people 6-year 
follow-up67 
i Wisconsin Epidemiologic Study of Diabetic Retinopathy 16-year follow-up in younger 
onset diabetics70 
j Wisconsin Epidemiologic Study of Diabetic Retinopathy 16-year follow-up in older onset 
diabetics70 
k RR 
l HR 
m OR 
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The Associations Between All-Cause Visual Impairment and Cause-Specific Mortality 
Visual Impairment and Cardiovascular Disease 
The United States National Health Interview Survey of adults within households found 
associations between self-reported visual impairment and cardiovascular disease related 
mortality, in women (HR 2.53, CI 1.68-3.81), but not men (HR 1.27, CI 0.78-2.07), who 
reported severe bilateral VI after multivariable adjustment.59 Risk of cardiovascular mortality 
was also significantly elevated in women (HR 1.36, CI 1.15-1.61) with some reported VI 
when compared with those reporting no VI after multivariable adjustment.59  
 
The MRC trial of assessment and management of older people in the community did not 
report data for the association between all-cause visual impairment and cardiovascular 
mortality.67 There were however, statistically significant associations between VI and 
cardiovascular mortality after multivariable adjustment in participants with VI due to 
refractive error and VI of unknown cause (RR 1.37, CI 1.03-1.82 and RR 1.81, CI 1.17-2.78 
respectively).67 
 
The Blue Mountains Eye Study at 7 and 11 years follow up reported no association between 
baseline VI and vascular mortality.56,57 The BDES found no association between baseline VI 
and cardiovascular mortality at 13 years from baseline.61 
 
The WESDR found significant associations with reduced baseline visual acuity and increased 
cardiovascular mortality risk in a diabetic population, after multivariable adjustment in both 
younger-onset and older-onset diabetic groups.70 Persons with severe visual impairment at 
baseline in the younger-onset diabetes group were at greatest risk (mild: HR 2.89, CI 1.42-
5.87; severe: HR 3.21, CI 1.58-6.51). In the older-onset group, those with mild visual 
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impairment were at greater risk (mild: HR 1.81, CI, 1.29-2.54; severe: HR 1.22, CI, 0.57-
2.61).70 
 
The AREDS was unable to determine the association between all cause visual impairment 
and cardiovascular mortality as ninety-one percent of participants who had reduced vision at 
baseline were in AMD Category 4.64 This group had a statistically significant risk of 
cardiovascular death.64 
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Visual Impairment and Cancer 
The United States National Health Interview Survey of adults within households found no 
association between self-reported visual impairment and cancer related mortality.59 The Blue 
Mountains Eye Study at 7 and 11 years follow up found cancer-related deaths were 
significantly less frequent in participants with baseline visual impairment (P=0.004 at 11 
years from baseline).56,57 The BDES found no association between cancer related mortality 
and baseline visual impairment after 14 years follow up.61 The WESDR found no 
associations between baseline visual impairment and 16 year mortality in a diabetic 
population.70 There was no association reported between baseline visual impairment and 
cancer related deaths in the AREDS at 6 years.64 The MRC trial of assessment and 
management of older persons in the community found no association between baseline visual 
impairment and cancer related mortality.67 
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The Associations Between Cause specific visual impairment and All-Cause Mortality 
Cataract and All-Cause Mortality 
The presence of cataract or previous cataract surgery has been associated with decreased 
survival in many populations studies,61,71-77 but not in other populations.56,57,68,78,79 
 
Benson et al reported an increased risk of mortality associated with cataract surgery 
performed between 1979 and 1980 at the West Virginian University Medical Center, 
Morgantown.72 During this period, 193 patients aged 50 to 89 years of age had cataract 
surgery. Their mortality was compared to 182 patients who elected one of three other surgical 
procedures during the same period. Patients who had undergone cataract surgery at this 
institution during this time period had a significantly higher mortality rate (P = 0.0005) than 
control group patients according to life-table analysis estimates adjusted for age and sex.72 
 
Increased five-year mortality risk after cataract surgery was also reported in a cohort of 
patients undergoing cataract surgery at the Worthen Center for Eye Care Research, Center for 
Sight, Georgetown University Medical Center, Washington, D.C. during 1984.71 Participants 
were aged 65 to 79 years during 1984. The risk of dying within five years after cataract 
extraction in 1984 was compared to the five-year mortality risk of the same aged persons in 
the United States population in 1984. Street et al reported that cataract surgery at a younger 
age was associated with an increased risk of 5-year mortality compared to patients having 
surgery at older ages. Patients who had cataract extraction and who were younger than 75 
years had significantly higher age-specific rates of mortality than predicted from United 
States life tables (P less than .001) (for age 65 years RR 1.34, CI 1.29-1.41). This risk 
progressively declined until the age of 75 years. At age 75 years and older, the risk of dying 
within five years of cataract surgery was not significantly different to that expected for the 
76 
 
United States population.71 However, cataract surgery did predict reduced five year mortality 
in women older than 79 years who had cataract surgery during 1984 (for age 79 years, RR 
0.90, CI 0.82-0.99).71  
 
Meddings et al reported the association between cataract surgery and mortality in persons 
who underwent surgery in British Columbia during either 1985 or 1989.73 Subjects were aged 
50-95 years at time of cataract surgery. Mortality rates were compared with the provincial 
population of comparable age, who did not undergo cataract surgery during the study period. 
The 1985 cohort included 8,262 patients undergoing surgery and a comparison population of 
804,303, and the 1989 cohort included 11,952 patients undergoing cataract surgery and a 
comparison population of 839,393. Cox regression analysis was used to determine hazard 
ratios.73  
 
For both cohorts, cataract surgery was associated with increased hazard ratios for dying 
during follow-up. In 1985, the results were similar between males and females for persons 
aged 50-54.9 years of age (HR 3.2, CI 2.0-5.0 and HR 3.3, CI 1.9-5.7 respectively).73 Hazard 
ratios decreased with older age, becoming nonsignificant for both males and females who 
were 80 years or older and who had cataract surgery in either 1985 or 1989.73 
 
McGwin et al examined a cohort of 384 persons with (n=286) and without cataract (n=98) 
from the Impact of Cataracts on Mobility (ICOM) Study.74,80 McGwin et al reported that 
persons with cataract had an increased rate of mortality at 6 years from baseline (crude 
mortality rate ratio (MRR) 2.5, CI 1.0-6.5).74 Of 286 participants who had cataract, 200 
elected to have cataract surgery. Patients with cataract who did not elect to undergo surgery 
had a significantly higher mortality rate when compared to those who had surgery and those 
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without cataract (MRR 3.9, CI 1.5-9.8 and 7.3, CI 2.8-19.1 respectively) after age and sex 
adjustment. After multivariable adjustment, the no-surgery cataract group had an elevated 
mortality rate (MRR 3.2, CI 1.2-9.0) compared to the no-cataract group. Those who 
underwent cataract surgery had a nonsignificant elevation in mortality rate (MRR 2.0, CI 0.8-
5.9).74 
 
In the AREDS study, nuclear opacity ≥4 and previous cataract surgery were associated with 
increased all-cause mortality that remained statistically significant after multivariable 
adjustment (RR 1.40, CI 1.12-1.75 and RR 1.55, CI 1.18-2.05 respectively).64 Cortical 
cataract and posterior subcapsular cataract demonstrated no statistically significant 
association in this population.64 
 
The Nurses’ Health Study was established in 1976.81 During baseline, 121,700 female 
registered nurses aged 30-55 years and residing in 11 large US states completed a mailed 
questionnaire on their medical history and lifestyle. Follow up questionnaires were sent every 
two years to update information on general health and to identify newly diagnosed coronary 
and other diseases. Cataract extraction was first assessed in 1984 and considered the baseline 
for the association between cataract surgery and mortality analysis.75 Women who reported a 
diagnosis cancer or cardiovascular disease at this baseline were excluded. Women less than 
age 45 years were excluded. Women were added to the analysis after 1984 as they reached 
age 45 years. In 1984, 1986, 1988, 1990, and 1992, participants were asked if they had a 
cataract extraction since the previous questionnaire. When cataract extraction was reported, 
the authors requested permission to review medical records. The confirmation rate reached 
100 percent for self-reported cataract extractions that occurred between 1984 and 1992. Only 
the first extraction was used as the exposure variable. In total, 60,657 women aged 45-63 
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years in 1984, 49.8% of the original cohort, were included in the analysis. Self-reported 
cataract extraction was used as the exposure variable. Deaths were reported by next of kin 
and the postal system or through the National Death Index. Fatal CHD was confirmed by 
hospital records or autopsy or if CHD was listed as the cause of death on the death certificate 
and evidence of previous CHD was available.75  
 
The Nurses’ Health Study demonstrated increased 10 year all-cause mortality after 
multivariable adjustment in women aged between 45 and 63 who had previous cataract 
surgery at baseline (RR 1.37, CI 1.13-1.66).75 In this population the entire increased mortality 
risk was explained by an increased coronary heart disease (CHD) mortality.75 
 
The BDES reported an association between increasing severity of nuclear sclerosis in 
nondiabetics and poorer 5 year survival from baseline (HR per level of severity 1.19, CI 1.00 
to 1.40).60 There was no association between nuclear sclerosis and mortality in people with 
diabetes (HR 0.96, CI 0.68 to 1.36) or with other forms of cataract in this population after 
multivariable adjustment at five years from baseline.60 After 13 years, poorer survival was 
associated with cortical cataract (HR 1.21, CI 1.06-1.37), any cataract (HR 1.16, CI 1.03-
1.32) but not with increasing severity of nuclear sclerosis (HR 1.07, CI 0.99-1.16, p = 0.06). 
Contrary to the results at five years, the associations tended to be slightly stronger in men 
compared to women after 13 years.60,61 
 
The MVIP study found no association between the presence of cataract and five year 
mortality in an Australian cohort aged 40 years and older.62 The Melbourne VIP study did 
previously report using the same data a significant increased risk of mortality in persons with 
cortical cataract at baseline (RR 1.45, CI 1.01-2.10), with the caveat that the reported risk 
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may be artifactual due to loss of significance when a more lenient definition of cortical 
cataract was used in the modelling.76 
 
The association between cataract and mortality has been reported in the BMES Cohort at 7 
and 11 years after baseline.56,57 In this Australian cohort, participants were aged 49 years and 
older at baseline. After adjusting for factors found significantly associated with mortality, the 
presence of age-related cataract, either nuclear sclerotic (RR 1.5, CI 1.1-1.9), cortical (RR 
1.3, CI 1.1-1.6), or posterior subcapsular cataract (RR 1.5, CI 1.1-2.0), was significantly 
associated with increased mortality risk at 7 years from baseline.56 Previous cataract surgery, 
was not associated with mortality after 7 years from baseline in this population study.56 At 11 
years after baseline the associations remained statistically significant. (Nuclear sclerosis (HR 
1.21, CI 1.00-1.46), cortical (HR 1.28, CI 1.10-1.48) and posterior subcapsular cataract (HR 
1.46, CI 1.17-1.82)).57  
 
The North London Eye Study is a population-based cross-sectional survey of persons aged 65 
years and older that aimed to estimate the magnitude of serious eye disorders and visual 
impairment in a defined elderly population of a typical metropolitan area in England.82 A 
random sample of people aged 65 years and older was drawn from a defined population of 
elderly people registered with 17 general practice groups. The baseline survey was carried out 
from April 1995 to October 1996. A total of 1547 people were examined and included in the 
sample. Mortality was monitored for three years by the Office for National Statistics. The 
monitoring covered a period from March 1995 (start of the survey) to December 1999 (3 
years from the end of the survey).82 The lens status at the time of the survey was ascertained 
by ophthalmologists using a slit lamp biomicroscope and the lens opacity classification 
system (LOCSII).83 The age and sex-specific mortality from various causes was estimated 
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and compared in those with and without cataract. Hazard ratios were estimated using Cox 
proportional hazards regression models.77 
 
This survey found an association between cataract and increased risk of 3-year mortality in 
nondiabetic women but not in nondiabetic men (HR 1.7, CI 1.1-2.7 vs. HR 0.9, CI 1.1-2.7) 
after age adjustment.77 The “sex cataract” interaction was apparent within each of the three 
main types of cataract. There was no significant effect modification by age. In diabetic 
patients, there was a significant association of cataract with mortality in both men and women 
after age and sex adjustment (HR 2.6, CI 1.1-6.0). Further adjustment for effects of smoking, 
for area of residence, and for ethnic group did not materially change the findings.77 
 
The Barbados Eye Study measured the prevalence and evaluated risk factors for the major 
causes of visual loss. Four thousand seven hundred and nine persons were identified by 
random sampling of Barbadian-born citizens.84 The baseline examinations were conducted 
between 1988 and 1992. Participants were aged 40 to 84 years of age at baseline. Four years 
later, surviving members were reexamined in the Barbados Incidence Study of Eye Diseases 
(BISED). Three thousand four hundred and twenty-seven participants or 85% of those 
eligible were included. The Lens Opacities Classification System II (LOCS II),83 was used to 
grade opacities. Lens opacities were defined as LOCS II scores of 2 or more in at least one 
eye. Death certificate data were obtained from the Ministry of Health, including dates and 
specific causes of death. Cox proportional-hazards regression analyses were used to examine 
the associations of mortality and lens opacities, while controlling for potential confounding 
variables. These factors were first evaluated in univariate analyses and significant variables 
(P < 0.05) were then included in the multivariable Cox regression model.84 
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The Barbados Eye Study reported significant associations between mixed opacity cataracts 
and nuclear cataracts and all-cause mortality at 4 years from baseline (Death Rate Ratio 
(DRR) 1.6, CI 1.1-2.4; DRR 1.5, CI 1.1-2.0 respectively).84 No statistically significant 
associations between mortality and any cortical or any PSC cataract were found.84 
 
The Copenhagen Eye Study of persons aged 60-80 years at baseline found no association 
between the presence of baseline cataract and mortality after adjustment for age and sex at 14 
years from baseline (RR 0.98, CI 0.82-1.17).68 Table 1.6 summarises the mortality risk of 
persons with cataract after multivariable adjustment. 
 
6 
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Table 1.6 Summary of mortality risk (risk ratios (RR), hazard ratios (HR) or death rate ratios 
(DRR) and 95% confidence intervals (CI)) in persons with nuclear sclerosis (NS) cataract, 
cortical (CO) cataract and posterior subcapsular (PS) cataract after multivariable adjustment. 
Study Cataract Mortality 
Risk 
95% Confidence 
Interval 
AREDS a NS≥4 
CO 
PS 
 
1.40 f 
Not Significant 
Not Significant 
1.12 – 1.75 
Not significant 
Not Significant 
MVIP b Any Not significant Not significant 
BMES c NS 
CO 
PS 
1.50 f 
1.30 f 
1.50 f 
 
1.10 – 1.90 
1.10 – 1.60 
1.10 – 2.00 
BMES d NS 
CO 
PS 
 
1.21 g 
1.28 g 
1.46 g 
1.00 – 1.46 
1.10 – 1.48 
1.17 – 1.82 
 
BBES e NS 
CO 
PS 
1.50 h 
Not significant 
Not significant 
1.12 – 1.65 
Not significant 
Not significant 
a Age Related Eye Disease Study 7-year follow-up64 
b Melbourne Visual Impairment Project 5-year follow-up62 
c Blue Mountains Eye Study 7-year follow-up56 
d Blue Mountains Eye Study 11-year follow-up57 
e Barbados Eye Study 4-year follow-up 84 
f RR 
g HR 
h DRR 
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Age-Related Macular Degeneration and All-Cause Mortality 
The Blue Mountains Eye Study reported there was no association between all-cause mortality 
and baseline ARMD at 7 years from baseline.56 After 11 years, baseline ARMD was 
associated with increased mortality after multivariable adjustment in persons younger than 75 
years at baseline (HR 1.59, CI 1.04-2.43) but not in persons older than 75 years at baseline 
(HR 0.90, CI 0.65-1.26).57  
 
An association between ARMD and all-cause mortality was reported for participants in 
AREDS.64 In this population, participants with advanced ARMD compared with participants 
with few if any, drusen at baseline had increased all-cause mortality (RR 1.41, CI 1.08-1.86) 
after multivariable adjustment.64 
 
The Copenhagen Eye Study of persons aged 60-80 year at baseline reported an association 
between the presence of baseline ARMD and 14-year mortality after multivariable 
adjustment.68 Adjustment was made for factors correlated to both age-related maculopathy 
and mortality, including visual impairment of ≤ 6/12. Buch et al reported the risk of mortality 
at 14 years was increased in persons with early but not late ARMD (HR 1.23, CI 1.02-1.49 
early vs. HR 1.25, CI 0.84-1.87).68 When stratified by sex, baseline early ARMD was 
associated with increased mortality in women, but not men (HR 1.60, CI 1.20-2.13 vs. HR 
0.97, CI 0.74-1.26 respectively). Late ARMD was not associated with significant increase in 
mortality in either sex.68 
 
The Beaver Dam Eye Study found no association between ARMD at baseline and mortality 
at five years and 13 years after multivariable adjustment (HR 0.88, CI 0.73-1.07; HR 0.97, CI 
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0.87-1.07 respectively per one step increases of severity).60 Similarly the Melbourne VIP 
study found no association between ARMD and 5 year mortality (OR 1.36, CI 0.96-1.94).62 
 
The Medical Research Council (MRC) trial of assessment and management of older people in 
the community reported no association between ARMD and increased mortality risk.67 
However, there was a significant association between those whose cause of visual 
impairment could not be ascertained with mortality (RR 1.33, CI 1.02-1.75).67 This may have 
led to an underestimation of the association between ARMD and mortality. 
 
The Atherosclerosis Risk in Communities (ARIC) Study is a population-based cohort study 
that examined the relationship between AMD and risk of coronary heart disease (CHD) 
events and all-cause mortality in men and women.85 There were 15792 participants at 
baseline. The baseline period was 1987 to 1989. Participants were aged 45 to 64 years old at 
baseline. The study population was selected by probability sampling from 4 U.S. 
communities: Forsyth County, North Carolina; Jackson, Mississippi; suburbs of Minneapolis, 
Minnesota; and Washington County, Maryland. The Jackson sample included African 
Americans only; the remaining 3 were representative of the populations in these 
communities.85 
 
Of the 15792 participants at baseline, 14 346 (93% of survivors) returned for a second 
examination in 1990 through 1992, and 12 887 (86% of the survivors) returned for a third 
examination in 1993 through 1995.85 Participants had retinal photographs of one eye taken 
between 1993 and 1995. The reported associations between ARMD, cardiovascular events, 
cardiovascular and all-cause mortality were derived from individuals who participated at the 
third examination. Of the 12887 who returned for this examination 11414 participants were 
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used in the final analysis. Photographs were evaluated for the presence of early and late AMD 
signs according to the Wisconsin grading system.86 Incident CHD events (acute myocardial 
infarction, silent myocardial infarction, fatal CHD, and cardiac revascularization procedures) 
and all-cause mortality were identified prospectively using standardised methods.85 Cox 
proportional hazards models were used to estimate the RR and 95% CIs for incident CHD 
and deaths by ARMD status, adjusting initially for age, gender, race, and centre, and then 
further for education, body mass index, systolic and diastolic BPs, diabetes status, total 
plasma cholesterol and HDL cholesterol, triglyceride, glucose, pack-years of cigarette 
smoking, and current alcohol consumption.85 
 
In the ARIC study, ARMD was not statistically significantly associated with all-cause 
mortality after multivariable adjustment (Early ARMD RR 0.95, CI 0.73-1.31; Late ARMD 
RR 1.95, CI 0.73-1. 38).85 
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Glaucoma and All-Cause Mortality 
The United States NHIS examined the associations between self-reported glaucoma and 
survival in a nationally representative sample of U.S. adults over an average follow-up period 
of 7 years.87 After multivariable adjustment, participants with reported glaucoma, but without 
reported visual impairment, were at significantly increased risk of death relative to 
participants without reported glaucoma irrespective of visual impairment status (HR 1.35, CI 
1.19-1.53). Similar associations were found for participants with reported glaucoma and 
visual impairment vs. participants with no reported glaucoma (HR 1.39, CI 1.14-1.71).87  
 
The Framingham Eye Study examined the relationship between high intraocular pressure 
(greater than or equal to 25 mm Hg) or history of treatment for glaucoma and survival.88 
After adjustment for age and sex, this study demonstrated an association between high 
intraocular pressure or diagnosed glaucoma and increased mortality risk (DRR 1.56, CI 1.11-
2.19). The association became non-significant after multivariable adjustment for other 
comorbidities linked to increased mortality.88 
 
The Barbados Eye Study reported no overall association between baseline open angle 
glaucoma and 9 year all-cause mortality after adjustment for confounders (RR 0.85, CI 0.64-
1.15).89 However, there was a significant association between all-cause mortality and baseline 
OAG in persons being treated with timolol (RR 1.70, CI 1.08-2.68). There was also a smaller 
but statistically significant association between elevated IOP (> 21mm Hg) at baseline and 
all-cause mortality (RR 1.01, CI 1.00-1.03). The presence of ocular hypertension was not 
associated with a statistically significant increase in all-cause mortality.89 
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A population based study of 32,918 elderly citizens of Malmo between 1992 and 1997 
examined mortality rates in glaucoma patients and matched controls.90 Two controls of the 
same age and gender were chosen for each glaucoma patient. Deaths for each group were 
determined based on centrally administered registers. After a mean follow-up time of 7.75 
years, the five-year mortality did not differ significantly between the groups (p=0.7406). 
Among glaucoma patients, neither IOP (p=0.1781) nor pseudoexfoliation (p=0.8882) was 
related to significantly increased mortality.90 
 
The BDES found no association between the presence of glaucoma at baseline and 5 year or 
13 year mortality (HR 0.84, CI 0.57-1.26 and HR 1.04, CI 0.84-1.28 respectively).60,61 The 
Melbourne VIP similarly found no association between glaucoma and 5 year mortality risk 
after multivariate adjustment.62  
 
The BMES reported no association existed between baseline glaucoma with seven and nine 
year all-cause mortality.56,91 The WESDR study found no association between baseline 
glaucoma and 16-year mortality after multivariable adjustment.70 
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Diabetic retinopathy and All-Cause Mortality 
The Early Treatment of Diabetic Retinopathy Study (ETDRS) is a randomized clinical trial 
that assessed photocoagulation and aspirin treatment for patients with diabetic retinopathy.92 
Participants were recruited from April 1980 through July 1985 and aged 18-69 at baseline. 
The ETDRS enrolled 3,711 subjects over this period. Inclusion criteria included the diagnosis 
of diabetes and diabetic retinopathy in each eye. Diabetic retinopathy was graded as mild, 
moderate, or severe nonproliferative diabetic retinopathy (NPDR) or mild to moderate 
proliferative diabetic retinopathy (PDR) with or without macular oedema.93 Time to the 
occurrence of death of any cause during the period of the study was determined. The 
Mortality and Morbidity Classification Committee, composed of internists and cardiologists 
who were not ETDRS investigators, coded study deaths. Multivariable adjusted Cox 
proportional hazards models using all statistically significant covariates were used to estimate 
the associations between mortality diabetic retinopathy.94  
 
The ETDRS reported no association between diabetic retinopathy and mortality in 
participants with type 1 diabetes, defined as onset before 30 years old, after multivariable 
adjustment.94 In participants with type 2 diabetes, defined as onset of diabetes after 30 years 
of age, there was a significant association between severe nonproliferative diabetic 
retinopathy (NPDR) and severe proliferative diabetic retinopathy (PDR) with mortality after 
multivariable adjustment (HR 1.48, CI 1.03-2.15 and HR 2.02, CI 1.28-3.19 respectively). 
There were no associations between mild NPDR, moderate NPDR and mild PDR with 
mortality after multivariable adjustment in this population.94 
 
The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) reported an 
association between increased mortality risk and increasing severity of retinopathy.95 
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Clinically significant macular oedema (CSME) was not significantly associated with all-
cause mortality in this population.96 The BDES found a significant association between the 
presence of baseline diabetic retinopathy and 13-year mortality after multivariable adjustment 
(HR 1.36, CI 1.14-1.63).61  
 
The BMES found a nonsignificant trend of increased mortality in people with diabetes with 
baseline diabetic retinopathy at seven years (RR 1.6, CI 1.0-2.7; p = 0.06).56 The 
EURODIAB prospective complications study found no significant association of diabetic 
retinopathy with mortality after multivariable adjustment.97  
 
A Finnish population of persons visually impaired due to diabetic retinopathy (DR) were 
reported to have a higher rate of cardiovascular mortality when compared to age and sex-
matched control groups from the same geographic location over a period of 4 years.98 In this 
study, Rajala et al identified 34 men and 73 women living in northern Finland with visual 
impairment caused by DR on 31 December 1993. These subjects were aged 27 to 71 years at 
baseline (median 71 years). Visual impairment was defined as decimal visual acuity <0.3. 
The 4-year mortality rate of this group was compared with that of 3 age, and sex matched 
control groups. The first control group were subjects treated for DR by laser coagulation from 
1990 to 1993 (decimal VA acuity was > 0.9 in 38 subjects, 0.6-0.9 in 30 subjects, 0.3-0.5 in 
24 subjects and < 0.3 in 7 subjects). The second control group were diabetic subjects with 
fundus photographs taken from 1991 to 1992. The third control group comprised nondiabetic 
subjects from the population register. One-hundred and seven subjects from each control 
group were matched for age and sex with the study subjects. The subjects in the 4 groups 
were aged 27 to 88 years at baseline (median 71 years). Each group consisted of 34 (32%) 
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men and 73 (68%) women. Information on deaths was obtained from official death 
certificates.98 
 
The 4-year mortality rate (MR) was highest in subjects with visual impairment caused by DR 
at baseline (MR 477/1000, CI 382-571/1000).98 The 4-year mortality rates for diabetic 
subjects with retinopathy previously treated by laser coagulation was higher than that of the 
nondiabetic subjects but lower than subjects with VI and untreated DR at baseline (MR 
224/1000, CI 145-303/1000 and MR 94/1000, CI 46-165/1000 respectively).98 
 
Compared with the nondiabetic control subjects, the risk of all-cause 4-year mortality was 
highest in the diabetic subjects with visual impairment due to DR (OR 5.1, CI 2.6-11.0), 
followed by diabetics with laser coagulation prior to baseline (OR 2.4, CI 1.1-5.6).98 The 4-
year mortality risk in diabetic subjects with fundus photographs taken, but without recorded 
VI or previous laser treatment, was not significantly different to non-diabetics in this 
population (OR 1.6, CI 0.68-4.0).98 
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The Associations Between Cause-Specific Visual impairment and Cause-Specific Mortality 
Cataract and Cause-Specific Mortality 
Cataract and Cardiovascular disease 
The Nurses’ Health Study cohort,81 found a significant association among women aged 45-63 
years who had cataract surgery between 1984 and 1992, and coronary heart disease (CHD) 
morbidity and mortality.75  
 
Incidence rates of CHD were calculated for women who reported an extraction. The relative 
risk of CHD was estimated with adjustment for 5-year age categories.75 Pooled logistic 
regression across the five 2-year intervals was used to adjust simultaneously for potential 
confounding variables.75 
 
During 10 years follow-up, after adjustment for age, smoking, and other coronary risk 
factors, cataract extraction was significantly associated with higher risk of CHD (any CHD: 
RR 1.88, CI 1.41-2.50; fatal CHD: RR 2.44, CI 1.54-3.89; nonfatal CHD: RR 1.63, CI 1.14-
2.34).75 The association between cataract extraction and total CHD may be greater among 
diabetic women (RR 2.80, CI 1.77-4.42 diabetic vs.. RR 1.51, CI 1.04-2.18 
normoglycaemic). After multivariate adjustment, cataract extraction remained significantly 
associated with increased mortality from cardiovascular disease (RR 1.84, CI 1.29-2.64).75 
 
The North London Eye Study found significant associations between all three cataract 
morphologies and cardiovascular mortality in nondiabetic women, but not nondiabetic men, 
after adjustment for age.77 (HR for nuclear opacity (1.8); cortical opacity (1.9); and posterior 
subcapsular opacity (2.1) were all significant with p<0.04 for each cataract type vs. p>0.3 for 
each type in nondiabetic men).77 
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The MRC trial of assessment and management of older people in the community reported no 
association risk of cardiovascular mortality and cataract in persons aged 75 years and older.67 
However, there was a significant association between cardiovascular mortality and VI after 
multivariable adjustment in participants for whom the cause of VI was uncertain (RR 1.81, CI 
1.17-2.78).67 This may have led to an underestimation of the association between cataract and 
cardiovascular mortality.  
 
The BDES found a significant association between stroke mortality and increasing severity of 
nuclear sclerosis, but not cortical or posterior subcapsular cataract at 13 years from 
baseline.61 The association with heart disease related mortality and cataract was not 
significant after multivariable adjustment for any cataract subtype.61 
 
The BMES examined cause-specific VI and cause-specific mortality 7 and 11 years from 
baseline.56,57 At seven years, causes of death in persons with baseline visual impairment did 
not reveal any substantial differences compared to persons without baseline visual 
impairment.56 At 11 years, the BMES reported an association of increased risk of vascular 
mortality in participants with any cataract (HR 1.57, CI 1.13-2.19), nuclear cataract (HR 1.48, 
CI 1.06-2.07) and posterior subcapsular cataract (HR 1.46, CI 1.00-2.12) after multivariable 
adjustment for factors significantly associated with mortality in this population, including 
visual impairment.57 The association with cortical cataract was not significant after 
multivariable adjustment (HR 1.22, CI 0.94-1.59). There was no association between 
previous cataract surgery and 11-year vascular mortality after multivariable adjustment.57 
 
93 
 
The Barbados Eye Study found no association between baseline cataract and cardiovascular 
mortality (RR 1.16, CI 0.67-2.02; RR 1.17, CI 0.79-1.75; RR 1.13, CI 0.76-1.67 for mixed 
opacity; any nuclear; and any cortical respectively, after age and sex adjust).84 
 
The AREDS study reported no statistically significant associations between the presence of 
nuclear sclerosis, cortical or posterior subcapsular cataract or previous cataract surgery and 
cardiovascular mortality.64  
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Cataract and Cancer 
In the AREDS study, grade ≥4 nuclear opacity (RR 1.56, CI 1.05-2.31) and previous cataract 
surgery (RR 2.29, CI 1.45-3.60) were associated with increased risk of cancer related death 
after multivariable adjustment.64 Grade ≥4 nuclear sclerosis, but not posterior subcapsular or 
cortical cataract, was also associated with non-cardiovascular and non-neoplastic causes of 
death (RR 1.64, CI 1.07-2.51; RR 1.63, CI 0.66-4.05; RR 0.82, CI 0.47-1.45 respectively).64  
 
In contrast to AREDS data, in the BMES population cancer-related deaths were significantly 
less frequent in participants with cataract (P<.001) at 11 years.57 No significant difference in 
respiratory or other causes of death between persons with and without cataract at baseline 
was observed at 11 years.57 
 
The North London Eye Study reported no association was present between cataract and 
cancer associated mortality after age and sex adjustment in their cohort.77 The MRC trial of 
assessment and management of older people in the community also found no significant 
association between cataract and cancer-related mortality after multivariable adjustment.67 
 
The Barbados Eye Study reported no significant associations between cataract and cancer-
related mortality (RR 2.37, CI 0.98-5.71; RR 1.85, CI 0.98-3.52; RR 1.39, CI 0.76-2.55 for 
mixed, nuclear and cortical cataract respectively after age and sex adjustment).84 
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Age Related Macular Degeneration and Cause-Specific Mortality 
Age Related Macular Degeneration and Cardiovascular disease  
In the BMES, cumulative 11-year vascular mortality was higher in participants with age 
related macular degeneration (ARMD) compared to those without ARMD at baseline (26.5% 
vs. 11.9%).57 After multivariable adjustment, the presence of any ARMD at baseline was 
associated with higher vascular mortality risk for participants younger than 75 years (HR 2.1, 
CI 1.17-3.77). The association remained significant after adjustment for the presence of 
visual impairment (HR 2.03, CI 1.07-3.84) but not after the addition of baseline fibrinogen 
and triglyceride levels and baseline disability in walking to the model (HR 1.41, CI 0.64-
3.09). The authors reasonably suggested the loss of significance may reflect ARMD sharing 
common antecedents with cardiovascular disease.57  
 
The 11-year BMES data also demonstrated an association between level of baseline ARMD 
and 11-year cardiovascular mortality in participants younger than 75 years.57  In analyses 
using three categories for ARMD (none, early, and late), late ARMD predicted higher 
vascular mortality (HR 3.8, CI 1.4-10.4), although early ARMD did not (HR 1.4, CI 0.7-2.7) 
in participants younger than 75 years. There was no association between ARMD and 
cardiovascular mortality in participants aged ≥ 75 years at baseline.57 
 
Over a 10-year follow-up, after controlling for age, gender, race, systolic and diastolic blood 
pressure, pack-years of cigarette smoking, and other variables, early AMD was not associated 
with incident CHD (RR 1.08, CI 0.82-1.42) the ARIC study cohort.85 Individuals with late 
AMD were significantly more likely to have an incident CHD event, however the numbers 
were small. There were 4 CHD events among the 15 participants with late AMD at baseline 
giving a 10-year cumulative incidence of 30.9%. There were 918 CHD events among the 
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11,399 participants without late AMD giving a 10-year cumulative incidence of 10.0%. This 
was a statistically significant difference (P = 0.049, Fisher exact test).85  
 
Participants in the Age-Related Eye Disease Study (AREDS) with advanced ARMD 
(Category 4 = unilateral advanced AMD or unilateral vision loss to worse than 20/32 
attributable to AMD) compared with participants with few, if any, drusen had significantly 
increased risk of cardiovascular death after multivariable adjustment (RR 1.92, CI 1.18-
3.12).64 
 
The Leiden 85-plus Study is a prospective population based study consisting of two cohorts 
of inhabitants of Leiden, The Netherlands, aged 85 years and older. For cohort ‘87, subjects 
aged 85 years and over on November 1st 1987 were enrolled.99 For cohort ‘97, people of 
exactly 85 years were enrolled between September 1st 1997 and September 1st 1999.100 
There were no inclusion criteria based on health or demographic characteristics.  
 
The Y402H polymorphism is a Single Nucleotide Polymorphism (SNP) in codon 402 of the 
Complement Factor H gene (CFH Y402H) that is strongly associated with ARMD.101-104 The 
polymorphism has also been associated with cardiovascular disease mortality.105 
 
Using the Leiden 85-plus Study population, Mooijaart et al examined the association of the 
CFH Y402H polymorphism with visual acuity and cardiovascular mortality. Mortality risks 
and 95% confidence intervals (CI) were calculated with a sex-adjusted Cox proportional 
hazards model.106  
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In this population, the risk of cardiovascular mortality was significantly increased in the HH 
haplotype compared to the YY haplotype (HR 1.51, CI 1.13-2.03).106 There was also a 
statistically significant association between visual impairment and CFH Y402H genotype 
(VA both eyes HH = 0.66 (0.62-0.69); HY = 0.63 (0.60-0.66); YY 0.58 (0.52-0.63) p = 
0.020) There was no statistically significant association of the CFH Y402H polymorphism 
with any cardiovascular risk factor (Male sex, diabetes, smoking, cholesterol, triglycerides 
and BMI). This study did not directly report an association between visual impairment or 
ARMD and mortality.106 
 
The MRC trial of assessment and management of older people in the community reported no 
association between ARMD and cardiovascular mortality after multivariable adjustment in 
persons aged 75 years or older (RR 1.03, CI 0.72-1.45).67 There was a significant association 
between persons with an unknown cause of visual impairment and cardiovascular disease 
(RR 1.81, CI 1.17-2.78).67 This may have led to an underestimation of the association 
between ARMD and cardiovascular mortality in this study. 
 
In the Copenhagen City Eye Study, death from respiratory conditions that included 
pulmonary disease caused by cardiac insufficiency was significantly higher in women with 
early and late ARM than in women without ARM at baseline (32% (28 of 87) vs. 19% (20 of 
105), P = 0.045).68 However, women without ARM at baseline were more likely to have died 
from ischemic heart disease or stroke than women with early and late ARM (50% (52 of 105) 
vs. 32% (28 of 87), P = 0.019). There was no association between ARMD and cardiovascular 
mortality in the male participants.68 
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Age Related Macular Degeneration and Cancer 
The Age-Related Macular Degeneration and Cancer Mortality study, using data from the 
ARIC study population86 reported an association between the 10 year risk of cancer mortality 
and ARMD after multivariable adjustment (Early ARMD RR 1.68, CI 1.03-2.73).107 This 
association was larger in African American persons (RR 3.93, CI 1.67-9.22) and not 
significant in white persons (RR 1.28 CI 0.71-2.32). In African American persons, there was 
a statistically significant increased risk of lung cancer death (RR 5.28, CI 1.52-18.40). 
Associations between ARMD and lung cancer death were not statistically significant for 
white persons or the population as a whole.107 In this same population there was no 
association between ARMD and cardiovascular mortality.85 
 
There were no associations with ARMD and cancer-related mortality in the MRC trial of 
assessment and management of older people in the community.67 There were no significant 
associations between ARMD and cancer mortality in the BDES.61  
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Glaucoma and Cause-Specific Mortality 
Glaucoma and Cardiovascular Disease 
The United States NHIS found an association between baseline glaucoma and seven-year 
cardiovascular mortality.87 Lee et al reported an increased risk of cardiovascular disease 
mortality for participants with reported glaucoma. The increased risk was present regardless 
of visual impairment status (without VI (HR 1.31, CI 1.11-1.55); with VI (HR 1.53, CI 1.15-
2.05).87 
 
The BMES reported a significant association between glaucoma and nine-year cardiovascular 
mortality in participants younger than 75 years with baseline open angle glaucoma.91 After 
multivariate adjustment, the increased cardiovascular mortality risk in glaucoma patients 
aged <75 years was RR 2.78 (CI 1.20-6.47). Further stratified analyses showed that 
cardiovascular mortality was higher among those with glaucoma diagnosed before baseline 
(RR 1.85, CI 1.12-3.04). An even greater risk of cardiovascular mortality was associated with 
glaucoma diagnosis before baseline and treatment with topical timolol (RR 2.14, CI 1.18-
3.89).91 
 
While the Barbados Eye Study found no statistically significant association between baseline 
open angle glaucoma and all-cause nine-year mortality, it did report an association with 
cardiovascular mortality.89 The association between baseline diagnosed OAG in all 
participants and cardiovascular mortality was not statistically significant (RR 1.38, CI 0.97-
1.98). The association was significant in participants using timolol for IOP control (RR 1.91, 
CI 1.04-3.50). In persons with elevated IOP (>21mm Hg) at baseline (ocular hypertension 
and diagnosed glaucoma combined) there was a statistically significant association with 
cardiovascular death (RR 1.02, CI 1.00-1.04). The association between baseline ocular 
100 
 
hypertension and cardiovascular mortality was not statistically significantly (RR 1.28, CI 
0.99-1.65).89  
 
The WESDR found no associations between any glaucoma, open angle glaucoma and 
rubeotic glaucoma with 16-year cardiovascular mortality risk after multivariable 
adjustment.70 
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Glaucoma and Cancer 
Lee et al reported an association between baseline glaucoma and seven year cancer-related 
mortality in data drawn from the United States NHIS.87 The risk was increased only in 
participants with reported glaucoma but without reported visual impairment (HR 1.57, CI 
1.25-1.98). Significantly, this association was stronger when the mortality analysis was 
restricted to cancers amenable to early screening, including breast, cervical, colon, and 
prostate cancer (HR 1.99, CI 1.41-2.81).87 
 
There were no significant associations between glaucoma and cancer mortality in the 
BDES.61 There were no significant associations between glaucoma and cancer mortality in 
the BMES.91 
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Diabetic Retinopathy and Cause-Specific Mortality 
Diabetic Retinopathy and Cardiovascular Disease 
The BDES reported an association between increasing severity of diabetic retinopathy with 
increased risk of heart disease related mortality after multivariable adjustment.61 
 
The BMES reported an association between any retinopathy at baseline and 12 year coronary 
heart disease mortality risk after adjusting for cardiovascular risk factors, both in persons 
with diabetes and without diabetes (HR 2.21, CI 1.20-4.05 and HR 1.33, CI 1.02-1.83 
respectively).108 The presence of moderate retinopathy at baseline predicted a greater risk of 
cardiovascular death than any retinopathy (HR 6.68, CI 2.24-20.0 and HR 2.29, CI 1.10-4.76 
in persons with and without diabetes respectively).108 
 
The WESDR authors reported a significant increase in 20-year cardiovascular mortality risk 
with increasing severity of diabetic retinopathy after multivariable adjustment (HR 1.3, CI 
1.1-1.5 per step increase in severity).95 This study also reported an association between 
CSME with increased risk of mortality due to ischaemic heart disease in participants 
diagnosed with diabetes after 30 years old and who were taking insulin after multivariable 
adjustment (HR 1.58, CI 1.07-2.35).96 An association between CSME and increased all-cause 
mortality risk after age and sex adjustment in participants of this cohort became 
nonsignificant after multivariable adjustment.96 There was no significant association between 
CSME and heart disease related mortality in participants diagnosed with diabetes before the 
age of 30 years old, nor in participants not taking insulin and diagnosed with diabetes after 
the age of 30 years after multivariable adjustment.96 In addition, CSME was not significantly 
associated with stroke mortality in this cohort.96  
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A Finnish population of persons with visual impairment caused by diabetic retinopathy (DR) 
were reported to have a higher rate of cardiovascular mortality, when compared to an age and 
sex matched control group without diabetes, over a period of 4 years (OR 5.6, CI 2.1-19).98  
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Diabetic Retinopathy and Cancer 
There were no significant associations between DR and cancer mortality in the BDES.61 
There were no significant associations between DR and cancer death in the WESDR 
population study of diabetics.70 
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Summary 
The Prevalence of Visual Impairment 
Visual impairment is a disability with high prevalence and significant negative impacts on the 
lives of persons in Australia and throughout the world. The global burden of BCVA <6/18 is 
estimated to be 161 million persons9,10 including 297,800 Australians with BCVA < 6/12.12 
The number of persons with low vision in Australia is projected to increase to 800,000 by 
2020.12  
 
The burden of visual impairment is not uniformly distributed. A higher prevalence is 
associated with older age,1-5,8 female sex,1-3,5,8,9 lower socioeconomic status,4,6,15-17 lower 
education level, 4,6,15-17,7 minority race6,16,18,19 and living in an underdeveloped nation7,9. A 
larger proportion of visual impairment is due to potentially modifiable or treatable causes 
such as cataract, diabetic retinopathy and glaucoma in persons of lower socioeconomic status, 
lower education level or living in an underdeveloped nation.4,7,15,16,18,19 
 
The Associations Between Visual Impairment and Morbidity  
Visual impairment has significant negative associations with function, independence, 
morbidity and mortality. Persons with visual impairment were significantly more likely to 
report lower self-rated health.20-23 This reported association appears greater in persons of 
younger age and female sex.20-22 The presence of visual impairment significantly negatively 
impacts measures of HRQOL,27,29,30,33 VRQOL,29,31,33 ADL,37,41,42 IADL37,41,42 and vision 
related functional tasks.35,36 Persons with visual impairment, were reported to have increased 
numbers of restricted activity days, bed days, doctors’ visits and hospital admissions.22  
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Visually impaired persons were more likely to have or subsequently develop mobility 
problems,43,46 use walking aids46 and were less likely to improve their mobility over time.43 
Visual impairment increases the risk of falls44,46 and fractures,46 including hip fractures.45,47-49 
The association between hip fractures and VI increases with age45 and level of visual 
impairment.48 The majority of the principal causes of visual impairment associated with hip 
fractures may be potentially modifiable and associated with social deprivation.49 Persons with 
visual impairment were reported more likely to be placed into nursing homes,46 and to be 
depressed.50,53,55 
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The Associations Between Visual Impairment and Mortality 
All-Cause Visual Impairment and Mortality 
The association between all-cause VI and all-cause mortality after age and sex adjustment 
was consistently reported statistically significant in the included studies56-62,64,65,67,70 with the 
exception of the Copenhagen Eye Study.68 The majority of these studies report that statistical 
significance was attenuated, but not eliminated, by multivariable adjustment. 56,57,59,62,64,65,67,70 
Others reported statistical significance was lost after multivariable adjustment.57,58,60 In the 
BDES and BMES, the associations were reported as both significant and non-significant 
depending on the number of years until follow up,56,57,60,61 age stratification56,57,60,61 and 
confounder adjustment.56,57,60  
 
In studies that compared levels of VI, greater VI was associated with higher mortality 
risk.65,67,70 Conflicting results regarding sex, VI and the association with mortality were 
reported with some finding increased risk in women59,65 and others in men.61 Studies that 
stratified age found the presence of VI at a younger age was associated with increased risk of 
mortality when compared to VI in older age groups.57,61 Cohorts of older mean age or shorter 
duration follow up were less likely to report statistical significance after multivariable 
adjustment.56-62,64,65,67,68,70  
 
Studies differ by definition of visual impairment, mean age, age range, duration of follow up 
and confounding variables adjusted for.56-59,61,62,64,65,67,68,70 Visual impairment was reported to 
be independently associated with many of the confounding variables associated with 
mortality and corrected for in these studies.20,50,67,84,106,109-114 Correcting for these covariates 
using traditional regression techniques may underestimate the total effect of visual 
impairment on mortality.115 
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All-cause visual impairment is associated with statistically significant increased risk of 
cardiovascular cause of death in some studies.59,70 Other studies reported no association 
between all-cause visual impairment and cardiovascular mortality.56,57,61 Women with visual 
impairment may be at higher risk of cardiovascular death.59 
 
All-cause visual impairment was not associated with cancer-related mortality in any of the 
included studies that examined this association except the BMES, which found an association 
between VI and lower cancer-related mortality risk.56,57,59,61,64,67,70 
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Cataract and Mortality 
In the studies reviewed that examined associations between previous cataract surgery and 
subsequent mortality, all reported increased mortality risk after multivariable adjustment 
64,71,72,75 except the BMES.56 One study of persons with baseline cataract found an increased 
risk of 6 year mortality that was significantly attenuated in persons who had undergone 
cataract surgery during the follow up period when compared to persons with cataract who did 
not elect to undergo surgery and with persons without baseline cataract.74 Cataract surgery at 
a younger age was associated with increased risk of mortality when compared to cataract 
surgery at older ages.71,73  
 
The presence of cataract was associated with increased all-cause mortality risk in 
most56,57,60,61,64,74,77,84 but not all included studies.62,68 
 
The mortality risk associated with the presence of cataract or previous cataract surgery may 
be sex-dependent with two reviewed studies showing increased risk in women compared to 
men.71,77 The BDES reported the increased risk of mortality associated with baseline cataract 
was higher in women after five years follow-up but higher in men after 13 years follow-
up.60,61 One study reported no sex difference in the association between all-cause mortality 
and the presence of cataract.73 The remaining studies did not report a difference in mortality 
risk between the sexes.56,57,64,68,72,74,75,84 
 
The reported associations between the morphology of baseline cataract and all-cause 
mortality were inconsistent after multivariable adjustment. In the BDES 5 year follow up, 
significant associations were reported between nuclear sclerosis and all-cause mortality but 
not between cortical or subcapsular cataract and all-cause mortality.60 At 13 years follow up, 
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the association between nuclear sclerosis and all-cause mortality was not significant, but the 
association between cortical cataract and all-cause mortality was.61 The BMES reported 
significant associations with nuclear, cortical and subcapsular cataract at 7 and 11 years 
follow up.56,57 Of the remaining studies examining morphology, only nuclear sclerosis was 
reported significantly associated with all-cause mortality.64,84 
 
Previous cataract surgery was reported associated with an increased risk of cardiovascular 
mortality in women after multivariable adjustment.75 In another study, all three morphologies 
of cataract were reported associated with cardiovascular mortality in nondiabetic women, but 
not men, after adjustment for age.77 The risk of 11-year vascular mortality in the BMES 
population was reported to be increased in participants with any cataract, nuclear and PSC 
after multivariable adjustment.57 This risk was not significant seven years from baseline.56 
 
The BDES found an increased risk of 13-year mortality due to stroke in participants with 
baseline nuclear sclerosis that increased with increasing severity of the cataract but the 
association with heart disease was not significant after multivariable adjustment.61 The 
Barbados Eye Study reported no significant increased risk of cardiovascular mortality in 
participants with baseline cataract after multivariable adjustment.84 The AREDS study 
reported no statistically significant increased risk of cardiovascular mortality and baseline 
presence of nuclear sclerosis, cortical or posterior subcapsular cataract or previous cataract 
surgery and cardiovascular mortality.64 
 
A significant association between ≥ grade 4 nuclear sclerosis or previous cataract surgery and 
cancer-related mortality was reported by the AREDS study.64 In contrast the BMES reported 
lower mortality risk (p < 0.001) in participants with cataract at 11 years from baseline.57 
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Other studies examining cancer-related death reported no significant associations between 
baseline cataract and cancer-related mortality.67,77,84 
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Age Related Macular Degeneration and Mortality 
The association between ARMD and all-cause mortality after multivariable adjustment was 
inconsistently reported. Of the seven studies reviewed that examined this association, only 2 
reported a significant increase in all-cause mortality in persons with baseline age related 
macular degeneration.56,57,60,62,64,67,68,85  
 
Younger persons with ARMD may be at higher risk of all-cause mortality.57 The BMES 
reported no significant association between ARMD and all-cause mortality overall at 5 and 
11 years from baseline. After age stratification, BMES participants younger than 75 years old 
were reported to have increased risk of all-cause mortality at 11 years from baseline.57 
Women with ARMD may have higher mortality risk.68 
 
The risk of cardiovascular mortality was reported increased in BMES participants younger 
than 75 years with baseline ARMD57 and in the AREDS after multivariable adjustment.64 The 
reported risk increased with increasing severity of baseline ARMD in two studies.57,64 The 
association between ARMD and cardiovascular mortality became non-significant after 
adjustment for baseline fibrinogen level, triglyceride level and disability in walking in the 
BMES cohort.57 The ARIC study reported ARMD was associated with higher risk of 
cardiovascular events but not mortality.85 Age related macular degeneration was not 
associated with cardiovascular mortality in the Copenhagen City Eye Study.68 
 
The CFH Y402H polymorphism may offer a biologically plausible cause for excess 
cardiovascular risk in persons with ARMD after adjustment for cardiovascular risk factors.106 
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One of the three included studies that examined the association between baseline ARMD and 
cancer-related mortality reported a statistically significant increased risk of cancer-related 
death after multivariable adjustment.107 In this population, there were no significant 
associations reported between ARMD and cardiovascular mortality after multivariable 
adjustment.85 The remaining two studies that examined the association between cancer-
related mortality and ARMD reported no significant association.61,67 
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Glaucoma and Mortality 
Ten of the reviewed studies examined the association between glaucoma and mortality. A 
significant association between baseline glaucoma and increased all-cause mortality after 
multivariable adjustment was reported in only one of these studies.87 The remaining 9 studies 
reported no significant association between baseline glaucoma and all-cause mortality after 
multivariable adjustment.56,60-62,70,88-91  
 
Combined high intraocular (>21mmHg) or diagnosed glaucoma at baseline was found 
statistically significantly associated with increased all-cause mortality in the Barbados Eye 
Study.89 The Framingham Eye Study, using a definition of high intraocular pressure > 
25mmHg, found no association between combined baseline glaucoma diagnosis or high 
intraocular pressure and all-cause mortality.88  
 
The Barbados Eye Study reported a statistically significant association in persons with 
elevated intraocular pressure or diagnosed glaucoma at baseline with an increased risk of 
cardiovascular mortality after multivariable adjustment.89 Glaucoma was found to be 
statistically significantly associated with increased risk of cardiovascular death in the BMES 
and an NHIS study.87,91 This associated risk may be higher in persons using timolol.89,91  
 
Two studies estimated the association of baseline timolol use and mortality, the Barbados Eye 
Study89 and the BMES.91 The Barbados Eye Study reported that participants with baseline 
open angle glaucoma using timolol had a significantly increased risk of all-cause and 
cardiovascular mortality.89 The BMES reported no increased risk of all-cause mortality, but 
did report an increased risk of cardiovascular mortality in participants using timolol for open 
angle glaucoma at baseline.91  
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One of three reviewed studies reported a significant association between baseline glaucoma 
and an increased risk of cancer-related mortality.61,87,91  
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Diabetic Retinopathy and Mortality 
Diabetic retinopathy was reported to be associated with increased risk of all-cause mortality 
in all of the reviewed studies61,94,95,98 with the exception of the BMES56 which found a non-
significant trend towards increased mortality risk (p = 0.06) and the EURODIAB study97 
which found strong associations between diabetic retinopathy and increased all-cause 
mortality risk that became non-significant after adjustment for cardiovascular risk factors. 
Two studies found increasing severity of diabetic retinopathy94,95 and greater VI98 due to 
diabetic retinopathy associated with higher all-cause mortality risk. 
 
Baseline diabetic retinopathy was significantly associated with cardiovascular mortality risk 
in all five studies examining this association.94-96,98,108 Greater severity of diabetic retinopathy 
was associated with higher cardiovascular mortality risk.61,94,95,108 The presence of CSME 
was associated with increased risk of cardiovascular but not all-cause mortality after 
multivariable adjustment.96 
 
There were no significant associations found between baseline DR and cancer.61,70 
 
The associations between mortality risk markers, visual impairment and mortality using 
structural equation modelling have not been examined. This may have lead to overcorrection 
of the associations between visual impairment and mortality.  
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1.2 Auditory Impairment 
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Prevalence 
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The MRC Institute of Hearing Research reported the prevalence of various severities of 
measured hearing impairment, the prevalence of self-reported hearing disability and the 
variation in prevalence of hearing impairment with age, sex, occupational group and 
occupational noise exposure in a population based cohort study in Great Britain.116 
 
The study was a 2-stage sample survey conducted in the cities Cardiff, Glasgow, Nottingham 
and Southampton.116 The first stage was a postal questionnaire. The second consisted of a 
clinical examination, interview and audiological assessment. Participants for the first stage 
comprised a sample of 48,313 persons selected at random from the electoral registers 
compiled in 1980, 1981 and 1984 for the four cities. Participants for the second-stage samples 
(n=2910) were drawn from responders to the first-stage postal questionnaire. All participants 
tested underwent an audiological assessment, a clinical interview concerning hearing and 
general health and otoscopic examination. Attendance rate was 42% of all people sampled for 
stage.116  
 
Audiological assessment was performed in sound-attenuating booths, conforming to ISO/DIS 
825318 for measurement of air conduction thresholds of 0 decibels hearing level (dBHL).116 
Air-conduction thresholds were obtained at 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 kHz. The analysis 
at stage 2 was restricted to subjects in the age-range 18-80 years.116 
 
Self-reported hearing disability was estimated from the stage 1 questionnaire and was 
associated with objectively measured hearing loss.116 Overall 26% of adults report great 
difficulty hearing speech in noise. These participants on average had a 25 dBHL impairment 
in their better ear (averaged for the frequencies 0.5, 1, 2, 4 kHz). Over 3% reported moderate 
or worse bilateral difficulty in quiet. These participants had an average of 45 dBHL HI in the 
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better ear. Overall 16% of persons aged 17-80 years had a >25 dBHL, 4% a ≥ 45 dBHL and 
1% a ≥ 65 dBHL impairment in both ears.116  
 
The prevalence of HI increased significantly with increasing age, male sex, manual 
occupation and occupational noise exposure > 90 dBALeq (time weighted average of the 
level of sound in decibels on scale A).116 The prevalence of hearing impairment in the better 
ear doubled for each ten-year age band. There was no significant association between 
occupational noise exposure of 81-90 dBALeq.116 
 
The Veneto Study is a random sample of 2700 noninstitutionalized persons aged 65 years and 
older, residing in the community in nine defined geographic areas of the Veneto region in 
northeast Italy on May 1, 1989.117 Five of these centres are rural, and four are urban. Eligible 
individuals were identified from the resident lists maintained by the municipalities. Random 
samples were taken from each of five age strata (65-69, 70-74, 75-79, 80-84, 85+ years). 
Eighty-nine percent (n = 2398) of eligible persons participated in the study. Participants were 
administered a questionnaire and a brief examination in their home. Self-reported assessment 
of Hearing Impairment included rate self-reported hearing impairment both at home (seven 
questions) and in a social environment (seven questions). Hearing impairment was assessed 
by speech intelligibility testing through speech audiometry using standard audiometric head 
phones (TDH 39) and a Hi-Fi portable tape voice recording set at 70 dB of sound pressure 
level (dBSPL) intensity. Intelligibility was indicated by the percentage of items repeated 
correctly. Hearing impairment was defined as intelligibility ≤75%.117 
 
Four single forward stepwise logistic regression analyses were performed to identify the 
association of self-reported hearing impairment: at home, in a social environment, at home or 
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in a social environment, and hearing impairment assessed by speech audiometry with 
sociodemographic characteristics (sex, age, level of education), mental and physical status 
indicators (cognitive impairment, depressive symptomatology, ADL disability, mobility 
disability, and self-rated health), health behaviour (alcohol use), and all medical conditions  
(arthritis, diabetes, hypertension, chronic respiratory disease, stroke, heart disease, kidney 
diseases, Parkinsonism, and cancer).117 All analyses were performed using SAS procedures. 
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In the Veneto study, speech audiometry testing detected a higher prevalence of hearing 
impairment than self-reporting by questionnaire.117 The prevalence of self-reported hearing 
impairment at home was 8.1% and 7.4% and in a social environment 11.1% and 9.3%, in 
men and women respectively. The prevalence of hearing impairment assessed by speech 
audiometry was 19% in both sexes.117 
 
Wilson et al reported the prevalence of hearing impairment, and the major demographic 
factors that influence its prevalence, in a representative South Australian adult population 
aged ≥ 15 years.119 This study used a 2 stage sample design. Stage 1 involved random 
sampling of persons aged ≥ 15 years from South Australian households using Australian 
Bureau of Statistics Census collectors’ districts as the sampling frame. The bi-annual South 
Australian Health Omnibus Survey (SAHOS) was then administered to the entire study 
cohort of 9027 persons over three consecutive SAHOS periods. Self-reported hearing 
impairment was defined as answering yes to either of the three following questions; Do you 
have trouble hearing what people say to you in a quiet room (a) when they speak loudly to 
you?; (b) if they speak normally to you?; (c) if they whisper to you? Audiological assessment 
was performed in sound-attenuated booths confirming to Australian Standard 1269-1983. 
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Cerumen that prevented view of the tympanic membrane was removed before audiological 
testing. Air conduction thresholds were obtained at 0.25, 0.5, 1, 2, 3, 4, 6 and 8 kHz. Of 1378 
(15.3%) persons who self-reported hearing impairment, 689 (50%) completed stage 2, the 
audiological examination. Of those reporting no hearing impairment, 300 were asked and 237 
(79%) completed the audiological examination assessed. Due to the complex recruiting 
process reweighting was required so that the data could be directly compared to the British 
National Study of Hearing data.116,119 The age range that allowed direct comparison was 15-
50 years, 51-60 years, 61-70 years and 71+ years. Variance estimates were provided by the 
ultimate cluster variance estimator. Logistic regression models were used to estimate ORs 
and 95% CIs. Occupation was classified using the Australian Bureau of Statistics Standard 
Classification of Occupations (ASCO). 119,120  
 
Wilson et al reported the prevalence of hearing impairment at ≥ 25 dB Hearing Threshold 
Level (dBHTL) in this South Australian population to be 16.6% in the better ear and 22.2% 
in the worse ear to be.119 The self-reported prevalence was 15.3%. While this did not differ 
statistically from the measured prevalence of 16.6% in the better ear, the false positive rate 
for self-reported hearing impairment was 46% and the false negative rate 17%. The 
prevalence of hearing impairment increased significantly with age, approximately 
quadrupling for every 10 year age band in persons older than 50 years. The OR for the risk of 
≥ 25 dBHTL in persons ≥ 71 years was 123.9, p = 0.01 when compared to the risk of hearing 
impairment in persons ≤ 50 years of age. For ≥ 45 dBHTL, the risk was OR, 369.3; p = 0.01 
for the same age comparison. There was also a significant sex difference in the prevalence of 
hearing impairment in this population. The risk of being hearing impaired was 70% higher in 
males compared to females (OR, 1.7; P = 0.01) and increased with time exposed to noise. 
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There was no statistically significant association between risk of hearing impairment and 
socioeconomic status.119 
 
The Epidemiology of Hearing Loss Study (EHLS) is a population-based study designed to 
measure the prevalence of hearing loss in adults aged 48-92 years, residing in Beaver Dam, 
Wisconsin.121 To identify eligible participants aged 43-84 years, a private census was 
conducted during 1987-1988 of the township of Beaver Dam. This cohort was subsequently 
invited to participate in the Beaver Dam Eye Study. Of the 5,924 eligible people, 4,926 (83 
percent) participated in the eye examination phase (1988- 1990). The hearing study occurred 
during the five years follow up visit for the BDES. Participants alive as of March 1, 1993, 
were eligible for the hearing study (n = 4,541). Of those eligible, 3,753 (82.6 percent) 
participated in the hearing study. The hearing examination included an otoscopic 
examination, screening tympanogram and pure-tone air- and bone-conduction audiometry. 
Audiometric testing was conducted according to the guidelines of the American Speech-
Language- Hearing Association using sound-treated booths. Pure-tone air-conduction 
thresholds were obtained for each ear at 0.25, 0.5, 1, 2, 3, 4, 6, and 8 kHz. A questionnaire 
was administered via interview and included ear and hearing-related medical history, noise 
exposure and self-reported hearing function. Questionnaire data on socioeconomic status, 
medical history, lifestyle factors, and medication use were obtained as part of the Beaver 
Dam Eye Study examination.121  
 
The presence of a hearing loss was defined as a pure-tone average of thresholds at 0.5, 1, 2 
and 4 kHz greater than 25 dB of hearing loss in the worse ear. Severity of hearing loss was 
classified as mild (>25 and ≤40 dB of hearing loss), moderate (>40 and ≤60 dB of hearing 
loss), or marked (>60 dB of hearing loss).121 The average age of participants was 65.8 years. 
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Fifty-eight percent of participants were female. The participant group was compared with 
1990 Census data for US non-Hispanic whites and was similar to all US non-Hispanic whites 
in age and sex distributions, but less likely to report high household incomes. Analyses were 
conducted using the 1990 SAS version 6.09 software (SAS Institute, Inc., Cary, North 
Carolina). Univariate analyses used the chi-square test of association for categorical 
variables, Mantel-Haenszel test of trend for ordinal data and t tests of mean differences for 
continuous data. Logistic regression was used to evaluate the odds of having a hearing loss 
associated with age, sex, and socioeconomic factors.121 
 
The overall prevalence of hearing loss in this population was 45.9%.121 The odds of hearing 
loss increased with age (OR 1.88 for 5 years, Cl 1.80-1.97). The prevalence of hearing loss 
was 90% in participants > 80 years of age compared to 21% in persons aged 48-59 years old. 
The odds of hearing loss were greater in men (OR 4.42, Cl 3.73-5.24). The greater odds of 
hearing loss in males remained statistically significant after adjusting for age, education, 
noise exposure, and occupation (OR 3.65, CI 2.97-4.49). Persons with occupational noise 
exposure had an increased likelihood of hearing loss (OR 1.31, CI 1.10-1.56).121 
 
The Blue Mountains Hearing Study (BMHS) is a population-based survey of age-related 
hearing loss in a representative older Australian community.122 The BMHS invited 
participants who attended the second cross-sectional survey of the Blue Mountains Eye Study 
(BMES 2). Persons who moved into the study area or study age group were identified by a 
repeat door-to door census in 1999 and were invited to participate. The BMHS was 
conducted during 1997 to 2000. The hearing questionnaire and examinations for the Blue 
Mountains Hearing Study were identical to those described for BMES 2 onwards. During 
1992 through 1994, 3654 participants 49 years or older were examined (82.4% participation 
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rate). Surviving baseline participants were invited to attend 5- and 10-year follow-up 
examinations, at which 2335 (75.1% of survivors; 543 had died) and 952 (75.6% of 
survivors; 1103 had died) participants were reexamined, respectively. During 1997 through 
2000, 2956 persons 50 years or older had audiometric testing performed.122  
 
A questionnaire eliciting medical history and information about occupational noise exposure, 
hearing and socioeconomic and lifestyle factors was administered to all participants by 
interview.122 An audiologist asked additional questions including the history of any self-
perceived hearing problem, including its severity, onset, and duration. Pure-tone audiometry 
at both visits was performed by audiologists in sound-treated booths. Hearing impairment 
was determined as the pure-tone average (PTA) of audiometric hearing thresholds at 0.5, 1, 2, 
and 4 kHz (PTA0.5-4.0kHz). Hearing loss was defined as; (a) any hearing loss = PTA 0.5-
4.0kHz > 25 dB HL (hearing level); (b) moderate to severe hearing loss = PTA > 40 dB HL 
in the better ear.122 
 
Of the 2956 participants, detailed audiometric data were available for 2940 subjects. Any 
level of hearing loss was present in 33.0% of participants.122 Hearing loss was more prevalent 
in men for each decade younger than 80 years (age adjusted OR 1.7, CI 1.4- 2.0). The 
prevalence of any hearing loss doubled for each age decade (OR 3.5, CI 3.1-3.9). The odds of 
hearing loss for persons aged > 80 years was 50 times greater than the odds in persons aged 
50-59 years (OR 50.7, CI 33.2-78.9). The prevalence of any hearing loss in persons aged 60 -
69 years was 28.7% in men and 17.0% in women. History of working in a noisy environment 
was associated with a 70% increased likelihood of any hearing loss (OR 1.7, CI 1.3-2.1) and 
a 90% increased likelihood of moderate to severe hearing loss (OR 1.9, CI 1.3-2.6).122 
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The prevalence of hearing loss in the Framingham Heart Study Cohort123 has been reported124 
The Framingham Heart Study is a prospective investigation of risk factors leading to the 
development of cardiovascular disease.123 The study population is located in Framingham, 
Massachusetts. The study included biennial physical examinations and extensive history 
taking for each subject. Six thousand and fifteen persons aged 30 to 59 were selected to 
participate. During the fifteenth cycle (exam 15) of examinations, from April 1978 to October 
1979, a hearing study was conducted to report the hearing status of the cohort and assess 
associations between hearing loss and cardiovascular risk factors.124 
 
A total of 2351 of the 3510 persons in the cohort known to be alive received a hearing 
examination, yielding a response rate of 89.26%.124 After exclusions, results from 2293 
hearing study participants were used for data analysis (935 men aged 58 to 88 (mean age. 68) 
and 1358 women aged 57 to 89 (mean age. 69.1). A certified audiologist obtained a hearing 
history from each subject and performed an otoscopic examination. Pure-tone air conduction 
thresholds for eight frequencies, from 0.25 to 8 kHz were measured using a sound-treated 
booth. Hearing loss was defined as a threshold level greater than 20 dB above audiometric 
zero for at least one frequency from 0.5 to 4 kHz. A logistic regression model was used to 
determine risk factors associated with hearing loss in the better ear.124 
 
In this population of persons aged 57-89 years old, the prevalence of hearing loss was 
estimated to be 83%.124 The prevalence of hearing loss was 94% in men and 76% in women. 
The risk factors for hearing loss in this population were age, sex, illness, family history of 
hearing loss, Meniere's disease, and noise exposure.124 
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Table 1.7 lists the reported overall prevalence of HI for the summarised studies that defined 
hearing impairment as >25 dBHL.  
 
7 Table 1.7 Summary of the reported overall prevalence of objective hearing impairment in 
studies defining hearing impairment as >25 decibels hearing level (dBHL). 
Study Participant Age 
(Years) 
Hearing Impairment 
(%) 
MRC a 17 – 80 16† 
 
SAHOS b  ≥15 17† 
22‡ 
 
EHLS c 48 – 92 45‡ 
 
BMHS d ≥49 33† 
a Medical Research Council Hearing Research study116  
b South Australian Health Omnibus Survey119 
c Epidemiology of Hearing Loss Study121 
d Blue Mountains Hearing Study122 
† In the better ear 
‡ In the worse ear 
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The Associations Between Auditory Impairment Morbidity 
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Auditory Impairment, Self-rated-health and Cognitive Impairment 
The Veneto Study117 examined the associations between hearing impairment, and SRH, mini 
mental state exam (MMSE) and chronic systemic disease that could impair quality of life.125 
Martini et al reported that persons with hearing impairment were twice as likely to report 
poor self-rated health. A MMSE score < 24 was associated with a higher prevalence of 
hearing impairment.125 
 
The Alameda County Study is a longitudinal study of factors related to health and mortality 
The study began in 1965 by enrolling 6,928 persons aged 16 to 94 originally selecting 
participants by a random household survey in Alameda County, California.126 Data collection 
was by mailed questionnaire supplemented by telephone and in-person interviews for 
participants unable to complete the questionnaires. Survivors were resurveyed in 1974, 1983, 
1994, and 1995. Response rates for these follow-up surveys were 85%, 87%, 93%, and 97%, 
respectively. Eligibility for the analyses of hearing impairment included the 2,504 
participants aged 50 and older in 1994 who completed both the 1994 and 1995 
questionnaires. After exclusions, the total remaining was 2,461 persons. Hearing Impairment 
was assessed by self-report. Participants were asked in 1994 how much difficulty they had 
(even with a hearing aid) hearing and understanding words in a normal conversation, hearing 
words clearly over the telephone, and hearing well enough to carry on a conversation in a 
noisy room. Responses were scored according to level of difficulty: a great deal (3), some (2), 
a little (1), or none (0) and summed. Hearing impairment was divided into three categories: 
no HI (score of 0), a little HI (score of 1-3), and moderate or more HI (score of 4 or higher). 
Outcomes were dichotomized for logistic regression analysis. Separate logistic regression 
models were performed for each functional outcome. Each 1995 outcome was regressed on 
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age, gender, education, chronic conditions, and hearing impairment with the two levels of 
1994 HI coded as indicator variables; the reference category was no HI.126 
 
The Alameda County Study found no association between self-rated health and self-reported 
HI (little hearing impairment OR 1.20, CI 0.87-1.65; moderate or more hearing impairment 
OR 1.39, CI 0.97-2.00).126 
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Auditory Impairment and Measures of Function and Health Related Quality of Life 
The EHLS reported the associations between hearing loss and health related quality of life 
(HQORL) using the Short Form 36 Health Survey (SF-36).127 Severity of hearing loss was 
significantly associated with decreased function in both the Mental Component Summary 
(MCS) score and the Physical Component Summary (PCS) score of the SF-36, as well as 
with six of the eight individual domain scores. There was no signiﬁcant association between 
severity of hearing loss and the SF-36 domain scores general health or bodily pain, although 
the scores in these domains did decline with increasing hearing loss.127 
 
The BMHS reported the associations of hearing loss with HRQOL using the SF-36.128 After 
multivariable adjustment, participants with bilateral HI had lower SF-36 scores in all 
dimensions when compared with those with unilateral HI (statistically significant in two SF-
36 dimensions (physical functioning and role limitation due physical problems, p ≤ 0.05) or 
those with normal hearing (statistically significant in four SF-36 dimensions (physical 
functioning, social functioning, role limitation due physical problems, role limitations due 
emotional problems and the PCS, p ≤ 0.05). Persons with unilateral HI did not have 
significantly different SF-36 scores when compared to persons with normal hearing. A non-
significant trend for lower SF-36 scores was present in persons with mild bilateral hearing 
loss compared to persons without hearing loss. Poorer scores in the PCS and MCS were 
significantly associated with higher levels of hearing impairment (PCS Ptrend = 0.04; MCS 
Ptrend = 0.003).128 
 
Self-reported hearing loss was significantly associated with HRQOL.128 Persons with self-
reported hearing loss had significantly poorer HRQOL compared to persons without self-
reported hearing loss. The mean PCS was 44.3 (standard error 0.3) in persons with compared 
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to 45.6 (standard error 0.3) in persons without self-reported hearing loss (p = 0.001). 
Similarly, the mean MCS was significantly lower (p = 0.001) in persons with (MCS = 51.5, 
standard error 0.3) compared to persons without self-reported hearing loss (MCS = 53.0, 
standard error 0.3).128 
 
Self-reported hearing disability in older people was reported associated with poorer PCS and 
MCS scores in the SF-12 in another Australian study.129 This study utilised data from the 
2003 Australian Survey of Disability, Ageing, and Carers (n = 43,233), a weighted 
population-based survey providing of self-reported disability and quality of life. Participants 
were aged ≥ 55 years. The study reported that, compared with population norms, hearing 
disability at all levels was associated with poorer physical and mental health scores on the 
SF-12 measure. The effect was more marked with increasing levels of hearing loss.129 
 
The EHLS study reported significant associations between hearing loss and activities of daily 
living (ADLs) and instrumental ADLs (IADLs).127 This study found that individuals with 
moderate to severe hearing loss were more likely than individuals without hearing loss to 
have impaired ADLs and IADLs after multivariable adjustment. (ADL OR 1.54, CI 1.06-
2.24; IADL OR 1.54, CI 1.18-2.00).127  
 
The BMHS also found significant associations between hearing loss and ADLs and 
IADLs.130 The BMHS reported a signiﬁcantly higher proportion of hearing-impaired persons 
had difﬁculties in performing three out of the seven basic ADL (Can you get to places out of 
walking distance; Can you go shopping for groceries or clothes; Can you do your 
housework). Hearing impaired persons were also more likely to report difficulties in 
performing six out of the seven instrumental ADL tasks compared to participants without 
133 
 
hearing impairment. After multivariable adjustment, increasing severity of hearing loss was 
associated with impaired ADL (Ptrend =0.001). Participants with moderate to severe hearing 
loss were almost three times more likely to report difﬁculties with ADL when compared to 
persons without hearing loss. The association between hearing loss and difficulty in 
performing ADL was higher in younger persons with hearing impairment. The association 
was greater with increasing levels of hearing impairment. Participants aged <75 years with 
moderate to severe hearing loss had 8-fold higher odds of difficulty in ADL compared with 
those without hearing loss (OR 8.60, CI 3.12-23.70) after multivariable adjustment. After age 
stratification, significant associations were not observed in participants aged ≥ 75 years.130 
 
The second supplement on ageing (SDOA-II) examined the health, activity, and social 
participation of a US population aged 70 years or older with self-reported vision impairment, 
hearing loss, or both and compared the health and activities of these three groups to those 
without sensory loss.131 Data for the SDOA II was obtained from the 1994 National Health 
Interview Survey (NHIS) core questionnaire, the access to care supplement to the 1994 
NHIS, phase I of the NHIS on disability and phase 2 of the NHIS on disability. A total of 
9447 persons were interviewed. Participants were community dwelling (non-institutionalised) 
adults aged ≥ 70 years.131 
 
In this study, older people with self-reported hearing loss reported greater difficulties in 
various activities, and social roles.131 Persons with hearing loss were significantly more likely 
to report difficulty dressing (OR 1.5, CI 1.3-1.8), bathing (OR 1.4, CI 1.2-1.6), preparing 
meals (OR 1.5, CI 1.2-1.8), using the telephone (OR 3.6, CI 2.8-4.6) and difficulties taking 
medications (OR 1.6, CI 1.2-2.0) and managing money (OR 1.8, CI 1.4-2.3) when compared 
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to persons without HI. Persons with HI were also more likely to be confused (OR 1.4, CI 1.1-
1.8).131 
 
The Alameda County Study found significant associations between both self-reported levels 
of hearing impairment (a little and moderate or more) and higher odds of ADL disability (OR 
1.71, CI 1.22-2.39 and OR 1.85, CI 1.26-2.71 respectively).126 Moderate or more hearing 
impairment was also associated with significantly higher odds of disability in IADL and 
physical performance disability (OR 1.37, CI 1.01-1.86 and OR 1.98, CI 1.38-2.84 
respectively).126 
 
In a prospective study of functional outcomes of 755 subjects presenting for Geriatric 
Assessment at the University of Nebraska Medical Center between January 1986 and 
December 1992, comparisons in mean ADL and IADL scores across mutually exclusive 
groups defined by sensory loss (i.e., no sensory impairment, hearing loss alone, vision loss 
alone, and both hearing and vision loss) were conducted using Bonferonni-adjusted multiple-
comparison tests.132 To determine the relative contributions of vision and hearing loss to 
diminished ADL and IADL function, ordinary least squares (OLS) regression models were 
estimated on ADL and IADL scores.132 
 
In this prospective study, the prevalence of hearing impairment was 64%.132 The mean ADL 
and IADL scores were lower in hearing impaired persons compared with those without 
hearing impairment (19/24 vs. 21/24 (P < .001) and 11/23 vs. 13/23 (P < .001 respectively). 
The association between hearing impairment and IADL was independent of mental status and 
comorbid illness whereas the association with ADL score was not. An OLS regression model 
that included vision, hearing, sex, cognitive status, and comorbid illness accounted for 40% 
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of the explained variance in IADL scores and 31% of the explained variance in ADL scores. 
In this model, all factors except sex were found to be independently related to IADL score. A 
similar model for ADL score found both sex and hearing were not independently related to 
the ADL score. An OLS regression model constructed with only hearing as the explanatory 
variables for ADL and IADL found hearing contributed to 2% of ADL variance and 3% of 
IADL mean score variance.132 
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Auditory Impairment, Mobility, Falls and Fractures 
Hearing impairment was found to be associated with catastrophic decline in mobility in a 
longitudinal cohort study investigating the associations between chronic health conditions, 
psychosocial and environmental factors, and catastrophic decline in mobility of community 
dwelling persons aged ≥ 65 years.133 Data were obtained from a national cross-sectional 
survey of 999 individuals (response rate 68%) aged ≥65 years, representative of British 
households. Of these persons, 789 (79%) agreed to further contact, and 531 (68%) responded 
to the postal questionnaire follow-up survey 12 months later. This represented 36% of the 
original sample. The survey was conducted from July 2000 to February 2001.134 The mean 
age of participants was 73.4 (SD 6.4). Mobility dependency was defined as either needing 
help in doing or being unable to do any of the three ADL items: walk 400 yards; climb up or 
down stairs; and get on a bus. Catastrophic decline in mobility was defined as change from 
independence in all three activities at baseline to needing help or being unable to do at least 
one of the activities at follow-up. Associations with chronic health conditions and socio-
demographic factors were examined individually. After exclusions, 427 individuals who 
reported intact mobility at baseline remained in the analysis. The annual incidence rates of 
catastrophic decline in mobility were calculated. The odds ratios (ORs) for catastrophic 
decline were adjusted for socio-demographic factors and health conditions.133 
 
Ayis et al reported similar annual rates of catastrophic decline for men and women (4.8%, CI 
2.7-8.3 and 4.6%, CI 2.4-8.6 respectively).133 Statistically significant associations were found 
between catastrophic decline and age > 70 years (OR 3.7, CI 1.1-11.8), hearing problems 
(OR 2.8, CI 1.1-7.3) and health deterioration (OR 4.3, CI 1.2-14.7) after multivariable 
adjustment.133 
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The Alameda County Study compared the independent impacts of two levels of self-reported 
hearing impairment on subsequent disability, physical functioning, and social functioning.23 
Outcomes were measured in 1995 and included physical disability outcomes using questions 
concerning physical performance, mobility, and lack of participation in activities. Physical 
performance disability was defined as having a lot of difficulty or needing help with one of 
the following items; pulling or pushing large objects; writing; handling small objects; 
standing up from a chair; getting up from stooping or kneeling; reaching or extending arms 
above the shoulder; lifting or carrying weights over 10 pounds; stooping, crouching or 
kneeling. The category a lot of difficulty was used for the physical performance items as 
many functional middle-aged adults reported a little or some difficulty with one or more of 
these items. Mobility disability was defined as any difficulty walking one-quarter of a mile 
without help or walking up ten steps without resting. Never participating in activities was 
defined as never going out to entertainment, sports events, community, or volunteer activities. 
All 1995 outcomes were adjusted for baseline 1994 values.23 
 
The Alameda County study found no significant association between self-reported hearing 
impairment and mobility in persons with hearing impairment (Mild HI OR 1.21, CI 0.88-1.66 
and ≥ moderate HI OR 1.07, CI 0.72-1.58).23 There was no significant association between 
self-reported hearing impairment and never participating in activities. There was no 
significant association between mild hearing impairment and physical performance (OR 1.12, 
CI 0.8-1.54). There was a significant association between ≥ moderate hearing impairment and 
physical performance (OR, 1.69, CI 1.15-2.48).23  
 
The second supplement on ageing (SDOA-II) reported that older people with self-reported 
hearing loss reported greater difficulties in various mobility associated activities and social 
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roles.131 Persons with hearing loss were significantly more likely to report difficulty in 
walking (OR 1.5, CI 1.3-1.7), inability to walk 10 steps or a quarter mile (OR 1.4, CI 1.2-1.6 
and OR, 1.5, CI 1.3-1.7 respectively), getting outside (OR 1.3, CI 1.1-1.5), buying groceries 
(OR 1.4 CI 1.2-1.6), difficulty in getting into and out of a bed or chair (OR 1.5 CI 1.3-1.8) 
and visiting relatives (OR 1.1, CI 1.0-1.3) when compared to persons without HI.131 There 
were no statistically significant increased odds of difficulties visiting friends, attending, 
church, going to the movies, eating out or getting exercise.131 Self-reported hearing loss was 
associated with an increased risk of falling in the previous 12 months, but not with injury 
from a fall or hip fracture, when compared to persons without HI (OR 1.7, CI 1.5-1.9; OR 
0.9, CI reported not significant; and OR 1.2, CI  0.9-1.5 respectively).131 
 
The Finnish Twin Study on Aging (FITSA), reported significant associations between 
severity of hearing loss and the incidence rate ratio of falls in women aged 63-76 years.135 
The nationwide Finnish Twin Cohort comprises all same-sex twins born in Finland before 
1958 with both co-twins alive in 1975. The FITSA participants were drawn from this 
cohort.136 Invitation to the hearing study was sent to 414 female twin pairs aged 63-76 years 
drawn on the basis of age and zygosity. The final FITSA sample consisted of 103 
monozygotic (MZ) and 114 dizygotic (DZ) twin pairs. After refusals and exclusions 417 
participants were included in the analysis. Audiometric measurements were performed by an 
audiology assistant in a sound-isolated booth using a clinical audiometer. Air conduction 
pure-tone hearing thresholds were measured at the frequencies of 0.125, 0.25, 0.5, 1, 2, 4, and 
8 kHz for each ear separately. Better ear hearing threshold level (BEHL) was defined as a 
mean of the pure-tone air conduction thresholds at 0.5, 1, 2 and 4 kHz. At least mild hearing 
loss was defined as BEHL 0.5-4 kHz ≥ 21 dB.136  
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Clinical examination by a physician and clinical tests on functional capacity and balance 
were performed.136 Postural balance was indicated as a centre of pressure (COP) movement 
in semi-tandem stance. Postural sway was measured and postural stability was recorded for 
20 seconds by physiotherapists. A larger postural balance battery including measurements in 
side-by-side stance with eyes open and closed and tandem stance with eyes open was also 
performed.136 After the completion of the hearing and balance assessments, information on 
falls was gathered for 12 months by the participants marking daily on a calendar whether they 
fell or not.135 During the fall follow-up, three persons died and 12 persons did not return all of 
their calendar pages. Their data were included up to the month their participation ceased. An 
adjusted Wald test was used to compare whether centre of pressure movements and 
proportion of fallers differed between the hearing acuity quartiles. Incidence rate ratios 
(IRRs) for falls were computed from a negative binomial regression model.135 
 
The mean hearing acuity (better ear hearing threshold level at 0.5-4 kHz) for the population 
was 21 dB (standard deviation (SD) 12).135 There were statistically significant increases in 
COP movements in semi tandem stance associated with increasing HI. The means of the COP 
velocity moment from the best to the poorest hearing quartiles increased significantly and 
linearly from 40.7 mm2/s (SD 24.4) to 52.8 mm2/s (SD 32.0) (ptrend = 0.003).135  
 
After one year from baseline, 199 participants had reported 437 falls.135 Age-adjusted 
incidence rate ratios (IRRs) for falls using the best hearing quartile as a reference, increased 
with increasing HI, becoming statistically significant for persons with ≥ third quartile hearing 
impairment (IRR 1.2, CI 0.4-3.8 second quartile; IRR 4.1, CI 1.1-15.6 third quartile; IRR 3.4, 
CI 1.0-11.4 fourth quartile) after age adjustment. Adjustment for COP velocity moment led to 
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the associations becoming non-significant. Twin analyses suggested the association between 
HI and postural balance was not explained by genetic factors.135 
 
The FITSA also examined whether hearing acuity correlated with walking ability and 
whether impaired hearing at baseline predicted self-reported walking difficulties after 3 
years.137 Maximal walking speed was measured over 10 m (m/s). Walking endurance was 
defined as the distance covered in 6 minutes. Difficulty in walking 2 km was assessed by 
self-report. At baseline, women with HI (n=179) had slower maximal walking speed (1.7 +/- 
0.3 m/s vs. 1.8 +/- 0.3 m/s, p = 0.007), lower walking endurance (520 +/- 75 m vs. 536 +/- 75 
m, p = 0.08), and more self-reported major difficulties in walking 2 km (12.8% vs. 5.5%, p = 
0.02) when compared to those without HI. During follow-up, major walking difficulties 
developed for 33 participants. Women with hearing impairment at baseline had twice the age-
adjusted risk for new walking difficulties when compared to those with normal hearing (OR 
2.04, CI 0.96-4.33).137 
 
A prospective study examined the prevalence and the association of HI with rehabilitation 
efficacy in 896 patients following hip fracture.138 Hearing impairment was defined as mean 
decibel level equal to or higher than 60dB in the better of the two ears. Hearing impairment 
was found in 231 (28.5%) of patients admitted for rehabilitation. In univariate analysis, the 
absolute efficacy of rehabilitation was significantly lower in patients in patients with HI 
compared to those without HI (p = 0.002). However, in multivariate analysis the association 
with HI became nonsignificant.138  
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Auditory Impairment and Depression 
The Alameda County Study found significant associations between self-reported moderate or 
more HI and higher odds of depression (OR 2.05, CI 1.37-3.06).126 
 
A community survey, carried out in Northern Italy by the Geriatric Research Group, Brescia, 
examined the associations between quality of life measures and sensory impairment in aged 
individuals living at home.139 A total of 1191 non-institutionalized persons age 70-75 years 
were given a comprehensive QOL questionnaire, free-field voice testing, and Snellen eye 
chart. The study reported that auditory impairment was significantly and independently 
associated with increased risk for depression (OR 1.8, CI 1.1-2.7).139 
 
The Research Team for the Care of the Elderly, at the Welsh National School of Medicine 
reported results from a random sample (40%) of all patients aged ≥ 70 years in a large urban 
general practice in a medium sized town in South Wales.140 The study used trained 
fieldworkers to interview 657 (response rate 96%) in their own homes using a standardised 
interview schedule. Information was sought on hearing difficulty and mental state using 
standardised measures of anxiety, depression, and memory loss. Of the 657 subjects 
interviewed, 33% reported having some difficulty hearing normal conversations and 6% 
reported much difficulty. In this cohort, hearing difficulty was significantly associated with 
both depression and anxiety. These associations became non-significant after adjustment was 
made for physical disability.140 
 
The Longitudinal Aging Study Amsterdam (LASA) is a longitudinal multidisciplinary study 
examining predictors and consequences of changes in autonomy and well-being in the ageing 
population.141 Of 3,805 participants approached, 3,107 (81.7%) took part in LASA at 
142 
 
baseline, including 1,506 men and 1,601 women. The age range at baseline was 55 to 85 
years. Data were gathered by structured interview in the homes of participants by trained 
interviewers. Hearing status was based on self-report. The questions used for the 
determination of hearing impairment were 1. Can you follow a conversation with one person, 
with or without a hearing aid? 2. Can you follow a conversation with four people, with or 
without a hearing aid? 3. Can you use a normal telephone? Answers were given on a 4-point 
scale: 1 = without difficulty; 2 = with some difficulty; 3 = with much difficulty; 4 = no I 
cannot. Scores on the questions were summed. A summed score of 5 or more was defined as 
hearing impairment. The presence of depressive symptoms was measured by using the Dutch 
version of the Centre for Epidemiologic Studies Depression Scale (CES-D). Items were rated 
on a 4-point scale ranging from almost never to almost always, concerning the time in the 
past week. Multiple linear regression analyses were conducted to examine the strength of the 
associations between hearing impairment, the different types of chronic diseases, and the 
psychosocial health status.141 
 
The overall prevalence of self-reported hearing impairment 12.2% (13.8% in men and 10.7 in 
women).141 After multivariable adjustment, hearing impaired elderly reported significantly 
more depressive symptoms, lower self-efficacy and mastery, more feelings of loneliness and 
a smaller social network when compared to persons with normal hearing.141 
 
The Study on Hearing (NL-SH) conducted in The Netherlands, is an ongoing prospective 
cross-sectional cohort study examining the relationship between hearing impairment and 
several domains in life.142 The study is conducted over the Internet. The cohort for the 
reported study consisted of 1511 participants. Participants were invited to participate through 
advertisements and flyers distributed at audiological centres and hearing aid dispensers. The 
143 
 
study examined the association between hearing status and psychosocial health in adults aged 
between 18 and 70 yr. Hearing status was determined using a speech-in-noise screening test 
over the Internet (the National Hearing test). The test uses digit triplets presented against a 
background of masking noise, according to an adaptive procedure. Twenty-three triplets are 
presented. The speech reception threshold corresponds to 50% intelligibility calculated by the 
average signal to noise ratio (SNR) of the last 20 presentations. Self-reported psychosocial 
health was determined by online questionnaire. Baseline data of were analysed using 
regression models.142 
 
After multivariable adjustment for all confounders, significant associations between hearing 
status and distress (b = 0.02, t = 2.16, p = 0.031) and somatization (b = 0.02, t = 3.96, p = 
0.001) were identified.142 The odds for developing moderate or severe depression increased 
by 5% for every dB SNR reduction in hearing (OR 1.05, CI 1.00-1.09). The odds for 
developing severe or very severe loneliness significantly increased by 7% for every dB SNR 
reduction in hearing (OR 1.07, CI 1.02-1.12). The risk for depression was highest in persons 
with poorest hearing (OR 1.05, CI 1.00-1.09). The association between hearing status and 
depression was age dependent. When stratified by age, the association of poor hearing with 
depression was significant only for the 40-49 year old age group after multivariable 
adjustment (OR 1.18, CI 1.08-1.28).142 
 
The Nord-Trøndelag Health Study (HUNT) is a population based study in which all adults in 
24 municipalities of Nord-Trøndelag County, Norway, were invited to take part in a health 
screening survey during the period August 1995 to June 1997.143 The population of 17 of 
these 24 municipalities were invited to the hearing loss study. Participants were aged 20 to 
101 years (mean, 50.2; SD, 17.0) at baseline. The participation rate was 68.7%. Valid 
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audiometry and questionnaire data were available for 50,398 participants. Participation rate 
was less than 50% for subjects <30 years old. The participation rate increased with age to 
approximately 60 years. The participation rate ranged from 75% to 87% for people 50 to 80 
years old.143  
 
Audiometric testing was performed in semi-portable, dismountable sound attenuation booths 
for the standard frequencies 0.25, 0.5, 1, 2, 3, 4, 6, and 8 kHz.143 Three hearing scores were 
computed: a) low-frequency hearing level (0.25-kHz and 0.5-kHz thresholds, averaged over 
frequencies and both ears), b) middle-frequency hearing level (1 kHz and 2 kHz), and c) 
high-frequency hearing level (3 kHz, 4 kHz, 6 kHz, and 8 kHz). Participants completed a 
one-page questionnaire which included ten items from the 25-item Hopkins Symptom 
Checklist (HSCL -25),144,145 four examining symptoms of anxiety, and six examining 
symptoms of depression. Separate scores for anxiety and depression and a global score were 
determined by summing the values (1-4) from each item.143  
 
Regression analyses were performed separately for men and women in the age groups 20 to 
44 years, 45 to 64 years, and older than 64 years. Multiple regression analyses were 
performed using occupational noise, educational level, marital status, and subjectively 
assessed health as covariates. Low, middle, and high-frequency hearing losses were entered 
as (continuous) independent variables. The analyses were run consecutively with anxiety, 
depression, self-esteem, and subjective well-being as dependent variables.143  
 
Low-frequency hearing coefficients were significantly associated with all ten items from the 
25-item Hopkins Symptom (P = < 0.05) except for depression and self-esteem among the 
oldest men and women, and subjective well-being among young and middle aged women.143  
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High-frequency hearing was significantly associated with low self-esteem among young and 
middle-aged women.143 Depressive symptoms and low self-esteem in young and middle aged 
men were significantly increased among subjects with a 50-dB low-frequency hearing 
reduction. The effects of low-frequency hearing loss decreased significantly with age (t ≥ 
2.78; p ≤ .005). Middle and high-frequency hearing level did not affect mental health 
significantly above what could be explained by low-frequency hearing level.143  
 
To assess for confounding, the covariates were entered stepwise into multiple regression 
analyses together with hearing loss.143 Noise and social background did not affect the results. 
Self-reported health decreased the association between hearing loss and the dependent 
variables anxiety, depression, self-esteem, and subjective well-being. After controlling for 
measured hearing loss, self-reported hearing loss was more significantly associated with self-
reported mental health compared to measured hearing loss. This effect increased with age.143 
 
The Veneto Study reported an increased risk of depression in persons with self-reported 
hearing impairment in the home, social environment and in both environments (OR 1.84, CI 
1.2-2.9; OR 2.05, CI 1.4-3.0; OR 2.29, CI 1.5-3.4 respectively).117 The second supplement on 
ageing (SDOA-II) reported no significant association between depression and self-reported 
hearing loss (OR 1.2, CI 0.9-1.5).131 
 
Hearing impairment was reported associated with the wish to die in an Australian 
epidemiological survey of people aged ≥70 years.146 The sample was selected from the 
electoral rolls for the adjacent cities of Canberra and Queanbeyan. At least some interview 
data were obtained from 945 community residents and 100 nursing-home or hostel residents, 
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representing a response rate of 69% for the community residents and 70% for the nursing 
home and hostel residents. Wish to die was assessed by one question: 'In the last two weeks, 
have you felt as if you wanted to die?' If the subject answers 'yes' or 'depends', they are asked: 
'Have you had such thoughts repeatedly?' Those who had repeated thoughts of wanting to die 
were defined as the case group and all other subjects (including those with a transient wish to 
die) as the control group. Data on this question were available from 923 subjects, 868 living 
in the community and 55 in residential care.146  
 
The association between hearing loss and the wish to die was found to be independent of 
depression using multiple logistic regression with HI entered simultaneously as a predictor 
together with the count of depressive symptoms (OR 5.6, CI 2.3-13.9).146 
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Auditory Impairment and Age Related Macular Degeneration 
The Beaver Dam Eye Study examined the association between hearing loss and the presence 
of age related macular degeneration (ARMD).147 Overall, the prevalence of ARMD was 
25.4% and of hearing loss was 45.0% in this population. Both conditions were present in 
15.1%. There was no statistically significant association between early ARMD lesions and 
hearing loss > 25dB. After multivariable adjustment, there was a statistically significant risk 
of hearing loss >25dB in persons with late ARMD (OR 3.17, CI 1.35-7.45).147 
 
The BMES also reported an association between hearing loss and age related macular 
degeneration.148 In this study population there was a significant association between any 
ARMD and the risk of hearing loss > 25 dB (OR 1.5, CI 1.1-2.0) after multivariable 
adjustment compared to persons without ARMD. This association was stronger in persons 
younger than 70 years (OR 2.0, CI 1.0-4.1).148 
 
Complement factor H Y402H is associated with increased risk of age related macular 
degeneration.101-104 This polymorphism has also been found associated with hearing loss in a 
Japanese population.149 Nishio et al conducted a case-control study of 72 persons with sudden 
sensorineural hearing loss (SSNHL) and compared them with 2161 control subjects selected 
randomly from the comprehensive Longitudinal Study of Aging (NILS-LSA).150 Participants 
in the NILS-LSA were selected randomly from resident registrations. The study region is 
located within 30 km of Nagoya University Hospital. Overall, 2161 participants aged 40-79 
years who completed the first-wave examination of NILS-LSA between November 1997 and 
April 2000 and underwent CFH genotype analysis, were randomly selected as controls. The 
odds ratio (OR) for SSNHL risk was determined using the additive-genetic model of CFH 
Y402H polymorphism.  
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In this case control study, the OR for SSNHL in Japanese persons aged 40-79 years risk was 
OR 1.788, CI 1.008-3.172) with no adjustments and OR 1.820, CI 1.025-3.232) after 
adjusting for age and sex.149 SSNHL was also found significantly associated with diabetes but 
not hypertension or dyslipidaemia. After stratification of the cohort into diabetics and 
nondiabetics, the OR for SSNHL risk was significant in persons with diabetes but not in 
persons without diabetes (OR 6.326, CI 1.885-21.22 vs.. OR 1.214, CI 0.581-2.538).149   
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The Associations Between Auditory Impairment, Noise Exposure and Mortality 
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Auditory Impairment and Mortality 
A community survey, carried out in Northern Italy by the Geriatric Research Group, Brescia, 
examined the associations between sensory impairment in aged individuals living at home 
and mortality.151 The cohort was an urban population of 1140 non-institutionalized elderly 
subjects, aged 70-75 years. Baseline information was collected in 1986 through a door-to-
door interview with a standardised questionnaire. Sensory assessment was performed using 
bedside tasks: the whispered voice test for hearing and the Snellen chart for vision. The 
overall mortality rate at 6 years was 25.5%, with a significant sex difference (males = 37.5%; 
females = 19.8%). There was a significant interaction between sex and sensory impairment. 
Bivariate logistic regression showed that hearing deficit was associated with a significant 
increase in mortality risk in men but not women (OR 1.97, CI 1.02-3.77 vs.. OR 0.77, CI 
0.36-1.62). This increase remained significant after controlling for demographic variables and 
physical health status. Multivariate logistic regression showed that the effect of hearing 
deficit on mortality became nonsignificant after controlling for psychosocial parameters 
(mood and social relationships level).151 
 
Barnett et al used US NHIS data from 1990 and 1991 linked with National Death Index data 
for 1990-1995 to examine the association between age of onset of self-reported deafness and 
mortality.152 Deafness was considered present if the participant indicated on the self-rated 
scale (SRS) that they had at least "a lot of trouble hearing" in both ears or at least "a little 
trouble hearing" in their better ear and indicated on the Gallaudet Hearing Scale (GHS) that 
they could not hear or understand any speech. The control group comprised the non-deaf 
adults with hearing problems in the 1990 and 1991 NHIS samples and a 20% random sample 
of adult respondents without hearing problems. Non-deaf adults with hearing problems were 
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defined as those for whom the answer was yes to the question "Do you have a problem 
hearing?" but did not meet the definition of deafness.152 
 
The NHIS data demonstrated that the relative frequencies of the age at onset of hearing loss 
for 2449 deaf adults responding in 1990 and 1991, showed two peaks: one before age 3 and a 
second after age 60.152 The mortality rate was higher for adults with postlingual onset 
deafness, regardless of age group, compared to the control group after adjustment for 
socioeconomic status. (Prelingual OR 0.97, CI 0.58-1.64; Postlingual 19-64 years old OR 
1.32, CI 1.05-1.49; Postlingual >65 years old OR 1.15, CI 1.03-1.27). After adjusting for 
health status, there was no significant relationship between deafness and mortality.152 
 
Lam et al used the US NHIS data to examine the association between reported hearing 
impairment and risk of mortality.153 Mortality linkage with the National Death Index of 
participants from 1986 to 1994 was performed through 1997. Mortality linkage identified 
8949 deaths with an average follow-up of 7.0 years. Hazzard ratios were estimated for the 
entire cohort using both self- and proxy-reported interview results. After multivariable 
adjustment, African American men, but not women, nor white or other-race participants with 
proxy and or self-reported hearing impairment had significantly increased risk of mortality 
(Self- and Proxy-Reported HR 1.31, CI 1.00-1.73; Self-reported HR 1.40, CI 1.00-1.95).153 
 
Feeney et al used data from the longitudinal Statistics Canada National Population Health 
Survey (NPHS) for 1994/95 through 2006/07 to examine the associations between hearing 
impairment and mortality.154 The NPHS is a closed cohort survey of household residents in 
the 10 Canadian provinces, excluding persons living on Indian Reserves and Crown Lands, 
residents of health institutions, Canadian Forces bases, and some remote areas in Ontario and 
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Quebec. Using a stratified, multistage sampling procedure, 17,276 household members were 
randomly selected to be interviewed every two years regarding health status, health service 
utilisation, and sociodemographic data. Deaths up to December 31, 2005, were confirmed 
against the Canadian Vital Statistics Database. Disability in hearing was assessed by the self-
reported level of disability in the HIU3 questionnaire. The Health Utilities Index Mark 3 
(HUI3), includes eight attributes, vision, hearing, speech, ambulation, dexterity, cognition, 
emotion, and pain and discomfort, with five or six levels per attribute that vary from no to 
severe disability.  
 
The levels for hearing are as follows;154 
1 Able to hear what is said in a group conversation with at least three other people, 
without a hearing aid. 
2 Able to hear what is said in a conversation with one other person in a quiet room 
without a hearing aid but requires a hearing aid to hear what is said in a group 
conversation with at least three other people. 
3 Able to hear what is said in a conversation with one other person in a quiet room 
with a hearing aid and able to hear what is said in a group conversation with at 
least three other people, with a hearing aid. 
4 Able to hear what is said in a conversation with one other person in a quiet room, 
without a hearing aid but unable to hear what is said in a group conversation with 
at least three other people even with a hearing aid. 
5 Able to hear what is said in a conversation with one other person in a quiet room 
with a hearing aid but unable to hear what is said in a group conversation with at 
least three other people even with a hearing aid. 
6 Unable to hear at all. 
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This study used HUI3 responses to estimate the association between self-reported hearing 
disability and 12 year mortality.154 Cox proportional hazards regression models were 
performed controlling for standard determinants of health and risk factors for two cohorts: 
those 18 years of age or older at baseline and those 60 years of age or older at baseline.154   
 
The study reported that among other HUI3 attributes, hearing impairment was significantly 
associated with increased mortality risk.154  This risk increased substantially and significantly 
with increasing level of hearing disability in a stepwise manner from level 1 (no disability) to 
level 6 (severe disability). The single-attribute utility score for hearing for the cohort as a 
whole was HR 0.18, CI 0.06-0.57 and for the cohort aged ≥60 was HR 0.14, CI 0.04-0.48.154 
  
A separate Canadian study, the Canadian Study of Health and Aging (CSHA) is a multicentre 
epidemiological study of dementia and other health problems in older Canadians.155 The 
study surveyed 10,263 randomly selected people aged 65 and older across Canada (excluding 
the Northwest and Yukon territories) in 1991. Deaths in the subsequent 5 years were 
determined from death certificates and interviews with the caregivers.156 Data from the 
CSHA found no associations between hearing impairment and mortality after multivariable 
adjustment.155  
 
The BMES reported no statistically significant association between hearing impairment and 
10-year all-cause mortality after multivariable adjustment (HR 1.24, CI 0.99-1.54).157 
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Noise Exposure and Mortality 
Occupational exposure to noise may be associated with increased risk of CVD and death 
from myocardial infarction.158,159 Davies et al identified a cohort of 27,464 blue-collar 
workers from 14 lumber mills in British Columbia who worked at least one year between 
1950 and 1995 and who were followed up over the same period.158 Cumulative noise 
exposure was quantitatively assessed. Vital status was ascertained from the Canadian 
Mortality Database. Standardised mortality ratios were estimated based on the general British 
Columbia population for the years 1950 to 1995. All person-years-at-risk calculations were 
begun one year after first employment. Ninety-five percent confidence intervals for the 
Standardised Mortality Rate (SMR) were estimated assuming the observed effect followed a 
Poisson distribution. Relative risks were estimated using an internal low-exposure group as 
controls. Subgroup analysis compared persons in the cohort employed before and after 
widespread use of hearing protection.158 
 
The mean age at entry into the cohort was 30 years, and mean follow-up period 24 years. 
During the follow-up period, 2510 circulatory disease deaths occurred. The association 
between noise exposure with acute myocardial infarction (AMI) mortality was not significant 
for the cohort as a whole (SMR 1.0, CI 0.97-1.1).158 There was a significant association found 
for persons who worked during the period before hearing protection became widely used 
(SMR 1.1, CI 1.0-1.2). There was also a statistically significant association between duration 
of exposure and cardiovascular mortality. The risk of fatal AMI increased significantly with 
increasing number of years of occupational noise exposure (85 dB(A) ptrend = 0.003; 90 dB(A) 
ptrend = 0.004; 95 dB(A) ptrend = 0.001). Persons working for > 19 years at noise levels ≥85 dB 
had the highest statistically significant risk of mortality (85dB(A) SMR 4.0, CI 1.8-9.3; 90 
dB(A) SMR 2.0, CI 1.0-3.7; 95dB(A) SMR 2.7, CI 1.4-4.9).158 
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The BMES reported a statistically significant association between work related noise 
exposure and cardiovascular disease and mortality.159 There was no association between 
hearing impairment and mortality after multivariable adjustment reported in this study. The 
BMES examined cross-sectional (prevalence) and longitudinal relationships (5-year 
incidence and 10-year mortality) between workplace noise exposure and cardiovascular 
diseases (CVD). History of cardiovascular disease, workplace noise exposure and hearing 
protection was determined by questionnaire. Cardiovascular disease deaths were confirmed 
using the Australian National Death Index. Analyses were stratified by those who reported 
using and not using hearing protection devices in the workplace. Multivariable logistic 
regression analysis was used to calculate adjusted ORs and 95% CIs.159 
 
Of 1070 participants reporting workplace noise exposure, 937 reported non-use of hearing 
protection devices.159 After multivariable adjustment, the risk of mortality in all participants 
with self-reported workplace noise exposure did not reach statistical significance (HR 1.32, 
CI 0.99-1.76). There was a significantly higher risk of CVD and angina, but not AMI, in 
persons who reported tolerable workplace noise exposure (HR 1.53, CI 1.13-2.09; HR 1.75, 
CI 1.2-2.48; and HR 1.25, 0.84-1.84 respectively).159  
 
There was a significant difference in CVD risk by duration of exposure. Persons with 1-5 
years of workplace exposure did not have statistically significant higher risk of all CVD and 
angina where as those with > 5 years of exposure did (CVD OR 1.27, CI 0.82-1.96; angina 
OR 1.54, CI 0.96-2.49 vs.. CVD OR 1.66, CI 1.17-2.35; angina OR 1.83, CI 1.23-2.71 
respectively). Conversely, in participants with 1-5 years of workplace noise exposure, the 
association with increased CVD mortality was significant, while in those with > 5 years of 
exposure, the CVD mortality risk did not reach significance (HR 1.60, CI 1.10-2.33 and HR 
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1.10, CI 0.78-1.56 respectively). There was no association between self-rated severity of 
exposure and cardiovascular mortality.159  
 
Exposure to a tolerable level of workplace noise compared to no exposure was associated 
with a higher likelihood of having CVD and angina (OR 1.59, CI 1.13-2.23 and OR 1.75, CI 
1.20-2.56 respectively).159 When both the duration and level of noise exposure were 
examined together, those exposed to a tolerable level of noise for >5 years were more likely 
to have CVD and angina when compared to those never exposed to workplace noise (OR 
1.75, CI 1.23-2.49 and OR 1.78, CI 1.19-2.66 respectively).159  
 
Workplace noise exposure was not associated with the prevalence of stroke (OR 0.87, CI 
0.61-1.26) or hypertension (OR 1.15, CI 0.79-1.64).159 Exposure to severe workplace noise 
for less than 1 to 5 years versus no exposure was associated with incident stroke (OR 3.44, CI 
1.11-10.63) but not stroke related mortality.159 
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Summary 
The Prevalence of Auditory Impairment 
The reported prevalence of hearing impairment varied between 19%-83% depending on the 
age and geographic location of the cohort studied.116,117,119,121 Older cohorts had higher 
prevalence of hearing impairment.116,117,119,121,124 
 
The prevalence of hearing impairment was significantly increased in males,116,119,121,122,124 in 
persons in manual occupations,116 and with work related noise exposure116,119,121,122,124 and 
increased with increasing age.116,119,121,122,124 
 
The correlation between self-reported hearing loss and measured hearing loss in inconsistent. 
The Veneto study reported the prevalence of measured hearing loss to be double that of self-
reported hearing loss.117 Two studies that examined the link between self-reported hearing 
impairment and measured hearing impairment reported opposing findings. Davies et al using 
MRC data reported that persons with great difficulty hearing speech in noise had on average 
a 25 dBHL impairment in the better ear. In persons reporting moderate or worse bilateral 
difficulty in hearing in quiet had an average of 45 dBHL hearing impairment.116 Wilson et al 
found that the while the prevalence of self-reported hearing loss and measured hearing loss 
did not differ significantly, the false positive rate was 46% and false negative rate was 17% 
for self-reported hearing loss.119  
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The Associations Between Auditory Impairment and Morbidity 
Hearing impairment is reported to be significantly associated with numerous morbidities 
including increased difficulties in physical and functional activities, lower QOL, greater 
social impairment and poorer mental health.  
 
The physical and functional difficulties reported to be significantly associated with hearing 
impairment in the studies reviewed include: poorer HRQOL;125,127-129 increased difficulties in 
ADL and IADL;126,127,130-132 lower SRH;125 increased risk of institutionalisation;160 increased 
risk of falls131,135 and fractures; poor mobility23,131,137 and a decline in mobility;133,137 poorer 
balance;135 worse cognitive impairment;125,161 and an increased risk of car accidents.162 
 
Psychosocial impairments reported significantly associated with hearing impairment 
included: getting outside;131 visiting relatives;131 loneliness;141,142 depression;117,126,139-143 
anxiety;140,143 and the wish to die.146 
 
Hearing loss is associated with ARMD in both the BMES148 and the BDES,147 and with the 
CFH Y402H polymorphism in a Japanese population.149 
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The Associations Between Auditory Impairment and Mortality 
Hearing impairment is independently associated with many mortality risk markers including 
stroke,163 ischemic heart disease,164 diabetes165,166 and smoking.167 In addition, occupational 
noise exposure is reported to be associated with a significant increased risk of CVD and death 
due to AMI.158,159 Despite these associations, the link between hearing impairment and 
mortality is inconsistently reported, with most studies finding the association to become non-
significant after multivariable adjustment.151-154,156,157  
 
An Italian study found significant associations between hearing impairment and increased 
mortality risk in men but not women.151 The association became nonsignificant after 
multivariable adjustment for psychosocial parameters.151 Using NHIS data, one American 
study found significant associations between self-reported deafness and mortality that became 
non-significant after multivariable adjustment152 while another found the association 
remained significant in African American men after multivariable adjustment, but not with 
any other cohort grouping.153 Two Canadian studies also reported opposing estimates of the 
association between hearing impairment and mortality risk with one finding significant 
associations and the other reporting no association after multivariable adjustment.154,156 The 
BMES reported no statistically significant association between hearing impairment and 10 
year all-cause mortality after multivariable adjustment.157 
 
The associations between mortality risk markers, hearing impairment and mortality using 
structural equation modelling have not been examined. This may have lead to overcorrection 
of the associations between hearing impairment and mortality.  
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1.3 Olfactory Impairment 
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Prevalence 
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The prevalence of olfactory impairment in the EHLS cohort at the 5-year follow up period 
(1998-2000) has been reported.168 The age of participants at this time was 53-97 years. The 
study utilised the San Diego Odor Identification Test (SDOIT), an 8-item odour identification 
test that uses common, natural odours typically found in the home (e.g., coffee, chocolate).169 
Test-retest reliability of this test was r=0.86 when tested with a mean delay of 5 days in a 
sample of 92 subjects.169 The test was administered to participants with their eyes closed with 
odorants wrapped in gauze and kept in opaque containers to minimize visual clues. An 
interstimulus interval of 45 seconds was used to minimize adaptation. Participants identified 
the odorants from a picture board with illustrations of the target items as well as distracters. 
Olfactory impairment was defined as scoring <6 of 8 odorants correctly. This cut point 
corresponded to approximately 2 SDs less than the mean score in a group of 75 healthy adults 
aged 20 to 40 years. Information about self-assessed olfactory loss was obtained by a 
questionnaire administered as an interview. Self-reported smell impairment was determined 
by the question, “Do you have a normal sense of smell (compared to other people)?” The 
olfaction questions were asked before the administration of the SDOIT.168 
 
In the EHLS at five years follow up, the mean (SD) prevalence was 24.5% (1.7%).168 The 
prevalence increased with age (62.5% (CI 57.4%-67.7%) of 80-to 97-year-olds had olfactory 
impairment) and was more prevalent among men (adjusted prevalence ratio 1.92, CI 1.65-
2.19). Despite the high prevalence, the sensitivity of self-report was low and became less 
accurate with age. The overall sensitivity of self-report was 20%, and the specificity was 
94%. In the oldest group, aged 80 to 97 years, the sensitivity of self-report was 12% for 
women and 18% for men. After multivariable adjustment, age, sex, current smoking, nasal 
congestion or upper respiratory tract infection, stroke, and epilepsy were associated with 
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statistically significant increased odds of olfactory impairment. Olfactory impairment did not 
differ for former smokers compared with those who had never smoked cigarettes.168 
 
The Skövde population-based study examined Rhinological disorders in the general 
population in Sweden.170 In this study, a random sample of 1900 individuals aged 20 years or 
older, drawn from the municipal roster in December 2000, was stratified by gender and seven 
age groups: 20 to 29, 30 to 39, 40 to 49, 50 to 59, 60 to 60, 70 to 79, and 80 or more years of 
age. Of 1900 randomly selected individuals, 1387 (73%) participated in the clinical 
investigation. The study was conducted between January and June 2001 at the University of 
Gothenburg (Gothenburg, Sweden). Medical history was obtained by structured interview. 
Olfactory function was assessed with the Scandinavian Odor Identification Test (SOIT). The 
SOIT consists of 16 odours; pine needle, peppermint, juniper, violet, anise, clove, vanilla, 
bitter almond, orange, cinnamon, lemon, lilac, vinegar, tar, ammonia, apple). There was four 
response provided alternatives for each odour. The cut-off scores out of 16 for the level of 
olfactory ability were defined as 10 to 12 for hyposmia and 9 or less for anosmia. Multiple 
logistic regression was used to determine meaningful interactions between significant (p ≤ 
0.05) explanatory variables. Odds ratios including 95% CIs were estimated for the 
dichotomous explanatory variables.170 
 
The overall prevalence of olfactory dysfunction in the Skövde study was 19.1% (CI 17.1%-
21.3%), separated into hyposmia 13.3% (CI 11.6%-15.2%) and anosmia 5.8% (CI 4.7%-
7.1%).170 Two-way ANOVA found that women performed better than men on the SOIT (P < 
0.01) and that performance declined with age (P < 0.001).170 
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The OR for olfactory dysfunction (hyposmia and anosmia) in men when compared to women 
was 1.7 (CI 1.3-2.3 OR) and in individuals with nasal polyps the OR was 2.1 (CI 1.0-4.3).170 
There was no statistically significant association between olfactory dysfunction and diabetes 
mellitus, current smoking, or the number of pack-years smoked (including both current and 
previous smokers). In an additional analysis, current heavy smokers (≥ 20 pack-years) were 
compared with those who never had smoked, and after gender and age adjustment, no 
statistical difference in performance on the SOIT was observed.170 
 
The prevalence of anosmia (SOIT score ≤ 9) was found to be related to age, and the risk 
increased with the presence of nasal polyps (OR 3.8, CI 1.6-8.8) and diabetes mellitus (OR 
2.6, CI 1.3-5.5), but there was no statistically significant relation to either gender or smoking. 
The sensitivity of self-reported olfactory dysfunction was 43.9% with a specificity of 
85.4%.170 
 
Bhattacharyya et al reported the estimated prevalence of olfactory disturbance in the United 
States by performing a cross-sectional analysis of the National Health Examination and 
Nutrition Survey (NHANES). The NHANES is a nationwide survey administered by the 
National Centre for Health Statistics (NCHS).171,172 The data were collected during 2011 and 
2012 and included all persons aged ≥40 years who completed the survey. The presence of 
olfactory disturbance was determined by self-report. Statistical analysis of the survey 
variables was used to estimate the national prevalence of olfactory disturbance.  
In this study, the prevalence of self-reported olfactory disturbance in persons aged ≥40 years 
during the 12 months prior data collection was reported to be 10.6%.171 The prevalence of 
self-reported olfactory disturbance increased with age (OR 1.147, CI 1.003 – 1.312 for each 
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decade increment in age). There was no statistically significant difference between the sexes 
(p = 0.146).171 
 
A cross-sectional study of patients of the Otorhinolaryngology outpatient clinic of the 
Department of Otorhinolaryngology of the University Of Dresden Medical School reported 
the prevalence of olfactory dysfunction.173 One thousand two hundred and forty patients, with 
a mean patient age of 41.7 ± 0.5 years (range, 5-86 y) and almost equal sex distribution (52% 
men vs. 48% women), were included in the study. The included participants were exclusively 
outpatients with relatively mild and transitory conditions. Patients who required 
hospitalisation, had oncological otorhinolaryngology follow-up, complained of a 
Rhinological problem or chronic sinonasal problems were excluded. The 1240 selected 
otorhinolaryngological patients were representative of the German population regarding age 
and sex according to the data published by the German Federal Statistical Office. All 
participants completed a questionnaire concerning sociological and demographic data, 
smoking habits, general diseases, medications, ratings of olfactory function, and ratings of 
consequences on life quality in cases of smell loss. Self-rated olfactory function was defined 
as either “absent,” “attenuated,” “normal,” or “above average,” corresponding to scores of 0, 
1, 2, or 3, respectively. After olfactory testing, all participants underwent a detailed, extensive 
nasal endoscopy.173  
 
Patients with pathological findings on endoscopy were excluded.173 Olfactory function was 
assessed by means of the “Sniffin’ Sticks” test battery (Burghart, Wedel, Germany).174 
Sixteen common odours were used, and participants selected the odour by a multiple-choice 
task with four descriptors per odour. Normative data for normosmia, hyposmia, and anosmia 
based on multicentric investigations in more than 1000 subjects174 were used to grade the 
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level of hyposmia. A score <8 was considered functionally anosmic, 8 to 12 hyposmic, and > 
12 normosmic.173,174 
 
The prevalence of undiagnosed and asymptomatic nasal polyps was 4.7%.173 These 
participants were more likely to be hyposmic and more likely to rate reduced olfactory 
function than participants without nasal polyposis. Participants with nasal polyps were 
excluded from further analyses of the effect of general diseases on olfactory function.173  
 
The prevalence of any olfactory loss was 21% in this population.173 The prevalence of 
functional anosmia was 4.7%. No significant sex-related difference in the rate of functional 
anosmia was detected. The prevalence of hyposmia was 16%. Hyposmia was more prevalent 
in men than women after adjustment for age. The prevalence of olfactory loss increased with 
age. There was no association between smoking and olfactory loss. After age adjustment, 
there was no association between olfactory loss and the number of drugs taken or the number 
of comorbid conditions.173  
 
Self-report was an inaccurate proxy for the prevalence of olfactory loss.173 While participants 
with measured olfactory loss were correctly able to identify olfactory deficit with statistical 
significance, (r55 = 0.34, P = 0.01 for anosmic and r189 = 0.18, P = 0.02 for hyposmic 
participants) the participants with normal olfaction were not accurate with statistical 
significance (r935 = 0.03, P = 0.3).173 
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The Associations Between Olfactory Impairment and Morbidity 
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Olfactory Impairment, Self-rated health status, measures of Function and health related 
quality of life 
Participants in a cross-sectional study of the prevalence of OI in an outpatient 
otorhinolaryngology clinic in Dresden Germany were asked about the impact on life quality 
attributable to self-reported sudden olfactory loss.173 The impact on life quality due to sudden 
olfactory loss was rated by participants as either none, slight, strong, or very strong, 
corresponding to scores of 0, 1, 2, or 3, respectively.173   
 
This study found no significant correlation between self-reported olfactory loss and measured 
olfactory loss in persons with normosmia.173 The association between measured OI and 
poorer QOL was not statistically significant. Participants who reported a higher loss of 
quality of life due to olfactory dysfunction were less likely to have an olfactory impairment. 
The impact on life quality due to self-reported olfactory loss was highest among normosmic 
participants and gradually decreased with hyposmia and anosmia. Participants with measured 
olfactory loss were less likely than normosmic participants to report that olfactory loss 
impacted their quality of life.173 
 
A cross sectional study of 127 non-institutionalised Korean elderly persons (85 women and 
42 men) aged 65-89 years (mean ± SD: 73.8 ± 5.1 years) residing in Daejeon city of South 
Korea, estimated the association between measured olfactory dysfunction and quality of 
life.175 All participants were interviewed with regard to the presence of major olfactory 
problems. Olfactory sensitivity was assessed using the T&T olfactometer (Daiichi Yakuhin 
Sangyo Co., Tokyo, Japan) consisting of 5 test odorants: α-phenylethyl alcohol (odour A), 
methyl-cyclopentenolone (odour B), isovaleric acid (odour C), γ-undecalactone (odour D), 
and skatole (odour E). Each odorant was diluted in an 8 log step concentration series ranging 
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from 10-2 to 105. Odorants were presented in ascending concentrations. Each odour was 
presented at eight concentrations. Following each odour concentration, subjects were asked 
whether they could detect an odorant (detection threshold) or identify it (recognition 
threshold). When the subject failed to detect or to recognize the odour at its highest level of 
concentration, an additional point was added to the detection or recognition threshold of that 
odour. Thresholds of detection and recognition were averaged across all odorants to estimate 
a general detection and recognition threshold, respectively. Based on the subject’s average 
recognition thresholds, olfactory function was classified as normal (≤1.0), slight impairment 
(1.1-2.5), moderate impairment (2.6-4.0), severe impairment (4.1-5.5), and functional 
anosmia (≥ 5.6).175 
 
A questionnaire was administered to record demographics, and self-rated health and olfactory 
sensitivity in everyday life.175 Self-rated health and olfactory sensitivity were assessed using 
a five-point Likert scale (1: very unhealthy/very insensitive to 5: very healthy/very sensitive). 
Quality of life was examined by the Korean version176 of the Geriatric Quality of Life 
(GQoL) which includes 25 questions on physical and mental health, degree of independence, 
and social relationships. Subjects answered each question using four-point Likert scales: 1 = 
unsatisfied, 2 = moderate, 3 = satisfied, and 4 = very satisfied. The mean score was used as a 
measure of QOL.175 
 
Associations between QOL and olfactory impairment were examined using t tests and 
analyses of variance (general linear model).175 Duncan’s multiple range test was performed to 
separate the means. Pearson and Spearman coefficients were used for correlation analyses 
between the degree of olfactory impairment and QOL. To control causal effects between the 
above variables, partial correlation analyses controlling the potential variables were 
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performed and stepwise linear regression models were used to explore the variables 
influencing QOL. The level of significance was set at p < 0.05.175 
 
The prevalence of olfactory impairment in this elderly population was 80.3% ranging from 
slightly impaired to functionally anosmic.175 Despite this very high prevalence, only 10.2% of 
the entire cohort self-reported olfactory loss. There were no sex-related differences in 
olfactory sensitivity. Higher olfactory detection and recognition thresholds were associated 
with higher age and lower education level. Lower SRH was associated with higher 
recognition, but not detection threshold. Subject groups with severely impaired olfaction and 
with functional anosmia rated their QOL significantly lower than the other groups (F(4, 122) 
= 3.35, p = 0.01). After partial correlation analyses controlling for depression and cognitive 
performance, no significant association between olfactory detection and recognition 
thresholds and QOL was found. Linear regression modelling confirmed no significant 
association between QOL and olfactory function in this population.175  
 
To investigate the hypothesis that persons with parosmia suffer more in their daily life than 
those who experience only quantitative olfactory loss, Frasnelli et al developed the 
Questionnaire of Olfactory Disorders (QOD).177 The QOD was designed to address olfactory 
dysfunction and its impact on daily life. The study comprised of 205 patients (84 males and 
121 females) of an outpatient Smell and Taste Clinic with self-reported olfactory loss and age 
and sex matched 25 healthy controls. The QOD was validated by comparison to three other 
standardised psychometric and QOL tests, the Beck Depression Inventory (BDI),178 the  
Befindlichkeitsskala (Mood Inventory, MI)179 and the SF-36 Health Survey (SF-36).180 Using 
these measures, Frasnelli validated the QOD; reported the associations of self-reported and 
quantitative OI with SRH and QOL; reported the associations of self-reported parosmia with 
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self-reported and measured OI; reported the associations between parosmia and QOL and 
SRH in persons with self-reported OI both with and without objective OI.177  
 
The QOD consists of 52 statements divided into three domains: 39 negative statements QOD-
NS), five positive statements (QOD-PS) and eight socially desired statements (QOD-DS).177 
Negative statements estimate the negative impact of olfactory impairment; positive 
statements estimate coping with olfactory impairment; socially desired statements represent a 
lie scale estimating whether answers are influenced by desire to give a correct answer. All 
tests were paper and pencil tests that participants completed alone.177 
 
This study utilised the Sniffin Sticks Threshold Discrimination Identification (TDI) score to 
objectively assess olfactory function.181 Olfactory function was scored based on the aggregate 
of the individual Sniffin Sticks test TDI. Normosmia was defined as a TDI score ≥31; 
Hyposmia was defined as 15 < TDI score <31; Functional anosmia was defined as a TDI 
score ≤ 15.177,181 
   
The mean age of the 205 patients (84 males and 121 females) was 53.6 (SD ±1.0 years).177 
All were questioned for the presence of parosmia. Patients with parosmia are referred to as 
P+, patients without parosmia are referred to as P-. All participants completed the QOD, the 
MI and the BDI. Fifty patients and all 25 controls completed the SF-36. Results of the QOD 
were analysed for significant correlation with the parameters: duration of the olfactory 
disorder and age.{Frasnelli, 2005 #94847 
 
Statistical analyses were performed using SPSS 10.0 (SPSS Inc., Chicago). The alpha level 
was 0.05.{Frasnelli,  #94847} After testing for normal distribution of the data for analysis of 
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group differences, Student’s t-test was applied; p values were adjusted according to 
Bonferroni. Pearson’s coefficient of correlation was calculated for analysis of bivariate 
correlations.177  
 
The QOD was found to be an appropriate and valid measure of the impact of olfactory 
dysfunction on daily life.177 Self-report of olfactory impairment was a poor predictor of 
olfactory function. All participants reported a significant loss of olfactory function, but only 
90% overall had measurable olfactory loss using Sniffin sticks. Of these, 50% were hyposmic 
and 40% functionally anosmic. Correlation analysis found that normosmic subjects were 
unable to rate their olfactory function correctly, but that anosmic and hyposmic subjects were 
accurate in identifying their OI.177 
 
The results of the four psychometric tests correlated significantly.177 Compared to the 25 
healthy subjects, self-reported olfactory loss demonstrated a non-significant trend towards 
reduced scores in all domains of the SF- 36 (P = 0.068). The number of healthy subjects 
being limited to 25 subjects compared to 205 abnormal participants, may have led to a lack of 
power to detect a significant difference. Loss of quality of life also correlated with lower 
measured olfactory identification score.177 
 
In this female weighted study of 205 persons (84 males and 121 females) with self-reported 
olfactory loss, no gender difference in anosmia was identified. However, men were more 
likely to be hyposmic compared to women after adjustment for age.177 There were gender 
differences in QOL measured by MI, BDI and QOD-NS. In each measure, women reached 
statistically significant higher scores than men, indicating a significantly higher degree of 
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impairment (MI: P<0.001, BDI: P=0.038, QOD-NS: P<0.001). Quality of life measured by 
the QOD was not influenced by the duration of self-reported OI (r<0.078, P>0.28).177  
 
There were significant age effects on TDI score. Anosmic subjects (age, 52.9 ± 2.6 y) were 
older than normosmic subjects (age, 40.5 ± 0.5 y) (t = 4.6, P < 0.001). There was no 
significant association between OI and medications, smoking or individual comorbidities 
(diabetes, hypertension, depression, cardiovascular problems, liver problems) except a 
significant association of lower TDI in persons with a history of cancer and women taking the 
oral contraceptive pill.177 
 
There were significant differences in QOD scores of persons who inaccurately reported 
olfactory impairment (normosmic patients).177 Normosmic patients reporting OI had 
significantly higher QOD-NS scores when compared to hyposmic or functionally anosmic 
patients. No other psychometric test (BDI, MI, SF-36) demonstrated significant differences 
between normosmic, hyposmic and functionally anosmic patients. In persons with objective 
OI, the QOD-NS, but not the QOD-PS or QOD-DS, was significantly associated with the 
TDI score (r205 = -0.15, P=0.034) meaning persons with measured OI by Sniffin Sticks had 
significantly higher QOD-NS score and therefore lower QOL.177 
Parosmia was reported by 28.3% of participants. Of these, 13.8% were functionally anosmic 
and 79.3% hyposmic leaving 6.9% of P+ who were normosmic.177 Comparing participants 
with quantitative olfactory loss and parosmia to those with quantitative olfactory loss without 
parosmia, parosmic participants had significantly more problems coping with their olfactory 
dysfunction (P+ had significantly lower scores on the QOD-PS vs. P-; p = 0.021). No other 
psychometric tests yielded significant differences between P+ and P- patient groups. Results 
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were not influenced by excluding participants with high QOD-DS scores. There was no 
significant association between parosmia and age (P+: 55.7; P-: 57.3; p = 0.57).177 
 
The organisation for anosmia is a Dutch organization founded in 2000 by volunteers 
experiencing problems in smelling and tasting. To compare health-related quality of life and 
depression between Dutch persons with anosmia and normosmia, all 105 members of the 
organisation were contacted in 2006 via an advertisement on the organisation's website and 
via a mailing letter.182 The response rate was 90%, and the final sample was 90 (86%) after 
exclusions. Smell dysfunction was self-reported. The age range was 24-86 years old (mean 
58.8; SD = 12.5). A comparison group of 89 normosmic persons was recruited via an 
advertisement in a regional newspaper and from acquaintances of the study’s authors.182 The 
age range of this group was 32-78 years old (mean 56.8 years; SD = 9.4). The SF-36183 and 
the QOD177 were administered to assess the degree of problems in daily life related to the 
smell impairment. Respondents also completed the questionnaire “Smell and Taste 
Impairments”, developed at Utrecht University, to diagnose and record smell and taste 
dysfunction. It consists of 52 items covering symptomatology and possible causes of 
olfactory impairment, duration of the impairment, comorbidities and medication use.182  
 
A multivariate analysis of variance (MANOVA) with between-subjects factor group (two 
levels: anosmia vs. comparison) was conducted on the three subscales of the QOD and the 
nine subscales of the SF-36.182 A significant MANOVA was followed by univariate ANOVA 
for each of the subscales. The scores on the BDI-II-NL were not normally distributed so the 
Mann-Whitney test was conducted. The corresponding effect size was calculated as follows: r 
= Z/N½. A chi-square test was conducted to compare the division of scores from the two 
groups over the four categories from “no” to “severe” depression. Pearson product-moment 
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correlations were calculated between the various subscales to explore relevant associations. 
For all statistical tests, α was set to 0.05; for correlations, α was set to .001 to correct for 
multiple comparisons.182 
 
The study reported that persons who were members of the organisation for anosmia had 
significantly lower QOL related to situations involving taste and smell.182 Compared to the 
comparison group, scores in the anosmia group significantly differed on the QOD-subscale 
Life Quality (p < 0.001). Scores on various subscales on the SF-36 indicated significant 
associations between anosmics and reduced energy, limitations in social activities and 
interactions, and a reduction of general health when compared to normosmics. Parosmia was 
associated with significantly reduced life quality concerning daily activities related to tasting 
and smelling, and health-related quality of life with significant correlations between the 
parosmia subscale of the QOD and other subscales of the QOD and SF-36, respectively.182 
 
To examine the impact of olfactory impairment in the UK, Phillcott et al enrolled members of 
the patient support organisation Fifth Sense in a study that utilised questions from the QOD 
to assess the associations between olfactory impairment and QOL.177,184 From a membership 
of over 1000 persons with olfactory disorders, 496 completed the online survey over 9-
months. The age range was 8-95 years old (mean = 55).184 
 
Responding members of Fifth sense reported reduced appreciation of food and drink (92%), 
exposure to certain dangers (e.g., gas, rotten food) (85%), going to restaurants less often than 
they used to (55%) and relationship difficulties with partner/family/friends (54%) due to 
difficulties with smelling.184 There was a significant sex difference, with women being more 
likely to be affected by OI than men (p = 0.01). There was also a high prevalence of 
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qualitative olfactory disorders with parosmia reported in 19% and phantosmia in 24% of Fifth 
Sense members. In both categories of qualitative disorders, there was a significant difference 
when compared to persons without qualitative disturbances for flavour perception, eating 
unhealthily, eating less, despair, being less sociable, and stress (P ≤ 0.05).184 
 
The BMES examined the associations of olfactory impairment with self-rated health, quality 
of life, functional disability and reduced independence in persons aged ≥ 60 years.185,186 
Olfactory function was assessed during the BMES 10 year follow up period using the 
SDOIT. Self-rated health was assessed by questionnaire and QOL was assessed by SF-36 
score.185 Use of community support services and dependence on informal supports was 
assessed by questionnaire. Dependence on community support services was defined as 
regular use of meals on wheels, home care or community nursing. Reliance on informal 
support was defined as receiving assistance from someone other than a spouse (family 
member/friend) for cleaning or shopping. Also, participants’ ability to go out alone was 
assessed. The Older American Resources and Services (OARS) ADL scale was used to assess 
functional disability. Participants reporting that they needed help with, or were completely 
unable to perform, one or more ADL activity were considered to have impaired ADL.186 
Olfactory impairment was defined as identification of ≤ 5 out of 8 SDOIT odours.185,186 
 
In this cohort, persons with olfactory impairment were more likely to report low self-rated 
health when compared to participants with normal olfaction.185 After multivariable 
adjustment, persons with olfactory impairment had statistically significant lower SF-36 
scores in physical functioning (p = 0.02), role limitation due to physical problems (p = 
0.004), general health perception (p = 0.05), vitality (p < 0.0001), social functioning (p = 
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0.004), role limitation due to emotional problems (p < 0.0001) and mental health (p = 0.05). 
The association with bodily pain was not significant (p = 0.08).185 
 
The use of community support services was reported by 15.2% or persons with OI compared 
to 5.2% of persons without OI.186 After multivariable adjustment, participants with OI 
compared to those without OI were more likely to use community support services (OR 1.82, 
CI 1.16-2.86). Olfactory impaired persons were also significantly more likely to use informal 
supports (OR 1.62, CI 1.14-2.32). ADL difficulty was reported by 16.9% of participants with 
olfactory impairment compared to and 4.4% of participants without olfactory loss. After 
multivariable adjustment, olfactory impaired persons had an increased likelihood of 
experiencing ADL difficulty (OR 1.98, CI 1.10-3.57). Olfactory impaired participants 
reported statistically significant higher frequencies of difficulty in 12 of the 14 ADL items.186 
Olfactory loss was significantly associated with impaired basic ADL (OR 1.57, CI 1.12-
2.20).186 The severity of olfactory impairment was not associated with the use of community 
or informal supports, nor with impaired ADL. Olfactory impairment was not associated with 
instrumental ADL.186   
 
Using the database at the Department of Otorhinolaryngology, Friedrich-Schiller-University 
Jena, Germany, Neuland et al recruited persons with ≥ six months of severe hyposmia and 
anosmia as assessed by the Sniffin Sticks test.187 All had received a complete 
otorhinolaryngologic examination. Severe hyposmia or anosmia was defined as TDI score < 
20. After exclusions, 527 patients were invited to participate via mail between 
May and October 2009 with a request to confirm their olfactory dysfunction and answer two 
questionnaires, the German version of the SF-36 Quality of Life Health Survey and the 
adapted version of the QOD, the QOD 29. The response rate was 53% (280 persons). Three 
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hundred and twenty age and sex matched persons from the German population without 
olfactory dysfunction were recruited as controls. The age range was 12-89 (mean = 60±14) 
years. The interval between olfactory assessments and of QOL assessment was on average 
3.6 ± 2.4 years (range, 0.3-9.7).187  
 
The QOD 29 has three-scale statements with three domains: 19 statements on life quality 
(LQ), six statements on sincerity (S), four statements concerning parosmia (P), and five 
visual analogue scales (VASs).187 
 
The sum of the LQ statements gives the LQ raw score (LQrv) with a maximum of 38 points. 
LQrv is transformed into the LQ score (LQsc) by the formula LQsc = (LQrv/38) x 100 (%). 
The sum of the S statements makes the S raw score (Srv) with a maximum score of 12 points. 
Srv is transformed into the S score (Ssc) by the formula Ssc = (Srv/12) x 100 (%). Maximal P 
raw score (Prv) is 8. Prv is transformed into the P score (Psc) by the formula: Psc = (Prv/8) x 
100 (%).187 
 
High scores of LQrv/LQsc indicate a strong impairment. Low scores of Srv/Ssc indicate a 
tendency toward giving socially desired answers. High scores of Prv/Psc indicate more 
parosmia (P).187 
 
The five visual analogue scales (VAS) were: VAS 1 annoyance; VAS 2 perceivable; VAS 3 
work-related impairment; VAS 4 recreational impairment; VAS 5 private impairment.187 The 
five VASs were 100-mm long. Absolute VAS values (in millimetres) were presented. 
Bivariate correlations were determined by using Pearson’s product moment coefficient. 
Mann-Whitney U tests for independent samples were used to analyse group differences. All 
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tests were two-tailed with a 5% significance level. Linear regression analysis, including all 
determinants significant in the univariate analysis, was performed to identify independent 
determinants of QOL.187 
 
Anosmia was present in 205 patients and severe hyposmia in 75 patients. The average TDI 
score was 12 ± 4 points.187 The average T score was 0.3 ± 1 points, the D score 6 ± 2 points, 
and the I score 6 ± 3 points. There was no sex interaction with overall TDI score. There was 
no age interaction for T and D scores. Participants older than the median study age of 62 
years had higher I and TDI scores than participants younger than the median age (P = 0 .014 
and P = 0.009 respectively).187  
 
The values of all domains of the SF-36 were significantly lower than in the age- and sex-
matched control group.187 The analysis of correlation (Pearson, bivariate) between SF-36 and 
TDI scores identified a significant correlation with the BP domain. Lower values in this 
domain correlated with lower TDI scores. There were no other significant correlations 
identified. Female participants had significantly lower values in several of the SF-36 physical 
health domains compared to male participants. Duration of olfactory dysfunction did not 
influence SF-36 measured HRQOL (all P > 0.05).187 The reported results for the different 
domains of the SF-36 questionnaire are summarised in Table 1.8.
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SF 36 Domain 
 
Study Group 
 
Control Group 
 
p Value  
Physical Functioning 71.53 ±27.50 75.89 ± 25.77 < 0.042 
Social Functioning 74.09 ± 25.72  86.76 ± 21.13  < 0.0001 
Physical Role 56.52 ± 42.77  72.47 ± 39.64  < 0.0001 
Emotional Role 63.10 ± 42.84  87.04 ± 31.04  < 0.0001 
General Mental 
Health 
 
66.36 ± 19.77  74.43 ± 17.99  < 0.0001 
Vitality 52.43 ± 20.69  60.93 ± 19.75  < 0.0001 
Bodily Pain 61.51 ± 30.31  70.20 ± 30.62  < 0.0001 
General Health 
Perception 
52.73 ± 20.08  58.83 ± 20.54  < 0.0001 
a Subgroup of German normative data (median age, 63 years; 52% female). 
  
8 Table 1.8 Comparison of the SF-36 Health Related Quality of Life between the 
anosmic/hyposmic patients (n = 280) and the age- and sex- matched control groupa (n = 
320)187 
181 
 
The analysis of correlation (Pearson, bivariate) between TDI score and QOD domains (life 
quality (LQ), sincerity (S) and parosmia (P), and five visual analogue scales (VASs) found 
significant negative correlations between TDI score and LQrv (r = -0.137; P = 0.022), Prv (r 
= 0.161; P = 0.007), VAS 3 (r = 0.129; P = 0.036), and VAS 4 (r = 0.136; P =0.025).187 A 
non-significant negative trend was found between TDI score and VAS 1 (r = 0.102; P 
=0.090) and VAS 5 (r = 0.114; P =0.060). Similar to the SF-36 physical health domains, 
female participants had worse QOD values than male participants and the duration of 
olfactory dysfunction had no influence on the QOD values (all P > 0.05).187 
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Olfactory Impairment and Depression 
Olfactory processing at the brain level recruits areas whose functioning is known to be altered 
in depression.188 These alterations may be reversed by antidepressants.188 Bilateral olfactory 
bulbectomy of a rat results in changes in behaviour, and in the endocrine, immune and 
neurotransmitter systems, that simulates many of those seen in patients with major 
depression.189 In addition, stress induces behaviour similar to some symptoms of depression 
and decreases neurogenesis in the hippocampus and olfactory bulbs.190 These findings 
describe possible biological pathways between depression and olfactory impairment. 
 
The BMES examined the associations between depression and olfactory impairment at 10-
year follow up.185 Participants were aged ≥ 60 years at the 10-year follow up. Olfactory 
impairment was assessed using the SDOIT. Olfactory impairment was considered present if 
the participant correctly identified ≤5 out 8 SDOIT odours. Depression was assessed using 
the Mental Health Index (MHI) component of the SF-36 and the Center for Epidemiologic 
Studies Depression Scale (CES-D-10).191 A score of ≥ 10 out of a total possible score of 30 
was used to define significant depressive symptoms.185 
 
In the BMES cohort overall, there was no significant association between depressive 
symptoms and olfactory impairment after multivariable adjustment.185 When stratified by 
age, olfactory impaired persons older than 70 years had a significantly increased likelihood of 
depression if scored by the CESD-10 (OR 1.66, CI 1.03-2.66) but not the MHI.185 
 
A cross sectional study of 127 non-institutionalised Korean elderly persons (85 women and 
42 men) aged 65-89 years (mean ± SD: 73.8 ± 5.1 years) residing in Daejeon city of South 
Korea, estimated the association between measured olfactory dysfunction and depression.175 
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Depression was assessed using the Korean version of the Geriatric Depression Scale (GDS-
K)192 developed by Yesavage et al.51 The GDS-K consisted of 30 questions, and the cut-off 
score for the determination of depression was 10 (maximum score 30).175 
 
For subjects with severely impaired olfactory function or functional anosmia, the mean 
depression scores exceeded the cut-off score of 10 points, indicating the presence of 
depression.175 When comparing olfactory thresholds between non-depressed and depressed 
subjects (above or below a score of 10 points on the GDS-K), depressed subjects exhibited 
significantly higher detection thresholds (t69.48 = -2.51, p = 0.02). For recognition thresholds, 
a nonsignificant trend was found for the same comparison (t84.88 = -1.91, p = 0.06). However, 
after partial correlation analyses controlling for cognitive performance and QOL, there was 
no significant association between olfactory detection and recognition thresholds and 
depression. Linear regression modelling confirmed no significant association between 
depression and olfactory function in this population.175  
 
To examine the effect of a major depressive episode on olfaction, Pause et al recruited 24 
inpatients with major depressive disorder (MDD) during their acute depressive phase.193 
Persons were considered depressed if their symptoms met the DSM IV194 criteria for a major 
depressive episode and had a BDI ≥ 11. The mean age was 48.4 (SD =13.2) and the mean 
BDI-score was 28.5 (SD = 11.4). Of these, 18 participated again after successful treatment, 2 
participants refused the second examination and four patients did not subjectively recover 
from depression. Twenty-four non-depressed (BDI mean=4.8, SD = 2.5) age, sex, and 
smoking status matched controls were also recruited. The difference in BDI scores between 
the test and control subjects was statistically significant (t (46) = 9.98; P<0.001). No 
participant had neurological or endocrine disorders known to affect olfaction.193 
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Olfaction was assessed with the following ten odorants: 5-a-androst-16-en-3-one (98%, 
Aldrich, body odour), butylcyclohexylacetate (99%, Aldrich, cedar-wood), citral (95%, 
Aldrich, citrus), eugenol (99%, Fluka, clove), isoamylacetate (98%, Aldrich, pear), isobutyr-
aldehyde (99%, Aldrich, butter-acid), linalool (97%, Fluka, lavender), menthol (99%, Merck, 
peppermint), n-octyl-acetate (Aldrich, apple) and 2-phenyl-ethylalcohol (PEA, 99%, Fluka, 
rose).193 Olfactory thresholds for eugenol and PEA were determined using a two-alternative 
staircase detection procedure. Valence and intensity ratings were obtained for all ten odours. 
Ratings were measured using a 7-point scale (valence from -3 to +3; intensity from 0 to 6). 
All participants completed the BDI and an anxiety inventory (State-Trait-Anxiety-Inventory, 
STAI).193 
 
On average, depressed participants were examined 16.1 (SD 9.5) days after admission. On 
the day of the investigation, 20 participants were being treated with antidepressants and 4 
were not.193 The second examination occurred after successful treatment (mean interval 
between sessions: 58.3 days, (SD 45.1). The reduction in the BDI score was statistically 
significant (P < 0.001). A control group of 18 healthy subjects was also tested again (mean 
interval between sessions: 49.5 days (SD 11.1). The reduced control group was matched by 
age, sex and smoking behaviour. The BDI score of the control group did not change between 
examinations (BDI mean = 4.6, SD = 3.4).193 
 
Participants with MDD had reduced sensitivity for odorants compared to controls, but this did 
not reach statistical significance.193 The BDI score trended negatively with olfactory 
sensitivity but was significantly reduced for eugenol threshold only. Measured intensity 
ratings for all odorants did not significantly differ between the test group and the controls. 
There was a non-significant trend for the valence ratings to differ between the groups. There 
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was a non-significant trend for olfactory scores to improve after the treatment of depression. 
The eugenol threshold of the MDD compared to the control group, which was significantly 
higher in MDD participants at the initial examination, became nonsignificant after treatment 
of depression.193  
 
In a study to characterise and compare the psychophysical dimensions of olfaction in groups 
of patients affected by psychiatric disorders, Lombion-Pouthier et al compared olfactory 
ability of a sample population of 49 depressed persons (mean age = 43.4 years; SD = 17.54: 
35 females) with 58 healthy subjects matched for sex, age and smoking habits 
(mean age = 38.4; SD = 13.96: 36 females).195 Severe depression was diagnosed using DSM 
IV194 criteria. Persons with other psychiatric diseases were excluded from the depression 
study. Olfactory assessment utilised the European Olfactory Abilities Test (ETOC).196 This 
test firstly evaluates the olfactory sensitivity with two odours: l-carvone and 
tetrahydrothiophene. Using a forced choice procedure for 5 successive concentrations, an 
overall score between 2 (high sensitivity) to 10 (low sensitivity) was calculated. The second 
part of the test evaluates detection and identification abilities using a panel of 16 odours 
(vanilla, lavender, eucalyptus, fuel, fish, violet, garlic, grass, orange, apple, cinnamon, lemon, 
anise, mulberry, chewing gum, mint). For each of odour, participants were required to select 
from four bottles, the bottle with an odour (detection test) and then identify the odour from a 
list of four names (identification test).195 
 
This study reported that depressed participants had poorer olfactory sensitivity, but similar 
identification abilities when compared to healthy controls.195 The authors used Fisher's 
Protected Least Significant Difference to demonstrate a significant difference between the 
higher mean olfactory scores (lower sensitivity) of the depressed participants compared to the 
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control group. More depressed participants gave ≥1 incorrect identification responses when 
compared to the control group, but this difference did not reach statistical significance (14% 
depressive patients vs.. 2.5% control group; p <0.1).195   
 
The association between anosmia and parosmia and depression was examined in members of 
the organisation for anosmia.182 The SF-36183 and Beck Depression Inventory-II-NL (BDI-II-
NL)178,197 were administered in addition to the QOD177 to assess levels of depression in both 
the anosmic and normosmic groups.182  
 
The study reported that persons with anosmia had higher scores on subscales of the SF-36 
indicating increased feelings of depression and nervousness compared to the normosmic 
group.182 The BDI scores were significantly higher in the anosmic group indicating higher 
levels of depression in persons with anosmia than without anosmia. In the anosmic group, 
22% were depressed (11% mildly depressed; 9% moderately depressed; 2% were severely 
depressed) compared to 5% overall in the normosmic group (4% mildly depressed; 1% 
moderately depressed).182 Persons with parosmia were also significantly more likely to be 
depressed compared to normosmic participants.182  
 
In a study of members of Fifth Sense, a UK patient support organisation for persons with 
olfactory impairment, the rate of depression as measured by the QOD was 43%, which is 
higher than the reported rate of depression in the adult population of 8-12% of the UK.184,198  
 
There were significant differences in depression and anxiety rates between the sexes in this 
group with women being significantly more likely than men to have depression and/or 
anxiety (47% (n = 151) vs.. 34% (n = 60) P = 0.003).184 There was also a significant age 
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effect. Members younger than 50 years were significantly more likely to report isolation (P = 
0.002), depression (P = 0.008), and being scared of dangers (P = 0.038). Older sufferers had 
significantly higher rates of resignation to their sensory loss (P = 0.03).184 
 
Phantosmic members reported significantly higher rates of depression (P = 0.008) compared 
to those without phantosmia.184 Parosmic members did not show significantly different rates 
of depression when compared to those without parosmia, but did report a significantly higher 
rate of anxiety (P = 0.007).184 
 
Amsterdam et al found no significant association between olfactory function and MDD in a 
study of 51 depressed participants compared with 51 age and sex matched controls.199 
Depression was defined by the DSM-III criteria200 for a major depressive disorder (MDD), 
with or without melancholic features, or atypical (bipolar II) depressive disorder. Olfaction 
was assessed using the University of Pennsylvania Smell Identification Test (UPSIT). Two-
way ANOVA with age as the covariate and gender and subject group (depressed, controls) as 
factors, found no significant difference between the UPSIT test scores of depressed 
participants compared to the control subjects.199 
 
To determine whether olfactory function could be useful in discriminating between the 
diagnoses of dementia or depression in elderly patients, Pentzek et al compared the olfactory 
function of 20 patients from an old age psychiatric Ward with probable Alzheimer’s disease 
(AD); 20 elderly patients with a depressive disorder; and thirty healthy elderly subjects.201 
Participants in the depression group were mildly to moderately depressed overall. In this 
study, no significant difference in odour identification between the depressed group and the 
controls was identified.201 This study is discussed at length in the following section.  
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A study of 48 persons with no history of neuropsychiatric diseases, including depression or 
anxiety disorders, examined the associations between olfactory sensitivity and olfactory 
identification with depressive symptoms.202 The mean age of participants was 28.2 years (SD 
5.8 years). Olfactory function was assessed using the Sniffin' Sticks test. Depressive 
symptoms were assessed using the Beck Depression Inventory. Pleasantness and arousal 
during the olfactory assessments were assessed using a non-verbal self-report scale with 
scores ranging from 1 (very unpleasant or low arousing) to 9 (very pleasant or high arousing). 
Descriptive mean scores were calculated for olfactory sensitivity, olfactory discrimination, 
pleasantness, arousal and BDI score. Pearson's correlation analyses were used to examine the 
relationship between degree of depressive symptoms with olfactory sensitivity and olfactory 
discrimination. Regression analyses with the independent variable olfactory sensitivity and 
olfactory discrimination, respectively, and the dependent variables depressive symptoms, 
pleasantness and arousal were carried out.202 
 
The mean BDI score was 3.3 (SD 3.1; minimum 0, maximum 9). All subjects reported a 
small number of depressive symptoms (BDI score < 10).202 The mean perception threshold 
was 11.7 (SD 2.0) and the mean discrimination score 12.5 (SD 3.1) out of 16. There was a 
statistically significant (p = 0.05) inverse correlation between the degree of depressive 
symptoms and olfactory threshold score (r = −0.36) indicating reduced olfactory sensitivity in 
participants with a high degree of depressive symptoms. There were no significant 
correlations for olfactory discrimination.202 
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Olfactory Impairment, Cognitive Impairment and Parkinson Disease 
A cross sectional study of 127 non-institutionalised Korean elderly persons (85 women and 
42 men) aged 65-89 years (mean ± SD: 73.8 ± 5.1 years) residing in Daejeon city of South 
Korea, estimated the association between measured olfactory dysfunction and cognitive 
impairment.(Seo, Jeon et al. 2009) Cognitive performance was measured by the Korean 
version of the Mini-Mental State Examination (MMSE-K)203 originally designed by Folstein 
et al.204 Impaired cognitive function was defined as MMSE-K score < 24 out of 30 
points.175,203,204 
 
Participants with severely impaired olfactory function and with functional anosmia, had a 
mean cognitive performance score < 24 points.175  This difference was statistically significant 
after partial correlation analyses controlling for depression and QOL when compared to 
participants with normal and slightly/moderately impaired olfaction. Linear regression 
modelling of cognitive performance found that detection threshold and education level were 
main modulators to account for the variance of cognitive performance (Y (degree of 
cognitive performance) = +23.892 - 1.020X1 (detection threshold) + 0.900X2 (education 
level).175  
 
To examine whether olfactory impairment was associated with cognitive impairment and 
subsequent cognitive decline, Swan et al assessed olfactory function and cognitive 
performance in 359 participants with a mean age of 74.3 (SD = 4.3) years in 1992 and again 
4.5 years later.205 Participants were recruited from the Western Collaborative Group Study 
health and aging follow up which began in 1960 with 3152 healthy males aged 39 - 59 
years.206 During 1986-1988, the wives of the participants were recruited and they form the 
basis for female participants. In 1992, 870 participants (712 men and 158 women) were 
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assessed for smell identification and cognitive performance. Of these, 52 (6.0%) participants 
had a positive history of stroke and 19 (2.2%) had a MMSE score of less than 23 and were 
excluded from further analysis. Of the remaining 802 individuals, eligible for inclusion in the 
follow-up 4.5 years later, 443 were either deceased (17.7%), too ill to participate (3.6%), 
refused participation (16.7%), participated by questionnaire only (23.9%), or lost to follow-
up (2.9%). There were no cases of confirmed Alzheimer disease (AD). The remaining 359 
individuals (286 men and 73 women) with repeat cognitive testing comprised the primary 
sample for the analysis of the association between odour identification and cognitive 
decline.205 
 
Odour identification was assessed using the CC-SIT.205 Impaired odour identification was 
defined as a CC-SIT score of ≤ 10 out of 12. Cognitive assessment was by means of a 
neuropsychological test battery consisting of several measures of executive control, verbal 
learning and memory, visual learning and memory, and global Function. The MMSE was 
performed by all subjects.205 
 
The association between olfactory dysfunction and potential confounders was examined with 
either chi-square or Student's t tests.205 Differences in variables of interest between the 
analysis sample and those not included in the analysis were examined with univariate tests. 
The primary analysis consisted of the use of the general linear model to examine differences 
between impaired and normal olfactory groups on mean change in cognitive performance on 
each of ten tests separately after multivariable adjustment.205 
 
Of all baseline participants, 53.3% had olfactory impairment at the initial assessment.205 
Seventy three percent of participants with MMSE score < 23 had olfactory impairment 
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compared to 52% of participants with MMSE ≥ 23. This difference was not statistically 
significant (χ2(1) = 3.23; p < 0.072). After exclusions, the prevalence of baseline olfactory 
impairment in the remaining 359 participants was 45.7%. After multivariable adjustment, 
there were no significant associations between baseline olfactory impairment and change in 
performance in any of the measures of executive control nor MMSE score. There were 
significant associations between baseline olfactory impairment and learning and memory 
tasks. After multivariable adjustment, persons with baseline olfactory impairment had 
significantly greater declines in visual memory and verbal learning and memory tasks 
compared to normosmic participants.205 
 
A Japanese study compared olfactory function of 85 persons (mean age 76.3; SD = 7.2) with 
confirmed AD and 30 age-matched (mean age 74.8; SD = 8.5) non-demented elderly 
controls.207 Two tests of olfactory function were administered to all subjects, the cross 
cultural smell identification test (CC-SIT)208 and the picture-based smell identification test 
(P-SIT). The CC-SIT is a scratch-and-sniff test of 12 microencapsulated odorants with four 
forced choice alternatives per item. The P-SIT uses six distinctive odorants (ground coffee, 
incense, ground sesame, green tea, fermented soybean paste and soap) that were confirmed to 
be intense and familiar to cognitively intact Japanese elderly persons by preliminary trials.207 
Twenty pictures of materials including six pictures corresponding to the smells and fourteen 
pictures unrelated to the odorants were presented. Subjects were asked to identify the 
odorants by choosing a corresponding picture after smelling each odorant. The number of 
correct choices was recorded as the score of the test. Cognitive impairment was assessed 
using the MMSE in all participants.207 
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The mean age of the two groups were compared by Student’s t-test.207 Gender difference of 
MMSE scores within each group and the mean P-SIT and CC-SIT scores of the two groups 
were compared by Mann-Whitney’s U-test. Differences were considered statistically 
significant if p < 0.05. The relationship between the age of the subjects and the scores of the 
P-SIT and the CC-SIT in both groups and the relationship between the MMSE scores and the 
scores of the two olfactory tests within the AD group were examined using Spearman rank of 
order correlation coefficients. Simple regression analyses were conducted for both olfactory 
tests within the AD group to calculate the predicted MMSE scores from the SIT scores as 
independent variables and compared coefficients of determination.207 
 
The mean MMSE score of the AD group (mean = 19.6; SD = 4.6) was significantly lower 
than that of the elderly controls (mean= 28.5; SD = 2.2) (p<0.0001).207 Within the AD group, 
there were no significant gender differences in age, MMSE scores and SIT scores.  The AD 
group had significantly lower P-SIT and CC-SIT mean scores when compared to the control 
group (1.5; SD = 1.3 vs.. 4.4; SD = 1.2, and 4.1; SD = 2.5 vs.. 6.8; SD = 1.7 respectively; p < 
0.0001 for both SITs). Chi square analysis estimated the P-SIT discriminated the AD group 
from elderly controls with a sensitivity of 94% and specificity of 81%. The positive 
predictive value was 0.93 and negative predictive value 0.83. The CC-SIT had lower 
sensitivity (90%) and specificity (51%) with a positive predictive value of 0.65 and negative 
predictive value of 0.83.207 
 
To examine the associations between olfactory impairment and Alzheimer disease, Doty et al 
compared olfactory function in 34 mildly to moderately severe AD patients with no other 
complicating diseases with 34 healthy non-institutionalised age, gender and ethnicity 
matched control subjects.209 Odour identification was assessed with the UPSIT. All AD 
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patients were administered a picture identification test identical in content and format to the 
UPSIT except that pictures, rather than odours, serve as stimulus items to identify individuals 
too demented to comprehend the non-olfactory components of the UPSIT. Nine AD patients 
failed or were unable to complete the picture identification test and were excluded, as were 
their matched controls, from further consideration. After exclusions, odour detection 
threshold was assessed in 25 AD patients and an equivalent number of age, race and gender 
matched controls using a single staircase, forced choice odour detection threshold test using 
the odorant phenyl ethyl alcohol.209  
 
The average UPSIT test scores of the remaining 25 AD patients were significantly lower than 
their 25 age matched controls (Wilcoxon matched-pairs signed-ranks test. T = 3, p < 
0.001).209 A Mann-Whitney U-test found no association between stage of AD and UPSIT 
score (U=58.5; p > 0.20). Alzheimer disease patients also had significantly higher detection 
thresholds when compared to matched controls (Wilcoxon matched-pairs signed-ranks test, T 
= 1, p < 0.001). No significant differences were present between the stage of the disease and 
the odour detection threshold. Self-report of olfactory deficit was not a reliable measure of 
the presence of olfactory impairment in the AD patients; only two of the 34 AD patients 
reported olfactory loss.209 
 
To compare olfactory impairment in vascular dementia (VD) with olfactory impairment in 
AD, Gray et al compared the UPSIT scores of age and sex matched AD patients, VD patients 
and a control group.210 There were 13 participants in each group. The age ranges for the 
groups were 71.6-79.2 years (mean 75.4) for the AD group, 76.1-86.4 (mean 79.2) for the VD 
group and 72.8-79.2 (mean 75.6) for the control group. The median UPSIT scores of the AD 
and VD were significantly lower than the UPSIT scores of the control group (Kruskal-
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Wallace, χ2 = 21.987, df = 2; p = 0.001). Post hoc comparisons demonstrated significant 
differences between the UPSIT scores of the AD (Wilkinson paired: Z = -3.189; p = 0.001) 
and the control group and between the VD group and control group (Wilkinson paired: Z = -
3.182; p = 0.001). There was no significant difference in the UPSIT score when comparing 
the AD with the VD groups in the post hoc comparisons (Wilkinson paired: Z = - 0.980; p = 
0.327).210 
 
Pentzek et al compared the olfactory function of 20 patients from an old age psychiatric 
Ward with probable Alzheimer’s disease (AD), 20 elderly patients with a depressive disorder, 
and thirty healthy elderly subjects.201 A diagnosis of AD was made according to the 
NINCDS-ADRDA research criteria.211 A diagnosis of a depressive disorder was made 
according to the ICD-10 criteria.212 The 30 control subjects with no history of AD or 
depression were recruited from a general hospital (n=12) and a facility for assisted living 
(n=18). All participants were non-smokers aged ≥60 with no history of other psychiatric or 
neurological disease including stroke, head trauma, chronic exposure to toxic agents, and 
acute or chronic diseases of the upper respiratory tract.201 
 
Cognitive status was assessed using the German version of the Alzheimer’s Disease 
Assessment Scale, cognitive subscale (ADAS-cog)213 and the German version of the Brief 
Cognitive Rating Scale (BCRS).214 Depressive symptoms were assessed using the Hamilton 
Depression Scale (HAMD).215 Odour identification ability was assessed with the 16-item 
identification subtest of the commercially available Sniffin’ Sticks.181 The total score ranged 
from 0 (no odour identified) to 16 (all odours correctly identified).201 
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Group means of the odour identification test, ADAS-cog score and HAMD score, were 
compared by univariate analyses of variance (ANOVA) and post-hoc Scheffé tests; diagnosis 
was treated as a between-subjects factor with three levels (AD, depression, healthy 
controls).201 The alpha level was set at 0.05. Non-parametric rank correlations (Kendall’s tau) 
of odour identification and the ADAS-cog score with age and years of education were 
calculated for the three groups.201 
 
The cognitive status of the AD group overall was in the mild to moderate dementia range.201 
The depressed group overall were mildly to moderately depressed. Post-hoc Scheffé tests 
showed significant differences between AD and depression and the number of correct 
odorants identified (mean difference = -7.25; p<0.001) and between AD and controls (mean 
difference = -6.85; p<0.001), but not between depression and controls (mean difference = 
0.40; p=0.72). The sensitivity of the odour identification test was estimated to be 100% for 
the differentiation of AD from both depressive patients and healthy subjects using a cut-off 
score of ≤10 correctly identified odours out of 16. Specificity was estimated to be 95% for 
the differentiation of AD from depression, and 100% from healthy controls.201 
 
Ansari et al were the first to describe olfactory deficits in PD in 1975.216 Twenty-two male 
PD patients aged 41-67 (mean 58), twenty with idiopathic Parkinson’s disease and two with a 
past history of encephalitis were examined. None had a past history of significant head 
trauma or nasal injury, acute or chronic sinusitis, recent upper respiratory tract infection, 
clinical evidence of liver dysfunction or other illnesses that might conceivably result in 
decreased olfactory acuity. Thirty-seven age-matched males (mean age 53, range 43-68 
years) hospitalised on the Neurology Service for conditions that included seizure disorder, 
multiple sclerosis, stroke and headache were used as controls.216  
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Olfactory loss was assessed by detection threshold for amyl acetate using a double blind 
testing procedure and serial binary dilutions of amyl acetate in odourless liquid paraffin.216 
Five test tubes of liquid were presented to each patient, two tubes contained 0.5 ml of the 
same dilution of amyl acetate, and the other three tubes contained diluent only. Participants 
were required to identify both test tubes containing the odorant to score correctly for that 
dilution. The highest dilution at which the subject correctly identified both tubes containing 
the odorant was designated as the olfactory threshold.216 
 
The mean detection threshold for PD patients was significantly lower (p < 0.05) when 
compared to the age matched control group.216 For PD patients, the threshold was 39 x 10-2 
vol per cent compared to 2.7 x 10-2 vol per cent in the control subjects. There was a 
significant association (p < 0.05) between threshold score and rate of progression of PD, with 
the greatest decrease in olfactory acuity in patients with rapidly progressive Parkinson’s 
disease.216 
 
Lehrner et al compared olfactory function between AD patients and non-demented Parkinson 
disease (PD) and an age matched control group.217 Twenty-two AD patients (2 males, 20 
females) and 21 nondemented patients with PD (13 males, 8 females) and 19 age matched 
controls were recruited into the study. Alzheimer disease patients were significantly older 
than controls and PD patients. The ages of the PD patients and the controls were not 
significantly different. All PD patients were taking anti-Parkinson medication. Cognitive 
status was assessed by MMSE. Olfactory assessment utilised a testing procedure previously 
described by the author.218 Olfactory threshold was assessed using 1-butanol and an 
ascending staircase, two-bottle, forced-choice method. Odour identification used 20 everyday 
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odours. An odour recognition memory task (retention time 15 min) was also administered to 
all participants.217  
 
Statistical comparisons among groups employed analysis of covariance (ANCOVA) using 
age as a covariate, due to the older age of the AD patients, and disease group as the 
independent variable.217 One-way ANCOVA revealed significant differences in olfactory 
thresholds between the groups (P < 0.003). Post hoc analysis (Scheffe's, P < 0.05) found AD 
patients had significantly higher thresholds than the controls. Olfactory thresholds of the PD 
patients did not differ significantly from the control group (p < 0.073). For odour 
identification a one-way ANCOVA revealed significant differences between the groups (P < 
0.001). Post hoc analysis (Scheffe's, P < 0.05) found that controls performed significantly 
better but there was no significant difference between the AD and PD groups in odour 
identification.217 
 
Lee et al compared olfactory function and brain volume of 40 right handed PD patients 
without dementia and 40 controls matched for age, years of education, gender, and 
handedness, using high-resolution T1-weighted brain MRIs and voxel based morphometry.219 
Olfactory function was measured using the UPSIT. Thirty-eight PD and 39 controls 
completed the UPSIT.219 
 
After adjusting for age, PD patients had significantly lower UPSIT scores compared to 
controls (mean UPSIT, 22.55/40; SD, 6.55 vs.. mean UPSIT, 34.38/40; SD, 5.38; P < 
0.0001).219 Compared to controls, PD patients sustained significantly greater grey matter loss 
localised to bilateral piriform cortex (P < 0.005) and orbitofrontal cortex (P < 0.05). Reduced 
olfactory performance in PD was significantly associated with lower grey matter volumes in 
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right piriform cortex and left orbitofrontal cortex (R = 0.33; uncorrected P = 0.028, one-
tailed; N = 38 and R = 0.37; uncorrected P = 0.015, one-tailed; N  
 
Olfactory impairment has been reported to predict cognitive decline and Alzheimer dementia. 
Devanand et al reported an increased risk of cognitive decline and Alzheimer dementia in a 
multiethnic community of North Manhattan, New York, in persons with olfactory 
impairment, at two and four years.220 Participants of the Washington Heights/Inwood 
Columbia Aging Project (WHICAP), a cohort study using a stratified random sample of 50% 
of all Medicare beneficiaries aged 65 years and older obtained from the Health Care Finance 
Administration, were recruited from a specific region of North Manhattan.221 Participants 
were recruited over two periods, one cohort recruited in 1992 (approximately 25% of 
subjects) and a new cohort recruited between 1999 and 2001 (approximately 75% of 
subjects).  
 
Participants received a standardised neuropsychological test battery at each visit. The battery 
included measures of learning and memory, orientation, abstract reasoning, executive 
function, language, and visuospatial ability. A function score was determined by summing six 
items for instrumental activities of daily living.222 A standardised neurologic examination was 
performed at each visit and included a 10-item version of the Unified Parkinson’s Disease 
Rating Scale,222 used to diagnose Parkinson disease.223 Assessment of odour identification 
utilised the UPSIT. Participants were required to complete ≥ 38 of the 40 UPSIT items to be 
included in the study. For participants who completed 38 or 39 items, a score of 0.25 was 
imputed for each missing item. Participants with a diagnosis of stroke or Parkinson disease 
were excluded.  
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The baseline UPSIT testing was administered between 2004 and 2006. The study sample 
comprised participants without dementia who received the UPSIT. Follow-up data was 
collected during 2006–2008 (2-year follow-up) and 2008–2010 (4-year follow-up). 
Diagnoses of dementia, including AD dementia, were made based on available clinical, 
cognitive, and functional information excluding UPSIT data. Cognitive decline was defined 
as a decline in the average of the three cognitive composite scores of 1 SD or greater for 4-
year follow-up or a decline of 0.5 SD or greater if follow-up was limited to 2 years. 
Outcomes at the last available follow-up time point were used.220 
 
Distributions and group differences in demographic and clinical variables were examined by 
χ2, t test, and general linear models.220 Spearman correlations between UPSIT scores and 
demographic, cognitive and functional measures were evaluated. The definition of cognitive 
decline was based on the trend in the composite cognitive domain scores during follow-up. 
Logistic regression analyses were used for the outcome of cognitive decline. Discrete time 
survival models were used to estimate associations between baseline UPSIT scores and the 
outcome AD dementia. The covariates used were age, sex, education, Selective Reminding 
Test (SRT) Total immediate Recall (SRT-TR) and functional impairment. Selective 
reminding test total immediate recall (SRT-TR) was a component of the composite cognitive 
domain scores for memory, selected a priori for inclusion in the modelling. Analyses were 
conducted in SAS 9.3 (SAS Institute, Cary, NC) and R (v.3.0.1) package pROC.220 
. 
A total of 1,037 participants of 1,119 (92.7%) without dementia were evaluated.220 In 757 
participants, follow-up occurred at 2 or 4-years. Of those 757 participants who completed at 
least one follow-up, 109 transitioned to dementia. Of those, 101 transitioned to AD dementia, 
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2 transitioned to vascular dementia, 3 transitioned to Lewy body dementia and 3 participants 
to other causes of dementia.220 
 For participants with baseline status of no MCI, nonamnestic MCI, and amnestic MCI, 
transition rates to any dementia at final follow-up were; 35/498 (7.03%); 32/129 (24.81%); 
and 42/130 (32.31%) respectively (χ2 = 67.11, p < 0.0001) and for AD dementia were: 33/498 
(6.64%), 31/129 (24.03%), and 37/130 (28.46%) respectively (χ2 = 57.69, p < 0.0001). 
Participants with cognitive decline (n = 151) had a mean baseline UPSIT score of 24.28 (SD 
= 6.35) compared to a baseline UPSIT score of 27.33 (SD = 6.70) in nondecliners (n = 581). 
Participants not followed (n = 25) had the lowest UPSIT mean score (21.24 (SD = 7.64)).  
 
Logistic regression analyses found a strong association between lower baseline UPSIT score 
and subsequent cognitive decline (RR 1.067 per point interval, CI 1.040 - 1.095; p = 0.0001). 
Lower baseline UPSIT scores remained significantly associated with subsequent cognitive 
decline after adjusting for sex, age, test language, education, STR-TR and functional 
impairment (RR, 1.065 per point interval, CI 1.034 - 1.095).220 UPSIT, but not SRT-TR, 
predicted cognitive decline in participants without baseline cognitive impairment. Lower 
baseline UPSIT scores were significantly associated with transition to AD dementia in 
discrete time survival analyses, (HR 1.099 per point interval, CI 1.067 - 1.131; p = 0.0001) 
and remained significant (HR 1.072 per point interval, CI 1.036 - 1.109; p = 0.0001) after 
including demographic, cognitive, and functional covariates.220 
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The Associations Between Olfactory Impairment and Mortality 
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Olfactory impairment has been termed the canary in the coal mine of human health.224 
Several mechanisms have been suggested to explain the association between olfactory 
impairment and increased mortality risk. The olfactory nerve is exposed to the environment. 
Respiratory exposures could reach the central nervous system via the olfactory nerve and 
cause death due to direct injurious effects.224 Alternatively, these exposures could be 
absorbed and cause systemic effects that increase the risk of mortality while simultaneously 
damaging the olfactory system.224 To function normally, the olfactory system is dependent on 
stem cell turnover to repair damaged olfactory epithelium.225 Impaired olfaction may 
represent a deterioration in age-related regenerative capacity.224 In addition, olfactory 
impairment may lead to unhealthy food choices, malnutrition or an increased risk of accidents 
such as gas fires and explosions.226 It has been suggested that underlying neurodegenerative 
disease may explain the association between olfactory impairment and mortality227,228 
however, longevity in Parkinson disease is similar to the general population229 and the 
decreased longevity in patients with dementia may not wholly explain for the magnitude of 
the association reported.224 
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An association between olfactory impairment and mortality was reported in participants of 
the Rush Memory and Aging Project, a longitudinal study involving annual clinical 
evaluations and brain donation at death.227,230 Participants were recruited from retirement 
communities and subsidised housing facilities in the Chicago metropolitan area starting in 
1997 and expanded in 2001.230 At the time of the analyses, 1232 individuals had completed 
olfactory testing during their baseline testing.227 Persons with dementia and PD were 
excluded from the analysis (n = 58 and n = 12 respectively) leaving 1162 participants. The 
mean age at the time of olfactory testing was 79.7 years (SD = 7.7) and 74.5% were women. 
Olfaction was assessed using the brief smell identification test (B-SIT). This test was 
previously known as the CC-SIT.208 The association of olfactory score with mortality was 
assessed with Cox proportional hazards models. All analyses included terms for age, sex, and 
education. Multivariable adjusted models for other significant covariates were also 
performed.227 
 
After a mean of 4.2 years (SD = 2.6; range 0-9) follow up, 321 (27.6%) participants had 
died.227 Those who died were older, more likely to be male, and more cognitively impaired 
than survivors. Baseline mean B-SIT scores were higher in survivors compared to those who 
died (9.2/12; SD = 2.1 vs.. 8.4/12; SD = 2.3 respectively). After adjustment for age, sex and 
education level, the risk of death decreased by about 6% for each additional correct choice on 
the B-SIT (HR 0.94, CI 0.90-0.98). Participants with a B-SIT score of 6 correct were ≈36% 
more likely to die than a participant with a score of 11. Further analyses examined 
confounding by naming ability on the Boston Naming Test, disability on the Katz scale, 
cardiovascular risk factors and conditions, characteristic patterns of cognitive, social, and 
physical activity and depressive symptoms. In each analysis the association of olfactory 
impairment with mortality remained significant.227 
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The association between olfactory impairment and 5-year all-cause mortality has been 
reported for the BMES population.228 Olfactory assessment was performed using the SDOIT. 
Olfactory impairment was defined as mild in participants scoring greater than 3 but less than 
6 and moderate as 3 or less out of a total of eight possible responses.228 At baseline, persons 
with olfactory loss were more likely to be older and male and to have visual impairment, 
cognitive impairment, diabetes, angina, stroke, lower BMI, and poor self-rated health and 
higher serum total cholesterol.228 The mortality rate was more than double in the olfactory 
impaired group when compared to participants with normal olfaction (21.8%, n = 96 vs.. 
8.3%, n = 99). After adjustment for age and sex, mortality risk was significantly increased in 
persons with any olfactory loss compared to normosmics (HR 1.69, CI 1.26-2.27). This risk 
was higher in persons with moderate olfactory loss (HR 1.99, CI 1.42-2.80). After 
multivariable adjustment for other covariates associated with increased mortality, the 
increased risk associated with moderate olfactory loss remained statistically significant (HR 
1.68, CI 1.10-2.56). The association became non-significant after the addition of cognitive 
impairment to the model (HR 1.51, CI 0.96-2.38).228 
 
The Washington Heights/Inwood Columbia Aging Project is a prospective cohort study of a 
stratified random sample of 50% of all Medicare beneficiaries aged 65 years and older from a 
specific region of North Manhattan, New York.221 Participants were recruited originally in 
1992 and a new cohort recruited between 1999 and 2001. The associations between olfactory 
impairment and 4-year mortality (mean = 4.1 years, standard deviation = 2.6, range = 0-9.8 
years), have been reported for this cohort.226 Participants with a history of stroke, PD, 
atypical Parkinsonian syndrome diagnoses, schizophrenia, and other psychotic disorders were 
excluded from the analysis of olfactory impairment and mortality.226 
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All participants completed standardised neuropsychological testing of learning and memory, 
orientation, abstract reasoning, executive function, language, and visuospatial ability.226 
Assessment of odour identification utilised the UPSIT. Mortality was ascertained and 
confirmed with family members and via the National Death Index. Age, gender, 
race/ethnicity, education and language of UPSIT administration were covariates in all 
analyses. Participant medical and social histories and qualitative grading of self-reported 
vision and hearing impairments were determined via interview.226   
 
Demographic and clinical variables were compared by chi-square tests and general linear 
models.226 The association of the UPSIT score with mortality was estimated using Cox 
proportional hazard models. The initial model included the UPSIT score alone. Subsequent 
models then estimated the association after adjustment for individual demographic covariates. 
The association of UPSIT score with mortality within 5 years was estimated by logistic 
regression analysis.226 
 
In the proportional hazard model (UPSIT score alone) the mortality risk was significantly 
increased with decreasing UPSIT score (HR, 1.068 per point interval, CI 1.053-1.083, 
p<0.001).226 After dividing UPSIT scores into quartiles, (0-20, 20-26, 26-31, and 31-40), 
compared to the fourth quartile with the highest UPSIT scores, HRs for mortality were 3.81 
(CI 2.71-5.34), 1.75 (CI 1.23-2.50) and 1.58 (CI 1.09-2.30) for the first, second, and third 
quartiles respectively. The association between lower UPSIT score and mortality remained 
significant after adjustment for age, gender, education, ethnicity, language, modified 
Charlson medical comorbidity index, dementia, depression, alcohol abuse, head injury, 
smoking, body mass index, and vision and hearing impairment (HR 1.05 CI 1.03-1.07).226 
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The National Social Life, Health, and Aging Project (NSHAP) is a nationally representative 
study of 3005 community-dwelling male and female older adults aged ≥57-≤85-years.231 The 
study was designed to examine associations between covariates and intimate social 
relationships, including marriage, family, social ties, and sexuality. The study collected 
information on physical and cognitive health, health behaviours, medications, and health 
service utilisation and a selection of biomarkers and other physiological assessments, 
including sensory functions.231  
 
Baseline data were collected during 2005 – 2006 by in-home interview. Data were collected 
from 1454 men and 1551 women living throughout the US. Five-year mortality data were 
collected by either speaking with the respondent (alive) or by conducting a proxy interview 
with a family member or neighbour or examining public records or news sources.224 Cases 
were pursued to determine whether respondents were likely alive, but not accessible for re-
interview, or deceased. At 5-year follow-up, 430 participants were determined to be deceased 
and 2,565 were determined to be alive, leaving 10 cases in which it was unknown whether the 
participant was alive or not. These participants were excluded from the analyses. An 
additional 77 participants were excluded from the 
analyses due to missing data in one of the primary independent variables (odour 
identification, demographics and comorbidity index) A total of N=2,918 participants 
remained for analyses of the association between olfactory impairment and 5-year mortality 
risk.224 
 
Olfactory function was assessed using a validated abbreviated five item version of the 
Sniffin’ Sticks odour identification test.232 Each odorant was presented one at a time and 
participants were asked to identify each odorant by choosing from a set of four picture/word 
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prompts in a forced choice protocol.233 Refusals were coded as incorrect. The target odours 
were rose, leather, orange, fish, and peppermint. The number of errors made was used to 
categorise olfactory impairment as follows: anosmic =4–5 errors; hyposmic =2–3 errors; and 
normosmic =0–1 error.233 
 
Adjustment was made for covariates known to be associated with mortality.224 Age was 
categorised into three groups: 57–64 years; 65–74 years and 75–85 years. Socioeconomic 
status was measured by education (highest degree or certification earned). Comorbid diseases 
were assessed with the Charlson Index modified for NSHAP.234 In addition, participants were 
asked whether a doctor had ever told them they had a particular disease. Nutrition measures 
included self-reported taste, the presence of poor appetite and body-mass index (BMI). 
Inability to perform one or more of seven activities of daily living (ADL) quantified frailty. 
Cognitive function was measured with a modified version of the Short Portable Mental Status 
Questionnaire (SPMSQ)235. Self-rated mental health was measured by a standard 5-point 
scale (excellent, very good, good, fair, or poor). Health behaviours affecting olfaction were 
current smoking, based on either salivary cotinine level or self-report, and problem 
drinking.224 
 
Statistical analyses were conducted with Stata Version 13.0 (Stata Corp LP, College Station, 
Texas, USA).224 Olfactory dysfunction (anosmia, hyposmia, or normosmia) or the number of 
odours incorrectly identified (0–5) was treated as the independent variable and death as the 
dependent variable in separate analyses. Multivariate logistic regression was used to estimate 
the associations between olfactory dysfunction and covariates of interest present at the 
baseline examination and 5-year mortality. P-values and 95% confidence intervals were 
based on the corresponding Wald statistic.224  
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The response rate was 75.5% and nonresponders were similar demographically to the 
responders.224 The 5-year mortality rates stratified by baseline olfactory function were 12.5% 
overall, 39% for participants with anosmia, 19% for participants with hyposmia and 10% for 
participants with normosmia (p = 0.001). The risk of 5-year mortality was significantly 
increased for participants with anosmia and hyposmia compared to normosmics (OR 3.37, CI 
2.04 – 5.07 and OR 1.47, CI 1.00 – 2.17 respectively) after adjustment for age, sex, 
comorbidity index and common diseases causing death.224 
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Summary 
The Prevalence of Olfactory Impairment 
The prevalence of olfactory impairment is reported to be 10.6-24.5%168,170,171,173 although one 
small Korean study reported a prevalence of 80% in persons aged 65-89 years old.175 In most 
studies the prevalence was higher in males168,170,173 and increased with age,168,170,171,187 upper 
respiratory tract infection,168 previous stroke,168 the presence of nasal polyps173 and a 
diagnosis of epilepsy.168  
 
The association with current smoking is inconsistent. Murphy et al reported a significant 
association168 while two other studies reported no statistically significant association.170,173 
There were no significant associations reported between former smoking and olfactory 
impairment.168,170 
 
The sensitivity of self-reported olfactory impairment is low168,170,173,175,177 (20-44%) and 
decreases with age.168 The specificity of self-reported olfactory impairment is reported to be 
85-94%.168,170 
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The Associations Between Olfactory Impairment and Morbidity 
Normosmic persons with self-reported olfactory loss were found to be more likely to report 
an impact on quality of life when compared to hyposmic persons.173,177  
 
The BMES reported persons with quantitative olfactory impairment had statistically 
significant lower self-rated health and SF-36 scores after multivariable adjustment.185 
Olfactory impaired persons were also more likely to use community and informal supports 
and more likely to report difficulty in ADL.185  
 
In a study of persons with ≥ six months of severe hyposmia or anosmia, participants were 
reported to have significantly lower SF-36 and QOD scores when compared to age and sex 
matched normosmic controls.187 
 
Significant associations between OI and QOL were also identified in patients of an outpatient 
clinic for taste and smell disorders.177 Frasnelli et al reported patients with quantitative 
olfactory impairment had statistically significant reduced NS-QOD scores when compared to 
age and sex matched normosmic controls. No significant associations were found with PS-
QOD. Parosmia was significantly associated with reduced PS-QOD scores when compared to 
persons without parosmia, but there was no association between parosmia and NS-QOD.177 
 
No significant correlation was reported between measured olfactory loss and QOL after 
multivariable adjustment in a small cross sectional Korean population based study.175 
 
Study participants who voluntarily joined a support organisation for persons experiencing 
problems with smell were reported to have lower HRQOL in two studies when compared to 
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normosmic persons from the general population.182,184 Olfaction was not measured in these 
studies.182,184 
 
Women with self-reported or objective OI were reported to have significantly lower QOL 
when compared to their male counterparts.177,184,187 
 
Biological pathways linking olfactory impairment with depression have been proposed.188-190 
Despite this, statistical associations in between olfactory impairment and depression appear 
weak. Few large population based studies exist. 
 
The BMES reported no significant associations between olfactory impairment and depression 
overall.185 In persons older than 70 years, olfactory impairment increased the likelihood of 
depression if scored by the CESD-10 but not the MHI component of the SF-36.185 A Korean 
population based study of persons aged 65-89 years reported no significant association 
between olfactory impairment and depression after multivariable adjustment.175 A study of 
elderly persons with mild to moderate depression found no significant association with odour 
identification when compared to age and sex matched controls.201 
 
Three studies of persons with diagnoses of major depression were reviewed and had 
conflicting results. One study compared 51 depressed patients with 51 age and sex matched 
controls; no significant associations were found between olfactory impairment and 
depression.199 Another study of 18 persons with major depression and 18 age and sex 
matched controls reported a statistically significant association between lower BDI score and 
higher olfactory sensitivity to the odorant eugenol.193 In this study, persons with major 
depression had lower sensitivity to all odorants assessed when compared to matched controls, 
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but the differences were not significant. After treatment of depression, the statistically 
significant lower threshold score for eugenol in depressed patients became non-significant.193 
The third study of persons with major depression compared 49 depressed persons with 58 
age, sex and smoking matched controls. This study reported statistically significant 
associations between olfactory sensitivity, but not identification, and depression.195  
 
A study of 48 persons with no current or previous history of depression reported a 
statistically significant negative correlation between olfactory sensitivity and the BDI score 
(persons with higher BDI score having lower olfactory sensitivity) but not between olfactory 
discrimination and BDI score.202 
 
Two included studies examined the associations with olfactory impairment and depression in 
support groups for persons with olfactory impairment.182,182 Olfactory function was not 
formally assessed in these studies. Persons who were members of the organisation for 
anosmia were reported to be significantly more likely to have depression when compared to 
normosmic matched controls.182 The rates of anxiety and depression were also reported to be 
higher in members of the UK support group for persons with olfactory impairment, Fifth 
Sense, when compared to the reported rate of depression in the general population of the UK. 
182,198 
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The Associations Between Olfactory Impairment, Cognitive Impairment and Parkinson 
Disease 
Strong associations have been reported between olfactory impairment and cognitive 
impairment,175 vascular dementia,210 Alzheimer disease,201,207,209 subsequent cognitive 
decline205,207 and Parkinson Disease.216,217 Loss of olfactory function correlates with loss of 
brain volume in PD patients.219 
 
Olfactory dysfunction may differ between AD and PD. One study comparing Alzheimer 
disease with non-dementing Parkinson disease and an age and sex matched control group 
reported both the Alzheimer and Parkinson groups had statistically significant reduced odour 
identification scores when compared to the control group.217 Alzheimer, but not Parkinson 
disease participants had statistically significant increased olfactory threshold compared to the 
age and sex matched control group.217 
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The Associations Between Olfactory Impairment and Mortality 
Higher mortality rate has been reported in persons with olfactory impairment.224,226-228 
Gopinath et al reported the association between olfactory impairment and mortality rate to be 
statistically significant after multivariable adjustment for covariates associated with mortality, 
but not after further adjustment for cognitive impairment.228 Two other studies excluded 
persons with dementia and PD. Both reported significant associations between olfactory 
impairment and mortality after multivariable adjustment including cognitive 
impairment.226,227 Pinto et al  
 
Olfaction and neurodegenerative diseases are linked clinically and pathologically. Cognitive 
deficits may be one small component explaining the effect of odour identification on 
mortality, but may not account for the majority of the role olfaction plays on this outcome. 
Correcting for cognitive deficit may lead to underestimation of the association between OI 
and mortality.224,226-229  
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Chapter Two: Methods 
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2.1 Study population: the Blue Mountains Eye Study 
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Choice of Site and Sampling Method 
The Beaver Dam Eye Study is a population based study of eye disease in a small United 
States community that began in 1987 that a very high response rate of 88%. It was thought 
that an Australian study could obtain a similarly high response rate in a compact urban 
“town” population. It was also thought that using a single well defined geographical sample 
would achieve a higher response rate and lower costs compared to a multisite random cluster 
sample such as that used in the Melbourne Visual Impairment Project. It was determined that 
a sample size of greater than 4000 would be required to provide a power of 90-99% to detect 
the major risk factors of visual impairment and blindness. 
 
The adjoining Blue Mountains urban townships of Katoomba, Leura and Medlow Bath (post 
code 2780) and Wentworth Falls (postcode 2782), approximately 100 kilometres west of 
Sydney, were subsequently chosen. When the study commenced in 1991, this area had an 
older age distribution compared to the state of NSW average, a population size that was 
adequate to provide greater than 4000 participants and relatively stable, and was 
representative of the state of New South Wales in terms of ancestry, occupation, education 
and income level.236 The choice was reinforced by the enthusiastic support of eye care and 
general practitioners canvassed when planning the study. 
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Identification of Eligible Participants 
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Eligibility Criteria 
To be eligible for the survey, three criteria were set: 
1. Resident in the postcode areas at the time of the door to door census. 
2. Permanent residency (residing at the address for more than 6 months per calendar 
year). Current residence was accepted if recently moved to the address.  
3. Born before January 1, 1943. Aged 49 years or older at the time of the 
commencement of the survey. 
 
There was no upper age limit. 
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Census of the Population 
To identify eligible persons, a census was conducted by sequential door knock of all 
dwellings in the area by a trained team of 14 census collectors, many of whom had worked as 
census collectors for the Australian Bureau of Statistics (ABS). Census methods were 
identical to those used in the ABS national census (Census 91) on August 6, 1991.237 The 
census was conducted from November to December 1991 in the Blue Mountains urban 
townships of Katoomba, Leura and Medlow Bath (postcode 2780), and repeated from March 
to April 1993 in the Blue Mountains township of Wentworth Falls (postcode 2782). In total, 
38 Census Collector Districts (CCDs) were surveyed including 28 in postcode area 2780 and 
10 in postcode area 2782.  
 
The census was preceded by a local newspaper article (Blue Mountains Gazette) and 
notification by mail to every residential and business address in the study area. Posters 
providing information about the study were displayed in prominent public places, optometrist 
offices and general practitioner surgeries. Detailed information regarding the Eye Study was 
also supplied to all healthcare providers servicing the area. 
 
The aim of the census was to determine the names, birthdates, addresses and telephone 
numbers of all eligible permanent residents living in each CCD. Call-back visits to each 
house were made until contact was made with the resident either by door knocking or by 
telephone. An electronic telephone directory and council listings of rate payers sorted by 
street were obtained for this purpose. Leaflets were left in the letterbox at each visit that 
failed to contact the resident requesting them to telephone the Study information line. 
Subsequently, a letter addressed to “The Resident” that included a reply paid envelope was 
sent to each dwelling where no contact had been made. The letter explained the study and 
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requested an indication of whether or not eligible persons lived at the residence, regardless of 
whether they wished to participate. Final classification of no contact was made after five 
separate calls to the house were made at different times (morning, afternoon, evening) on 
different days of the week (including weekends) and after a total of three mail outs to the 
household identified no eligible residents. 
 
An attempt was made at initial contact to complete a short questionnaire for each eligible 
resident. In some cases it was completed at the time of booking an appointment for the 
examination. Questions identified the person’s general practitioner, self-reported vision or 
hearing problems and past diagnoses of cataract, glaucoma, macular degeneration and 
diabetic retinopathy. Past medical history and last attendance to an optometrist or 
ophthalmologist was also determined. In some cases the questionnaire was completed by the 
spouse or relative of persons who were unable or refused to attend. 
 
Persons who refused to provide answers to the door step questionnaire or to participate in the 
Eye Study were re-contacted up to ten times. Evening and weekend appointments, home 
visits and transport were offered at all stages of the recruitment process. Financial incentives 
were not offered at any time. 
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2.2 Interview and Examination Procedures 
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Baseline Study 
After the initial contact and interview, an information sheet was given to each eligible 
resident. This provided details about the Eye Study, and indicated that they would be invited 
to take part at a later date. All identified eligible residents were subsequently invited to attend 
the study examinations at the Blue Mountains District ANZAC Memorial Hospital. The 
protocol received ethical approval from the Western Sydney Area Health Service Human 
Research and Ethics Committee. Signed informed consent was obtained from all participants 
at the time of the examination. 
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Study Protocol 
The examinations were conducted according to a standardised study protocol based on the 
Beaver Dam Eye Study protocol. This allowed meaningful comparison with other Australian 
and international population based studies. The Blue Mountains Eye Study questionnaire and 
flow sheet is provided in appendix A. The examinations began in January 1992 and were 
completed in January 1994. Trained interviewers administered a comprehensive demographic 
and medical questionnaire for each participant. The questionnaire detailed past and current 
medications, family and social history, medical and surgical history, alcohol and smoking 
history and a self-rating of global health and vision. The questionnaire also assessed 
independence, mobility and exercise, women’s health, coffee and tea intake, driving ability 
and sun exposure. Questions detailing previous diagnoses of, or a family history of, specific 
eye diseases were also asked. 
 
The examination and interview procedures were divided into four sections conducted in four 
separate rooms to facilitate completion. The whole procedure took on average one and a half 
hours to complete.  
 
  
225 
 
Measurement of Visual Acuity and Refractive Error 
The current glasses of each participant were neutralised using the Humphrey automatic lens 
analyser model 330 (Allergan Humphrey, San Leandro, CA) and the printout affixed to the 
study flow sheet. The type of glasses was also coded. 
 
Objective refraction of each participant was performed using the Humphrey 530 Automatic 
Refractor (Allergan Humphrey, San Leandro, CA). The sphere, cylinder and a reflex reading 
was measured for each eye and the printout affixed to the study flow sheet. 
 
Visual acuity was measured using a retro-illuminating logarithm of the minimum angle of 
resolution (LogMAR) chart (Vectorvision CSV-1000TM Vectorvision Inc, Dayton, Ohio) read 
at 2.4 metres. The CSV-1000 uses a fluorescent light source and monitors and calibrates the 
light level to 85 candelas per square metre ± 0.1 log units using a series of photocells. 
 
Distance visual acuity was first assessed for each eye using current distance glasses if worn, 
then with a 1.2mm pinhole aperture held over the current distance glasses and finally after 
subjective refraction. If no letters could be read at 2.4 metres, the chart was moved to 0.95 
metres (0.4 log units closer to the participant). If no letters could be read at 0.95 metres, 
vision was assessed as “count fingers” at 0.5meteres, “hand movements”, “perception of 
light”, or “no perception of light. Table 2.1 lists the equivalent scores for the LogMAR and 
Snellen charts. 
 
Distance visual acuity was first measured in the right eye and then the left, using a different 
test face for each eye. With the opposite eye covered, the participant was asked to slowly read 
from the first letter on the left hand side at the top of the chart. Each letter that was read 
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correctly was circled on a scoresheet identical to the face of the chart. Only one attempt was 
allowed for each letter. If the participant had difficulties with any letter they were encouraged 
to guess. 
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Letter Score      
2.4 metres 
Snellen Visual 
Acuity 2.4 
metres 
logMAR Visual 
Acuity 2.4 
metres 
Snellen Visual 
Acuity 0.95 
metres 
logMAR Visual 
Acuity 0.95 
metres 
5 6/60 1.0 6/150 1.4 
10 6/48 0.9 6/120 1.3 
15 6/38 0.8 6/95 1.2 
20 6/30 0.7 6/75 1.1 
25 6/24 0.6 6/60 1.0 
30 6/19 0.5 6/48 0.9 
35 6/15 0.4 6/38 0.8 
40 6/12 0.3 6/30 0.7 
45 6/9.5 0.2 6/24 0.6 
50 6/7.5 0.1 6/19 0.5 
55 6/6 0.0 6/15 0.4 
60 6/4.8 -0.1 6/12 0.3 
65 6/3.8 -0.2 6/9.5 0.2 
70 6/3.0 -0.3 6/7.5 0.1 
 
 
  
9  Table 2.1 Equivalent letter scores comparing the logarithm of the minimum angle of 
resolution (logMAR) and Snellen charts 
228 
 
Distance visual acuity was recorded as the number of letters read correctly from 0 to 70 and 
then calculated according to the test distance. Participants with 54 letters or better read 
correctly at 2.4 metres without glasses were recorded as emmetropic. Participants with 54 
letters or better read correctly at 2.4 metres with their current glasses were not refracted. The 
results from the automatic lens neutraliser were recorded as the refractive error. If visual 
acuity was less than 54 letters read correctly then subjective refraction was performed using 
the Beaver Dam modification of the Early Treatment Diabetic Retinopathy Study (ETDRS) 
protocol3 using the 0.5D and 0.25D Jackson cross cylinder. Refractive error was tested in 
0.25D steps. Cylinder powers were measured and recorded in the negative form. Astigmatic 
axes were measured to the nearest 2.5 degrees for powers of 1D or less, or to the nearest 
degree for higher power. The result from the automatic lens neutraliser was used as the initial 
trial lens. 
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Examination of the Eye 
The eye lids, conjunctiva and anterior chamber of the eye were examined using a slit-lamp. 
Participants with a shallow anterior chamber or iris clip intraocular lens were identified and 
excluded from the dilated examination. The remaining participant’s pupils were dilated with 
Tropicamide 1% and Phenylephrine 10% and the lens and retina examined. The examination 
included retro-illumination photographs of the lens and stereoscopic photographs of the optic 
disc and retina. 
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Identification of Eye Disease 
The presence of cataract was determined by slit-lamp examination and documented with both 
slit-lamp (TopconSL-7e camera, Topcon Optical Co., Tokyo, Japan) and retro-illumination 
(Neitz CT-R cataract camera, Neitz Instrument Co., Tokyo, Japan) lens photographs. Details 
of the cataract238 photographs and grading system used in the Blue Mountains Eye Study 
have been previously reported and closely follow the Wisconsin Cataract239 Grading System. 
 
Retinal diseases were diagnosed by the examining ophthalmologist (PM) and confirmed by 
grading of stereoscopic retinal photographs. Details of the age related maculopathy240 
photographs and grading system used in the Blue Mountains Eye Study have been previously 
reported and closely follow the Wisconsin Age-Related Maculopathy241 Grading System. 
Inter-grader and intra-grader reliability was assessed on a random subsample of gradable 
photographs with good agreement achieved.240 Diabetic retinopathy was diagnosed if typical 
retinopathy lesions were present in subjects with a history of diabetes or with fasting blood 
glucose ≥ 7.8 mmol/l. Retinopathy lesions were also graded in non-diabetic participants.  
 
Intraocular pressure (IOP) was measured using Goldmann applanation tonometry. Open-
angle glaucoma was diagnosed by the presence of glaucomatous visual field changes using 
automated perimetry (Humphrey 30-2 test) with matching optic disc rim thinning and an 
enlarged cup to disc ratio (>0.6) or cup to disc ration asymmetry (>0.3) between the two 
eyes.242 
 
Spherical equivalent refraction, measured in dioptres, was calculated using the spherical 
dioptric power plus half the cylindrical power. Myopia was defined as a mean spherical 
equivalent of the two eyes ≥ -1 dioptre.  Unilateral amblyopia was diagnosed if the best-
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corrected visual acuity was ≥ 6/9 in the affected eye and was not attributable to any 
underlying structural abnormality of the eye or visual pathway.  
 
Estimation of the proportional causes contributing to decreased visual acuity was made for 
each eye with impaired vision by the examining ophthalmologist (PM). Confirmation of these 
causes was made during masked grading of the lens and retinal photographs.  
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Socio-demographic variables 
Socio-demographic variables were evaluated and defined dichotomously. Attainment of 
higher education was determined by the achievement of a trade certificate or higher 
qualification, according to the ABS Classification of Occupation.243 Occupational prestige 
was assessed based on the participant’s principle occupation using the Daniel Occupational 
Prestige Scale. Occupational prestige was categorised as “average to high” if the score was ≤ 
4.0 (equivalent to a trade certificate or better) or low if the score was > 4.0.244 It was also 
determined by questionnaire whether the participant owned their own home, was renting or 
was living in a relative’s home. The participant’s marital status, whether they lived alone, or 
with a spouse or other persons was also determined by questionnaire.  
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Medical, Smoking and Alcohol History 
Medical, alcohol and smoking histories were determined by interviewer-administered 
questionnaire by a trained examiner. A history of angina, myocardial infarction, diabetes, 
hypertension, stroke, arthritis, asthma, migraine, gout, thyroid disease, Parkinson disease, 
dementia, kidney disease, liver disease or cancer was determined by responses to the question 
“Has a doctor advised you that you have….?” History of smoking was defined as never, past 
or current smoking. Current smokers included those who had stopped smoking within the 
past year. Alcohol consumption was categorised as none or light to moderate (≤4 standard 
drinks per day) and heavy (>4 standard drinks per day). Participants were also asked if they 
had hearing loss. 
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Anthropometric Variables, Self-Rated health, Functional Disability and use of Support 
Services 
Weight in kilograms, height in meters, and systolic and diastolic blood pressures 
(Auscultatory) were recorded. Body mass index was calculated using the formula: weight 
(kg)/height (m)2. Functional assessments were performed for all participants by asking 
questions about the participant’s ability to complete activities of daily living, such as driving, 
cleaning, and shopping and whether they received home help or whether they were able to do 
out alone and how frequently. Disability in walking was assessed by one trained examiner 
based on an observed difficulty in walking or the use of a cane, walking frame or wheelchair. 
Participants were also asked if they had fallen in the previous twelve months and whether 
they walked regularly for exercise. Self-rated health was assessed by questionnaire and 
dichotomised into two levels: poor or fair vs.. good or excellent. 
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Use of Eye Care Services 
Details of the proceeding two visits to either an ophthalmologist or optometrist were 
documented, including the name and office address of the eye care practitioner. If an 
ophthalmologist had not been seen in the previous two visits the participant was asked if they 
had ever seen an ophthalmologist.  
 
The designation of the optometrist and ophthalmologist was verified by reference to a booklet 
of ophthalmologist members of the Royal Australian College of Ophthalmologists. The 
interviewer was trained regarding the names of ophthalmologists and optometrists working in 
the local area and in Western Sydney and then referred to the booklet as required. The names 
of the ophthalmologists and optometrists given by the participants were again cross checked 
to confirm their status during data entry and cleaning procedures. 
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Examination of Nursing Home Residents 
To provide a representative sample of nursing home residents, three Blue Mountains nursing 
homes (Burlington, Martyn Claver and Sans Souci) were selected from the postcode area 
2870. Questionnaires and examinations were attempted on all eligible nursing home residents 
after obtaining informed consent form the either the resident or their legal guardian. The 
nursing home medical records were also reviewed to complete the questionnaires. Visual 
acuity was assessed with the CSV-1000 logMAR with current glasses if worn and a 
subjective refraction attempted if their visual acuity was less than 54 letters read correctly. 
Participants who were unable to read letters on the vision chart were assessed using the 
Sheridan-Gardiner letter matching test, providing Snellen equivalent visual acuity. Bjerrum 
visual field testing was attempted in all nursing home participants. The eye lids, conjunctiva 
and anterior chamber of the eye were examined using a slit-lamp (standard or portable). 
Intraocular pressure was measured using either Goldmann applanation or Tonopen 
tonometry.  The pupils were dilated with 1% Tropicamide and 10% Phenylephrine. Direct 
and indirect ophthalmoscopy was performed and biomicroscopy of the retina and optic disc 
attempted in all nursing home participants.  
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Longitudinal Studies 
The Blue Mountains Eye Study has been repeated every five years since the baseline 
examinations began in 1992. The baseline study examined 3654 residents aged >49 years 
during 1992 to 1994(BMES 1), representing a participation rate of 82.4%. Of the baseline 
participants, 2335 (75.1% of survivors) returned for five year follow-up examinations during 
1997-9 (BMES 2), and 1952 participants (53.4% of the original cohort, or 76.6% of 
survivors) returned for ten year follow-up examinations during 2002-4 (BMES 3). At the 
BMES 2, a detailed hearing questionnaire and the mini mental state examination was added 
to the study protocol and repeated at follow-up (BMES 3 and 4). At BMES 3 a detailed 
olfactory questionnaire and examination was also added to the study protocol. The study 
questionnaires and flow sheets for BMES 4 are provided in appendix A. 
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Identification of Deaths 
To identify and confirm persons who died after the baseline examination, demographic 
information including surname, first and second names, gender and date of birth of the 3654 
participants were cross-matched with Australian National Death Index (NDI) data for deaths, 
to the end of 2005. A probabilistic record linkage package was used, adopting a multiple pass 
procedure in which both data sets were grouped based on different characteristics (e.g. date of 
birth, name, sex) each time. Matches were divided into exact and non-exact. A pair of records 
matched on each demographic characteristic was defined as an exact match. All non-exact 
matched records were examined manually and accepted if there was only one non-exact 
matched characteristic that was not critical. Information provided by family members during 
follow-up was also included if the participant was reported to have died on or before 
December 2005. The International Classification of Diseases, Ninth Revision 245 and 
International Statistical Classification of Diseases, 10th Revision 246 cause of death codes 
were also obtained. The primary cause of death was used in statistical modelling. 
  
239 
 
Hearing Questionnaire 
An audiologist-administered questionnaire (Appendix A2) included history of any self-
perceived hearing problem, including its severity, onset and duration, whether primary care 
practitioners or other professionals had been consulted and if a hearing aid had been 
provided. Hearing-related questions included family history of hearing loss, past medical or 
surgical treatment of otologic conditions, diseases associated with hearing loss and risk 
factors for ear disease. Other questions addressed exposure to noise at work, or during 
military service or leisure activities, the presence of tinnitus and past use of ototoxic drugs. 
The severity of the noise exposure was subjectively classified in three ways: mostly quiet, 
tolerable level, unable to hear speech. The duration of the noise exposure was categorised in 
years. 
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Hearing Examination 
Pure-tone audiometry was performed by audiologists in sound treated booths, using TDH-39 
earphones and a Madsen OB822 audiometer (Madsen Electronics, Copenhagen, Denmark). 
Audiometer calibration was conducted regularly and complied with the International 
Standards Organization protocol 389 (1991). Audiometric thresholds for air conducted 
stimuli (right and left ears) were established for frequencies at 250, 500, 1000, 2000, 4000, 
Tielsch, 1991 #355160, and 8000 Hz, with 3000 Hz added if a 20 dB difference existed 
between the 2000 & 4000 Hz thresholds. Bone conduction was measured if AC thresholds 
were greater than 15 dB HL for the frequencies 500, 1000, 2000, and 4000 Hz. Acoustic 
impedance and speech discrimination testing was also conducted.  
  
241 
 
Olfactory Examination 
Participants were tested individually with the San Diego Odour Identification Test (SDOIT), 
an 8-item odor identification test with a test-retest reliability relatively similar to the 40-item 
UPSIT (r = 0.86 SDOIT; r = 0.94 UPSIT).247 Odorants were presented to participants in 
random order, in an opaque container covered with gauze. An inter-stimulus pause of 45 
seconds was used to prevent adaptation.248 A picture board illustrating the odorants as well as 
distracters was used for participants to identify each odorant. Scores were calculated by the 
number of odorants identified correctly. Self-reported olfactory loss was also determined by 
interviewer-administered questionnaire (Appendix A). 
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The Blue Mountains Hearing Study 
The Blue Mountains Hearing Study (BMHS) is a population-based survey of age-related 
hearing loss in a representative older Australian community. The BMHS invited participants 
who attended the second cross-sectional survey of the Blue Mountains Eye Study (BMES 2). 
Persons who moved into the study area or study age group were identified by a repeat door-to 
door census in 1999 and were invited to participate. The BMHS was conducted during 1997 
to 2000. The study was approved by the Human Research Ethics Committee of the University 
of Sydney and was conducted adhering to the tenets of the Helsinki Declaration. Signed 
informed consent was obtained from all the participants at each examination. The hearing 
questionnaire and examinations for the Blue Mountains Hearing Study were identical to those 
described for BMES 2 onwards. 
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2.3 Definitions 
• Visual impairment was defined as: presenting visual impairment (PVI), VA less than 
6/12 Snellen equivalent (<40 letters read correctly) in the better eye using current 
glasses; correctable visual impairment (CVI), PVI correctable to 6/12 Snellen 
equivalent or better by subjective refraction; and non-correctable visual impairment 
(NCVI), PVI correctable to worse than 6/12 Snellen equivalent in the better eye after 
subjective refraction 
• Hearing impairment was defined as: any hearing impairment, the pure-tone average of 
air-conduction hearing thresholds >25 decibels hearing level (dB HL) for the pure 
tone average (PTA) of four frequencies (0.5, 1, 2, and 4 kHz) in the better ear; mild 
hearing impairment, >25 to ≤45 dB HL; moderate to severe hearing impairment, >45 
dB HL for the average of four frequencies (0.5, 1, 2, and 4 kHz) in the better ear 
• Olfactory impairment was defined as: any olfactory impairment, less than 6 correct 
responses;  mild olfactory impairment, less than six but greater than three correct 
responses; and moderate, three or less correct responses out of a total of eight possible 
responses in the SDOIT 
• The definition of hypertension was based on the 2003 World Health Organization/ 
International Society of Hypertension guidelines.249 Hypertension was defined as; any 
hypertension, systolic blood pressure was greater than 140 mm Hg or diastolic greater 
than 90 mm Hg or previously diagnosed with hypertension and taking 
antihypertensive medications; hypertension stage 1, systolic blood pressure 140 to 
159 mm Hg or if diastolic blood pressure 90 to 99 mm Hg; Hypertension stage 2, 
previously diagnosed with hypertension and taking antihypertensive medications or 
systolic blood pressure 160 mmHg or greater or diastolic blood pressure 100mmHg or 
greater 
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• Body mass index (BMI) was calculated using the formula weight (kg)/ height (m)2 
and was defined as; underweight, <20 kg/m2; normal weight, 20-25 kg/m2; 
overweight, 26-30 kg/m2; and obese (>30 kg/m2) 
• Disability in walking at baseline was defined as present if the participant was 
observed by a trained examiner to have walking difficulties, or used walking aids or a 
wheelchair 
• Cognitive impairment was defined as mini mental state examination score of ≤24 
• One unit of alcohol was defined as 12 grams 
• High serum urate was defined as serum urate >0.5 mmol/l 
• Renal impairment was defined as GFR<30 mL/minute/1.73m2. There was no 
significant difference when estimating GFR using the Cockcroft-Gault or the 
Modification of Diet in Renal Disease (MDRD) equation. Results of Cockcroft-Gault 
estimation are used 
• Hypercholesterolemia was defined as total cholesterol >5.2 mmol/l 
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2.4 Data Handling and Statistical analysis 
Data were entered into Dbase IV (BMES 1) or Microsoft Access (BMES 2, BMES 3) using 
automatic skips and range checks. Statistical analyses were performed using SAS software 
v9.13 (SAS Institute, Cary, NC) and Mplus.250  
 
Simple statistics included student t tests for comparing means and chi-square tests for 
comparing proportions. Age and sex and multivariable adjusted Cox regression models were 
used to estimate hazard ratios (HR) and 95% confidence intervals (CI). Age and sex and 
multivariable adjusted logistic regression models were used to estimate odds ratios (ORs) and 
95% confidence intervals.  
 
Log-linear models were used to assess the concomitant presence of the three sensory 
impairments (visual, auditory and olfactory). Observed frequencies of concomitant sensory 
impairments were compared to the expected frequencies estimated assuming that they occur 
independently (no clustering tendency). Models that included two- and three-way interactions 
among the three impairments were used to test the significance of these interaction terms. 
The likelihood ratio was used to choose the best fitting models.251 
 
Structural equation modelling (SEM) pathway analysis252 was used to model the relationship 
between visual or hearing impairment with mortality and co variables found to be 
significantly associated with mortality by Cox regression. The model was fit using maximum 
likelihood and Monte Carlo integration methods. Standard errors were calculated using the 
delta method and hazard rates obtained from the coefficients by exponentiation. Each 
mediating variable was adjusted for age, gender and sensory impairment (visual or hearing). 
The indirect effect of the sensory impairment was then calculated for each co-variable by 
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multiplying the effects of that co-variable on mortality and the sensory impairment on that 
co-variable. The total indirect effect of the sensory impairment was then calculated by 
summating the coefficients of the estimated indirect effects of each mediating variable, and 
then converting to hazard ratios. The total estimated effect of the sensory impairment on 
mortality was calculated by summating the coefficients of the indirect and direct effects, and 
then converting to hazard ratios (Figure 2.2). Models were simplified by removing indirect 
pathways for individual co variables that were not significant at a p value level of 0.1. 
 
A p value of less than 0.05 was considered statistically significant. 
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1  Figure 2.1 Calculation of direct, indirect and total effects using structural equation 
modelling pathway analysis 
γ1 
 
Intermediate 
Variable 
 
 
Sensory Impairment 
 
 
Mortality 
γ3 γ2 
γ = regression coefficient 
Direct = γ1 
Indirect = γ2·γ3 
Total = γ1 + γ2·γ3 
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Chapter Three: Prevalence and Neurodegenerative or 
Other Associations with Olfactory Impairment in an Older 
Community 
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Abstract 
Purpose: To determine the prevalence of olfactory impairment and its associations with 
neurodegenerative and other conditions in an older population. 
 
Methods: Olfactory ability, medical conditions and cognitive function were assessed in 
1636 participants, aged ≥60 years and enrolled in the Blue Mountains Eye Study (2002-4). 
Assessment was by questionnaire, clinical examination, blood testing and the San Diego 
Odor Identification Test, with subjects classified as having no impairment (score 6, 7 or 8), 
mild impairment (4 or 5), moderate impairment (≤3), or any impairment (<6). 
 
Results: The prevalence of any olfactory impairment was 27.0% (95% confidence interval, 
CI 22.9-31.4%). After multivariate adjustment, the likelihood increased 2-fold with each 
decade of life after 60 years (odds ratio, OR, 2.22, CI 1.8-2.7) and was higher in men than 
women (OR 2.0 CI 1.5-2.7). Inverse associations were observed between olfactory 
impairment and body mass index (OR per 5 kg/m2 increase, 0.8, CI 0.7-0.9) and between 
moderate impairment and hypertension (OR 0.6, CI 0.4-0.9). There was no significant 
relationship with angina, previous myocardial infarction or diabetes. Persons with Parkinson 
disease had an increased likelihood of both mild (OR 9.8, CI 2.0-47.5) and moderate 
impairment (OR 16.1, CI 3.8-68.2), as did persons with impaired cognitive function (OR 3.3, 
CI 1.3-8.6 and OR 3.7, CI 1.5-9.6, respectively).  
 
Conclusions: Over one in four older persons had olfactory impairment. The prevalence was 
higher in males, increased with age and decreasing BMI, and was substantially higher among 
persons with Parkinson disease and cognitive impairment.
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Background 
The sense of smell is clinically under-appreciated and infrequently tested but makes a 
significant contribution to the quality of life and the ability to experience pleasure. 
Olfaction determines flavor and serves as a warning for smoke, toxic fumes and 
spoiled foodstuffs. It has been long presumed that loss of olfaction in older persons is 
a consequence of the normal biological aging process.168,253 The prevalence of 
impaired olfaction in the “healthy” ageing population may, however, be greater than 
previously thought, and co-morbidities that increase with advancing age may be 
responsible for the observed increase in the prevalence of impaired olfaction.254 
 
Olfactory dysfunction in older age is associated with impaired global cognition and a 
more rapid decline in perceptual processing speed, and in episodic and verbal 
memory.255 Olfactory impairment and the lack of ability to self-report such 
impairment predicts future cognitive decline256 and predates Parkinson disease by four 
or more years.257 Olfactory testing may therefore be a useful screening tool to detect 
individuals at-risk for neurodegenerative disorders in older persons.258 
 
Olfactory dysfunction is also linked to numerous other disorders including diabetes,259 
renal disease,260 epilepsy,261 and many others.262 Olfactory dysfunction also correlates 
with food intake and nutrition in the elderly,263 and is associated with nursing home 
placement.253 Very few studies to date have examined the link between cardiovascular 
risk factors or disease with olfactory impairment despite their adverse effect on 
cognitive function.264 To our knowledge, no study has examined the potential 
association between total cholesterol level and olfaction despite there being a link 
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between olfaction, Alzheimer Disease and APOE ε4265 which also predicts familial 
hypercholesterolemia. 
 
In this study, we examine the prevalence of olfactory impairment in the surviving 
participants of the Blue Mountains Eye Study (BMES) who returned to 10-year 
follow-up examinations during 2002-2004. We aimed to investigate the association of 
olfactory impairment with cardiovascular risk factors and disease, and to confirm the 
relationship between neurodegenerative disease and olfactory dysfunction in this 
population. We hypothesized that due to the adverse effect of cardiovascular risk 
factors and disease on cognitive function, their presence would be positively 
associated with the prevalence of smell impairment in older persons. Further, given 
that APOE ε4 increases the risk of developing hypercholesterolemia and Alzheimer 
disease,266 we hypothesized that there would be a positive correlation between total 
cholesterol level and smell impairment.  
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Methods 
The San Diego Odour Identification Test (SDOIT)267 and related olfactory and taste 
questions were a component of the BMES 3 examination. Complete olfaction and 
taste data where obtained from 1636 of 1952 (83.8%) BMES 3 participants.  
 
Participants were tested individually with the SDOIT, an 8-item odor identification 
test with a test-retest reliability relatively similar to the 40-item UPSIT (r = 0.86 
SDOIT; r = 0.94 UPSIT).247 We defined mild olfactory impairment as less than six 
but greater than three correct responses and moderate as three or less correct 
responses out of a total of eight possible responses.  
 
Information about self-reported olfactory abnormality medical problems and cognitive 
function was obtained from an interviewer administered questionnaire (Chapter 2, 
Methods and Appendix A, BMES 4 Study Questionnaire and Flow Sheet). Patients 
who answered that they had a reduced or no sense of smell were considered to have 
self-reported olfactory impairment.  Participants with mini mental state exam scores 
<24 were considered cognitively impaired. Body mass index (BMI) was calculated 
using the formula weight (kg)/ height (m)2 and was categorized as underweight (<20 
kg/m2), normal weight (20-25 kg/m2), overweight (26-30 kg/m2) and obese (>30 
kg/m2).Fasting blood samples were used to determine creatinine, blood glucose, total 
cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL) and 
triglyceride levels. There was no significant difference when estimating GFR using 
the Cockcroft-Gault or the Modification of Diet in Renal Disease (MDRD) equation. 
Results of Cockcroft-Gault estimation are used. 
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All statistical analyses were performed using Statistical Analysis System software 
v9.13 (SAS Institute, Cary, NC). Chi-square tests were used for proportions and 
Student-t tests for means, to examine categorical and continuous variable 
characteristics of participants with and without olfactory impairment. Multivariable-
adjusted logistic regression models were constructed to estimate associations between 
cardiovascular disease risk factors, cardiovascular disease and neurodegenerative 
conditions. Co-variables included age, sex, smoking, nasal congestion, BMI, GFR 
<30, hypercholesterolemia (>5.2 mmol/L), stage I and II hypertension, stroke, 
Parkinson disease, impaired cognitive function (MMSE <24) and epilepsy. Odds 
ratios (OR) and 95% confidence intervals (CI) are presented. A p value of less than 
0.05 was considered statistically significant. 
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Results   
The mean age of the 316 subjects who did not have olfaction data collected was 75.7 
years and 65.2% were female, compared with a mean age 73.5 years among 
participants included in this report, 58.1% of whom were female. 
 
Of the 1636 participants, 441 participants had impaired olfaction (27.0%, CI 22.9-
31.4%). The age- and sex- specific prevalence of olfactory impairment is shown in 
Figure 3.1. Of the 8 odors tested, honey and cinnamon were the most difficult for 
impaired participants to detect as shown in Figure 3.2. The highest prevalence of mild 
and moderate olfactory impairment was observed in persons aged 80 years and over 
and both levels were more frequent in men than in women (16.8% vs.. 11.7% and 
18.0% vs.. 9.7%, respectively). 
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2  Figure 3.1 Prevalence of mild and moderate olfactory impairment stratified by age, 
sex and severity in BMES participants.  
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3  Figure 3.2 The frequency distribution of odors correctly identified by those with 
impaired olfactory function. 
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Baseline characteristics of participants with and without olfactory impairment are 
shown in Table 3.1. Compared to those with normal olfaction, participants with 
impaired olfaction were more likely to be male, aged older than 70 years, or to smoke. 
They were also more likely to have current nasal congestion, be underweight or 
cognitively impaired. They were also more likely to have Parkinson disease, renal 
failure, diabetes or a previous history of stroke or angina (Table 3.1).  
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 Olfactory impairment No. (%)  
Characteristics 
Yes  
(n=441) 
No 
 (n=1195) p value 
Men 
Women 
238 (54.0) 
203 (46.0) 
447 (37.4) 
748 (62.6) 
 
<.0001 
Age, years 
60-69 
70-79 
≥80 
 
73 (16.6) 
191 (43.3) 
177 (40.1) 
 
468 (39.2) 
530 (44.4) 
197 (16.5) 
 
<.0001 
Self reported loss of smell 103 (32.2) 70 (7.0) <.0001 
Nasal congestion 83 (18.8) 150 (12.6) <.0001 
Smoking 
Never 
Past 
Current 
 
202 (46.5) 
197 (45.4) 
35 (8.1) 
 
679 (57.9) 
417 (35.6) 
76 (6.5) <.0001 
Body mass index 
Underweight 
Overweight 
Obese 
 
25 (5.8) 
175 (40.2) 
73 (16.8) 
 
34 (2.9) 
501 (42.5) 
311 (26.4) <.0001 
Hypertensive 301 (68.9) 849 (71.4) 0.58 
Diabetes 71 (18.9) 154 (14.3) 0.03 
Stroke a 37(8.5) 57 (4.8) 0.005 
Angina a 79 (18.2) 159 (13.4) 0.02 
Myocardial infarction  a 50 (11.6) 112 (9.5) 0.22 
Mean total cholesterol (mmol/L) 4.7 ± 1.6 5.1 ± 1.5 0.09 
Glomerular filtration rate 
30-60 
<30 
 
176 (47.4) 
20 (5.4) 
 
333 (31.0) 
15 (1.4) <0.0001 
Impaired cognitive function b 32 (7.6) 17 (1.5) <0.0001 
Parkinson disease 19 (4.3) 3 (0.3) <0.0001 
Epilepsy  a 4 (0.93) 3 (0.3) 0.07 
aSelf-reported  
bMini mental state exam score <24  
10  Table 3.1 Characteristics of the Blue Mountains Eye Study 10-year follow-up 
examination participants by olfactory impairment 
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Table 3.2 lists the odds ratios with 95% confidence intervals for associations after 
adjusting for age and sex. Increasing age, male sex, current nasal congestion, past and 
current smoking, BMI >30, impaired cognitive function and Parkinson disease were 
all significantly associated with increased odds for mild and, except for smoking and 
BMI, moderate smell impairment, after adjusting for age and sex (Table 3.2). 
Glomerular Filtration Rate (GFR) <30, stroke and epilepsy were associated with 
increased odds of moderate smell impairment only. Hypercholesterolemia and stage II 
hypertension were associated with decreased odds of moderate smell impairment. 
When analyzed separately, significant associations were not observed between fasting 
HDL or triglyceride levels and olfactory impairment (data not shown). There was no 
significant association between other cardiovascular risk factors or diabetes and smell 
impairment, after adjusting for age and sex. After adjusting for variables listed in 
Table 3.3, all of the age-sex-adjusted associations remained, with the exception of 
epilepsy (Table 3.3). 
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Characteristic n (%) 
Mild 
Impairment 
OR (95% CI) 
p 
Value n (%) 
Moderate 
Impairment 
OR (95% CI) 
p 
Value 
Age per 10 years - 2.04 (1.67 - 2.50) <0.001 - 3.25 (2.60 - 4.06) <0.001 
Male Sex  115 (17) 1.91 (1.43 - 2.56) <0.001 123 (18) 2.57 (1.88 - 3.52) <0.001 
Nasal Congestion  45 (19) 1.79 (1.23 - 2.62) 0.003 38 (16) 1.70 (1.12 - 2.60) 0.01 
Smoking       
Past  104 (17) 1.54 (1.12 - 2.13) 0.01 93 (15) 1.01 (0.72 - 1.42) 0.95 
Current  26 (23) 2.97 (1.77 - 4.98) <0.001 9 (8) 0.93 (0.429 - 2.00) 0.84 
BMI a        <20 13 (22) 1.66 (0.81 - 3.37) 0.16 12 (20) 2.24 (1.05 - 4.81) 0.04 
         20-25 84 (17) 1.0 (Ref)  78 (16) 1.0 (Ref)  
         26-30 85 (13) 0.74 (0.52 - 1.03) 0.08 90 (13) 0.91 (0.64 - 1.30) 0.61 
          >30 40 (10) 0.62 (0.41 - 0.94) 0.02 33 (9) 0.66 (0.42 - 1.05) 0.08 
Impaired cognitive 
functionb  10 (5) 3.09 (1.34 - 7.09) 0.01 22 (45) 5.93 (2.86 - 12.29) <0.001 
Parkinson disease 7 (32) 12.20 (2.89 - 51.5) 0.001 12 (55) 26.03 (6.56 - 103) <0.001 
Epilepsy  1 (14) 1.67 (0.17 - 16.7) 0.66 3 (43) 9.92 (1.71 - 54.0) 0.01 
GFR c  ≥60 103 (11) 1.0 (Ref)  72 (8) 1.0 (Ref)  
      <60-30 87 (17) 1.06 (0.722 - 1.56) 0.77 89 (17) 1.17 (0.77 - 1.76) 0.47 
     <30 4 (11) 0.93 (0.30 - 2.92) 0.90 16 (46) 2.94 (1.35 - 6.42) 0.01 
Hypercholesterolaemia  
(>5.2 mmol/L) 6 (8.3) 0.85 (0.63 - 1.56) 0.30 18 (25) 0.672 (0.48 - 0.95) 0.02 
Stroke  17 (18) 1.52 (0.85 - 2.71) 0.15 20 (21) 1.83 (1.03 - 3.24) 0.04 
Angina 36 (15) 1.06 (0.70 - 1.58) 0.80 43 (18) 1.27 (0.851 - 1.87) 0.24 
Myocardial Infarction  25 (15) 0.95 (0.59 - 1.53) 0.84 25 (15) 0.89 (0.55 - 1.45) 0.64 
Hypertension d    Stage I 24 (11) 0.69 (0.41 - 1.16) 0.16 29 (14) 0.83 (0.50 - 1.38) 0.47 
Stage II 133 (14) 0.80 (0.57 - 1.12) 0.20 115 (12) 0.61 (0.43 - 0.87) 0.01 
Diabetes  34 (15) 1.21 (0.80 - 1.83) 0.38 37 (16) 1.47 (0.96 - 2.27) 0.07 
Gout  30 (16) 1.01 (0.65 - 1.57) 0.97 36 (19) 1.17 (0.75 - 1.81) 0.49 
a Per 5 kg/m2 increase in body mass index (BMI) 
b Mini-mental state exam score <24 
c Glomerular filtration rate - GFR 
d Hypertension stage I - 140/90-160/100; stage II: >160/100 or treated 
11  Table 3.2: Age- and sex-adjusted associations (odds ratios, OR, and 95% confidence 
intervals) with olfactory impairment 
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Characteristic 
Any impairment 
OR (95% CI) 
Mild 
OR (95% CI) 
Moderate 
OR (95% CI) 
Age per 10 years 2.22 (1.82-2.71) 1.89 (1.48 - 2.42) 2.71 (2.04 - 3.60) 
Male Sex 2.02 (1.50-2.71) 1.81 (1.26 - 2.60) 2.26 (1.49 - 3.42) 
Nasal Congestion 1.99 (1.39-2.87) 1.84 (1.18 - 2.87) 2.16 (1.32 - 3.56) 
Smoking a    
Past 1.31 (0.97-1.77) 1.57 (1.09 - 2.28) 1.03 (0.68 - 1.54) 
Current 1.59 (0.91-2.76) 2.68 (1.47 - 4.87) 0.49 (0.16 - 1.49) 
BMI b 0.77 (0.66-0.91) 0.74 (0.60 - 0.91) 0.81 (0.64 - 1.02) 
GFR <30 c 2.41 (1.13-5.14) 1.04 (0.32 - 3.36) 4.22 (1.82 - 9.77) 
Hypercholesterolaemia d 0.71 (0.54-0.94) 0.87 (0.61-1.23) 0.54 (0.36-0.79) 
Hypertension e   Stage I 0.87 (0.55-1.37) 0.77 (0.42 - 1.40) 0.99 (0.54 - 1.80) 
         Stage II 0.73 (0.53-1.00) 0.91 (0.61 - 1.35) 0.58 (0.37 - 0.90) 
Stroke 1.31 (0.78-2.21) 0.97 (0.49 - 1.95) 1.94 (1.01 - 3.75) 
Impaired cognitive functionf 3.70 (1.68-8.14) 3.31 (1.28 - 8.57) 3.73 (1.45 - 9.57) 
Parkinson Disease 13.21 (3.49-50.0) 9.76 (2.01 - 47.5) 16.11 (3.80 - 68.2) 
Epilepsy 2.59 (0.45-14.9) 0.87 (0.08 - 9.13) 6.38 (0.85 - 47.7) 
a   Compared  to non-smokers 
b Body Mass Index - per 5 kg/m2 increase 
c Glomerular filtration rate - GFR estimated by Cockcroft-Gault formula.  
d  Serum total cholesterol >5.2 mmol/L 
e Hypertension Stage I - 140/90-160/100; Stage II - >160/100 or treated  
f Mini-mental state exam score <24 
 
  
12  Table 3.3 Multivariable-adjusted associations (odds ratios, OR, and 95% confidence intervals) for 
all characteristics found to be significant in age-sex-adjusted models 
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Self-report of poor smell correlated poorly with measured olfactory impairment. Only 32.2% of 
participants with measured olfactory impairment reported they had lost their sense of smell. Of 
participants who reported an abnormal sense of smell, 48.6% (CI 39.7-57.5) had no measured 
impairment (SDOIT scores 6 or greater). Similarly, of participants who did report smell loss, 40.5% 
(CI 33.1-48.2) had no measured impairment.
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Discussion 
We observed a high prevalence of olfactory impairment (27.0%) in a population-based 
sample of Australians aged 60 years and over. Based on these data and the 2006 Australian 
census, we estimate that 868,000 Australians aged 60 years or older have impaired odor 
perception.  
 
There have been only two other large-population based studies that have assessed the 
prevalence of olfactory impairment, the Wisconsin Epidemiology of Hearing Loss Study 
(EHLS)168 and the Swedish Skövde study,170 with only the former having focused on an older 
population. The size and response rates of these studies were comparable to ours (73% of 
1900 persons in Skovde; 82% of 3407 persons in the EHLS; 77% of 2548 persons in the 
BMES). The BMES olfactory impairment prevalence is comparable to the 24.5% rate 
observed in the EHLS for persons aged 43-86 years,168 but slightly lower than the reported 
prevalence of 32.9% in persons aged 53 years or older in the Skövde study.170 These 
differences could be due to different age ranges and distributions of the three study samples. 
After age and sex standardizing our BMES prevalence to the EHLS,168 we observed a slightly 
lower prevalence of olfactory impairment of 24.3% (22.4-26.3) in our study compared with 
29.8% (27.8-31.9) in the EHLS (for participants aged >60 years).  
 
In agreement with the greater prevalence of olfactory impairment observed among men in the 
EHLS, Skövde and other smaller cross-sectional studies,253,268,269 we found that men were 
twice as likely to have impaired olfaction compared with women, after multivariable 
adjustment. 
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As in previous studies,170,168,253 we also observed a significant age-associated increase in the 
prevalence of olfactory impairment, with the highest prevalence of mild (19.8%) and 
moderate impairment (27.5%) seen in those aged 80 years and over. Factors that co-vary with 
age, such as medication use and medical conditions could be responsible, at least in part, for 
the increased prevalence of olfactory impairment with age. We found, however, a significant 
inverse association between hypertension, total cholesterol and measured olfactory 
impairment. This apparent protective association is difficult to explain. It may be confounded 
by premature death in participants with these co-morbidities, by the medications used to 
control these risk factors, or some shared mechanistic pathway. This association with 
olfaction warrants further investigation given the previously reported relationship between 
blood pressure and cholesterol and the incidence of cognitive decline.264,266 We did not find 
associations between other cardiovascular risk factors including diabetes, cardiovascular 
diseases, except stroke, and prevalent olfactory impairment in our older population. 
 
BMES participants with moderate olfactory impairment were twice as likely to be 
underweight (BMI <20 kg/m2) than those without impaired olfaction. Several smaller studies 
demonstrated similar findings.263,270 Elderly patients with a poor sense of smell may be much 
less likely to enjoy food and more likely to subsequently eat inadequately, resulting in lower 
body weight. Olfactory capabilities may stimulate appetite and interest in eating and thus 
protect individuals against under-nutrition.270  
 
Ours is the first community-based study to demonstrate that older people with mild renal 
impairment are much more likely to have moderate (but not mild) olfactory impairment. A 
previous inpatient clinic study demonstrated similar findings and postulated the cause to be 
the accumulation of uremic toxins.271 
265 
 
BMES participants with cognitive impairment had approximately 3-fold higher odds of mild 
and approximately 6-fold higher odds moderate olfactory impairment. Participants with a 
diagnosis of Parkinson disease had a 10- and 16-fold higher risk of having mild and moderate 
olfactory impairment, respectively, after multivariable adjustment, consistent with previous 
literature.257,272  
 
We found that self-reported smell loss was an unreliable indicator of measured olfactory 
decline. Of those with olfactory deficit, 67.8% did not report a loss of smell function. Of 
participants that did report smell deficit, 40.5% had no measurable loss. This is in agreement 
with previous population reports.168,170  
 
Strengths of this study are its high participation and follow-up rates. Two limitations are that 
the study sample represents survivors of this population-based cohort and that the data are 
cross-sectional in nature. As with any olfactory function test, the SDOIT tests only a limited 
number of stimulants, possibly resulting in under-detection of deficits in the rare spectrum of 
the olfaction function. In addition, olfactory threshold is not assessed with this measure. It is, 
however, substantially more reliable than self-reported methods. This simple and quick test 
may be useful in screening older persons at risk of neurodegenerative disease and 
malnutrition. Our study could have under-estimated the true prevalence as those who did not 
have olfaction data collected tended to be older and therefore more likely to have olfactory 
impairment. 
  
266 
 
Summary 
Olfactory impairment was frequent in this older Australian population, with over one in four 
having impaired olfaction. Male gender and aging were the most important risk factors for 
olfactory impairment. Our data support an essential role for olfactory function in maintaining 
a healthy nutritional status and body weight.  We provide additional data to support the link 
between impaired olfaction and neurodegenerative disorders, including dementia and 
Parkinson disease. Of note in our study, over 50% of participants with olfactory impairment 
had a normal BMI and did not have cognitive impairment or Parkinson Disease. Given that 
olfactory impairment may be a biomarker for both these neurodegenerative conditions and 
malnutrition, longitudinal studies are needed to assess the prognosis of older persons with 
olfactory deficit. These data may be useful in identifying persons at risk of certain conditions 
in their pre-clinical stage with the aim of initiating protective therapy.
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Chapter Four: Prevalence and Dependent Clustering 
Characteristics of Visual, Auditory and Olfactory 
Impairments in Older Persons 
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Abstract 
Purpose: To assess the clustering patterns of visual, auditory and olfactory impairments in an 
older population sample.  
 
Methods: The Blue Mountains Eye Study (BMES) examined 3,654 persons aged 49+ during 
1992-1994, and after 5 and 10 years. At the 10-year follow-up (during 2002-4), 1,497 (74.3% 
of all participants) had complete vision, auditory and olfactory data, and were included in the 
current study. Visual impairment (VI) was defined as either presenting (PVI) or non-
correctable (NCVI). Auditory impairment (AI) was defined as the pure-tone average (0.5-
4kHz) of air-conduction hearing thresholds >25 decibels hearing level (dB HL). Olfactory 
impairment (OI) was defined as a San Diego Odour Identification Test score <6/8. 
 
Results: The observed prevalence of having all three sensory impairments in persons with 
PVI (or NCVI) was 2.6 (or 3.0) times greater than predicted if this occurred independently. 
VI, AI and OI clustered differently in women compared to men. OI was associated with 
concomitant PVI and NCVI while AI associated with concomitant OI in men only; Visual 
impairment was associated with concomitant OI in women and AI in men. 
 
Conclusion: Visual, auditory and olfactory impairments aggregate mutually and dependently 
in older persons. Separate hearing and vision services may not adequately support older 
persons with multiple impairments.
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Background   
Visual, auditory and olfactory impairments are common disabilities associated with significant 
morbidity and mortality in older persons. The prevalence of  non-correctable visual impairment 
(NCVI) is estimated at between 2% and 4%13,273,274 while the prevalence of reduced presenting 
visual acuity is 8 to 12% among persons aged ≥40 years.275,276 Auditory (hearing) impairment (AI) 
is the third most frequent chronic condition reported by elderly persons in the 2002 United States 
National Health Interview Survey,277 affecting between 35% and 45% of persons aged 50+ 
years.121,278 The prevalence of olfactory impairment (OI) is estimated to be 25% in older persons in 
persons aged older than 53 years.168 
 
Visual, auditory and olfactory impairments share common risk factors and consequences. Shared 
risk factors include increasing age, poorer cognitive status, lower education level, diabetes, 
workplace exposures, diet, cerebrovascular disease and smoking.121,170,253,279-288 Shared impacts 
include measures of independence, functional and physical decline, low SRH, quality of life, and 
nursing home placement.47,133,289,290 Visual and hearing impairments are also reported to be 
associated with an increased risk of all-cause mortality.56,57,60,61,64,151,152,156 
 
Despite the high prevalence of these disabilities and their similar associations, no studies have 
examined the prevalence of aggregated visual, auditory and olfactory impairments in older persons, 
or whether they aggregate dependently or randomly. Dependent aggregation of sensory impairments 
could indicate common underlying mechanisms. The presence of more than one sensory 
impairment may lead to greater negative impacts on the health-related quality of life148 and 
mortality risk151,153,156,291 of affected individuals. A trend for multiple sensory impairments in older 
persons may also imply particular needs for health care service provision to older persons. 
Identifying this aggregation could lead to improved interventions. 
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Using an Australian population based study of older persons, we aimed to assess the prevalence of 
aggregated visual, auditory and olfactory impairments and determine whether presence of a single 
impairment was associated with an increased likelihood of concomitantly having other sensory 
impairments; i.e. whether these three impairments tended to cluster. 
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Methods 
Vision, hearing and olfaction were assessed in BMES 3. Visual impairment (VI) was categorized as 
either presenting visual impairment (PVI), VA less than 6/12 Snellen equivalent (<39 letters read 
correctly) in the better eye using current glasses, or non-correctable visual impairment (NCVI), PVI 
correctable to 6/12 Snellen equivalent or worse in the better eye, after subjective refraction. 
Auditory impairment (AI) was defined as the pure-tone average of air-conduction hearing 
thresholds >25 decibels hearing level (dB HL) for the four frequencies (0.5, 1, 2, and 4 kHz) in the 
better ear (bilateral hearing loss). Olfactory impairment (OI) was defined as less than 6 correct out 
of a total of 8 possible responses. The presence of multiple sensory impairments was defined either 
as: a) >1 impairment using PVI, this included two or three of the impairments (AI, OI and PVI); 
and b) >1 impairment using NCVI, this includes two or three of the impairments (AI, OI and 
NCVI). 
 
Statistical analyses were performed using SAS software v9.13 (SAS Institute, Cary, NC). Simple 
statistics included student t-tests for comparing means and chi-square tests for comparing 
proportions. Log-linear models were used to assess the concomitant presence of the three sensory 
impairments (visual, auditory and olfactory). Observed frequencies of concomitant sensory 
impairments were compared to the expected frequencies estimated assuming that they occur   
independently (no clustering tendency). Models that included two- and three-way interactions 
among the three impairments were used to test the significance of these interaction terms. The 
likelihood ratio was used to choose the best fitting models.251 
 
Logistic regression models were used to examine the presence of a single sensory impairment and 
the likelihood of other concomitant sensory impairments. Hypotheses tested were that:   a) persons 
with AI are more likely to have concomitant OI or VI (compared to persons without AI); b) persons 
with OI are more likely to have concomitant AI or VI (compared to persons without OI); c) persons 
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with VI are more likely to have concomitant AI or OI (compared to persons without VI). Finally we 
wished to examine potential gender differences in the clustering patterns of sensory impairment in 
analyses stratified by gender. Associations are presented as odds ratios (OR) with 95% confidence 
intervals (CI). 
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Results 
Study Population 
Participants with a history of hearing loss from birth, otosclerosis or conductive hearing loss were 
excluded from the analyses. Of the remainder at BMES 3, 1497 (74.3% of all participants) had 
complete vision, auditory and olfactory data.  
 
Table 4.1 presents the prevalence of single and combined sensory impairments in the study 
population. Auditory impairment was the most frequent sensory impairment followed by OI, PVI 
and then NCVI. The prevalence of single and multiple sensory impairments increased with age. 
Auditory and OI were more frequent in men than in women, while VI was more frequent in women. 
Associations were universally greater for persons with NCVI compared to PVI (Tables 4.1-4.4). 
Men were also more likely to have multiple sensory impairments than women (for multiple 
impairments, including PVI, OR 1.66, CI 1.26-2.20; for multiple impairments, including NCVI, OR 
1.96, CI 1.46-2.63) after multivariable adjustment.
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  Age  Sex  
 % (n) 
60-69 
% (n) 
70-79 
% (n) 
≥80 
% (n)  
Female 
% (n) 
Male 
% (n)  
Sensory Impairment n = 1499 n = 508 n = 662* n  =  329* p value n = 857 n = 642* p value 
Auditory Impairment 43.1 (646) 18.7 (95) 47.0 (311) 73.0 (240) <0.0001 41.0 (351) 46.0 (295) 0.0534 
Presenting Visual  
Impairment (PVI) 
 
10.7 (160) 3.9 (20) 9.2 (61) 24.0 (79) <0.0001 12.1 (104) 8.7 (56) 0.0342 
Non Correctable  
Visual Impairment (NCVI) 
 
3.1 (46) 0.4 (2) 2.3 (15) 8.8 (29) <0.0001 3.9 (33) 2.0 (13) 0.0436 
Olfactory Impairment 26.9 (403) 13.4 (68) 27.8 (184) 45.9 (178) <0.0001 21.1 (181) 34.6 (222) <0.0001 
> 1 impairment using PVI 20.7 (310) 4.9 (25) 19.5 (129) 47.4 (156)  <0.0001 18.4 (158) 23.7 (152) 0.0132 
> 1 impairment using NCVI 17.4 (61) 4.1 (21) 16.8 (111) 39.3 (129) <0.0001 14.5 (124) 21.4 (137) 0.0005 
*n total 661 for 70-79 and 328 for ≥ 80 for NCVI 
13  Table 4.1 Frequencies of individual and combined sensory impairments. 
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Number of 
Impairments % (n) identified 
% Predicted if 
independent* % (n) identified 
% Predicted if 
independent* % (n) found 
% Predicted if 
independent* 
 All  Female  Male  
Presenting Visual 
Impairment   n total = 857  n total = 642 
 
0  43.1 (646) 37.2 46.7 (400) 41.0 38.3 (246) 32.1 
1  36.2 (543) 46.3 34.9 (299) 44.9 38.0 (244) 47.5 
2  17.6 (264) 15.3 16.0 (137) 13.1 19.8 (127) 18.9 
3  3.1 (46) 1.2 2.5 (21) 1.1 3.9 (25) 1.4 
Non Correctable 
Visual Impairment   n total = 857  n total = 640 
 
0 45.5 (681) 40.3 49.6 (425) 44.8 40.0 (256) 35.0 
1  37.1 (555) 46.7 35.9 (308) 44.8 38.6 (247) 47.7 
2  16.2 (243) 12.7 13.4 (115) 10.0 20.0 (128) 16.9 
3 1.2 (18) 0.4 1.1 (9) 0.4 1.4 (9) 0.5 
* If visual, auditory and olfactory sensory impairments cluster independently of each other, this is the predicted % of having none, single or multiple sensory 
impairments
14  Table 4.2 Frequencies of none, single and multiple sensory impairments identified compared to predicted if sensory impairments occurred 
independently, stratified by visual impairment and sex. 
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Conditional impairment Concomitant impairment 
Age-sex adjusted 
OR (95% CI) p value 
Multivariable adjusted* 
OR (95% CI) p value 
Olfactory  Auditory 1.44 (1.11-1.88) 0.0064 1.44 (1.07-1.94)† 0.0174 
 Presenting visual impairment 1.33 (0.92-1.92) 0.1326 - - 
 Non correctable visual impairment 1.66 (0.88-3.13) 0.1182 - - 
Auditory Olfactory 1.46 (1.12-1.90) 0.0054 1.43 (1.10-1.88) † 0.0098 
 Presenting visual impairment 1.13 (0.77-1.65) 0.5428 -  
 Non correctable visual impairment 1.84 (0.88-3.88) 0.1068 -  
Presenting visual acuity‡ Olfactory 1.13 (1.05-1.20) 0.0005 1.11 (1.04-1.19) 0.0030 
 Auditory 1.09 (1.01-1.17) 0.0201 1.09 (1.01-1.18) 0.0380 
Non correctable visual acuity‡ Olfactory 1.17 (1.07-1.28) 0.0004 1.14 (1.04-1.24) 0.0042 
 Auditory 1.15 (1.04-1.26) 0.0070 1.14 (1.02-1.28) 0.0241 
* Olfactory impairment adjusted for sex, age, smoking, nasal congestion, Parkinson disease and presence of other sensory impairment; auditory 
impairment adjusted for low education (no post-school qualifications), family history of hearing loss (including parents and siblings), history of work 
in noisy industry and presence of other sensory impairment 
† Adjusted for decreasing PVA 
‡ Continuous 1 line (5 letter) decrease 
 
 
 
15  Table 4.3 The likelihood of concomitant olfactory, auditory and visual impairments expressed as age-sex adjusted and multivariable adjusted odds 
ratios (OR) with 95% confidence intervals (95% CI) given the presence of the initial listed (conditional) impairment. 
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Conditional impairment Concomitant impairment 
Women 
OR (95% CI)* p value 
Men 
OR (95% CI)* p value 
Olfactory  Auditory† 1.45 (0.94-2.22) 0.0921 1.46 (0.96-2.21) 0.0800 
 Presenting visual impairment 1.34 (0.83-2.16) 0.2369 2.34 (1.28-4.27) 0.0056 
 Non correctable visual impairment 0.81 (0.36-1.82) 0.6132 15.5 (1.96-122.50) 0.0094 
Auditory Olfactory† 1.28 (0.86-1.89) 0.2249 1.58 (1.08-2.32) 0.0180 
 Presenting visual impairment 1.34 (0.83-2.16) 0.2369 0.84 (0.45-1.58) 0.5957 
 Non correctable visual impairment 1.70 (0.69-4.14) 0.2473 1.78(0.50-6.87) 0.4050 
Presenting visual acuity‡ Olfactory 1.13 (1.01-1.25) 0.0260 1.03 (0.90-1.18) 0.6538 
 Auditory 1.05 (0.96-1.14) 0.2794 1.24 (1.09-1.39) 0.0007 
Non correctable visual acuity‡ Olfactory 1.18 (1.02-1.35) 0.0221 1.06 (0.86-1.31) 0.5913 
 Auditory 1.05 (0.95-1.16) 0.3571 1.47 (1.21-1.78) 0.0001 
*Olfactory impairment adjusted for sex, age, smoking, nasal congestion, Parkinson disease and presence of other sensory impairment; auditory 
impairment adjusted for low education (no post-school qualifications), family history of hearing loss (including parents and siblings), history of work 
in noisy industry and presence of other sensory impairment; Visual impairments adjusted for age and presence of other sensory impairment 
†Adjusted for decreasing presenting visual acuity  
‡Continuous 1 line (5 letter) decrease.
16  Table 4.4 The likelihood of concomitant olfactory, auditory and visual impairments expressed as sex-stratified multivariable adjusted odds ratios 
(OR) with 95% confidence intervals (95% CI), given the presence of the listed (conditional) initial impairment. 
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Concomitant Sensory Impairments 
Analysis using log-linear models assuming that these three sensory impairments occur 
independently estimated the predicted prevalence of two or more concomitant sensory 
impairments, which was found to be significantly lower than the observed prevalence 
(Likelihood Ratio = 92.39, p<0.001) (Table 4.2). The observed prevalence of having all three 
sensory impairments was 2.6 times more likely than the predicted proportion for persons with 
PVI and 3.0 times more likely than the predicted proportion for those with NCVI, had these 
impairments occurred independently (Table 4.2). The best-fitting model (Likelihood Ratio = 
0.27, p=0.60) was the one that included the three main effects (AI, OI, VI) and all two-way 
interaction terms (AI*OI, AI*VI, OI*VI, p<0.002). 
 
 
Associations between Sensory Impairments 
No significant increase in the likelihood of other concomitant types of sensory impairment 
was found, given the presence of either PVI or NCVI (data not shown). However, when 
decreasing visual acuity (DVA) was modelled as a continuous variable (per 5 letter /1 line 
reduction), significant associations with other sensory impairments were found (Tables 4.3 
and 4.4). The presence of OI was significantly associated with an increased likelihood of 
concomitant AI, but not VI, after age-sex and multivariable adjustment (Table 4.4). Similarly, 
the presence of AI was significantly associated with an increased likelihood of concomitant 
OI but not VI, after age-sex and multivariable adjustment (Table 4.3). 
 
For each 1-line (5-letter) reduction in presenting visual acuity (PVA), there was an 11% (CI 
4-19%) increased likelihood of concomitant OI and a 9% (CI 1-18%) increased likelihood of 
concomitant AI, after multivariable adjustment (Table 4.4). Similarly, for each 1-line (5-
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letter) reduction in non-correctable visual acuity (NCVA) there was a 14% (CI 4-24%) 
increased likelihood of concomitant OI and a 14% (CI 2-28%) increased likelihood of 
concomitant AI, after multivariable adjustment (Table 4.3). 
 
When analyses were performed for men and women separately, we found that the increased 
likelihood of concomitant AI, given the presence of OI, was not significant but that there was 
a trend towards a non-significantly increased likelihood of concomitant AI that was of similar 
magnitude in both genders. Visual, AI and OI appeared to cluster differently in women 
compared to men (Table 4.4). After adjusting for age and other co-variables, OI was 
associated with concomitant PVI and NCVI while AI associated with concomitant OI in men, 
but not in women (Table 4.4). The increased likelihood of concomitant AI and OI was not 
significant after gender stratification, but there was a trend towards a marginally non-
significantly increased likelihood of AI, given the presence of OI, with similar magnitude in 
both sexes. The presence of AI did not increase the likelihood of either PVI or NCVI in men 
or women. In women, each one-line reduction in PVA and NCVA increased the likelihood of 
concomitant OI, but not AI. In contrast, each one-line reduction in PVA and NCVA increased 
the likelihood of concomitant AI but not OI in men (Table 4.4). 
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Discussion 
We recorded prevalence rates for NCVI, PVI, OI and AI in our population of persons aged 
49+ years to be 3.1, 10.7%, 26.9% and 43.1% respectively. Consistent with previous reports, 
we also found that auditory and olfactory impairments were both more frequent in men, 
visual impairment was more frequent in women and the prevalence of VI, AI and OI 
increased with age.13,273 
 
In this study, we found that the prevalence two or more sensory impairments in older persons 
was higher than the predicted prevalence if these impairments were assumed to have occurred 
randomly and independently, suggesting that sensory impairments tend to occur in clusters in 
older persons. The clustering tendencies of these sensory impairments suggest that common 
mechanisms may underlie VI, AI and OI. The finding of stronger associations in persons with 
NCVI compared to PVI supports this hypothesis. That sensory impairments are known to 
share common risk factors including increasing age, poorer cognitive status, lower education 
levels, diabetes, workplace exposures, diet, cerebrovascular disease and smoking, adds 
further weight to the possibility of common pathways.121,170,253,278-288,292-294 Auditory and VI 
have been associated with oxidative stress,106,111,295 but to date, this risk factor has not been 
investigated for OI.  
 
We also found that the clustering patterns differed between men and women. In women, VI 
was associated with an increased likelihood of AI. Similar gender differences were reported 
for age-related macular degeneration and AI, which could reflect a common cause.147 These 
data suggest that the mechanisms and/or exposures (e.g. workplace or environmental 
exposures, smoking status, genetic, hormonal or other sex differences) potentially underlying 
these sensory deficits could differ between men and women. The finding that OI strongly 
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tends to co-exist with either PVI or NCVI in men, but not in women, could indicate that OI is 
a marker of gender-specific exposures that also increase the likelihood of VI. However, due 
to the relatively small numbers with two or more impairments in women and men separately, 
we cannot exclude the possibility that these are chance findings, so that confirmation will be 
important.   
 
While not examined in this study, it is important to consider that presence of all three sensory 
impairments may increase the burden of shared adverse health outcomes on affected 
individuals and their families and carers. Associations of each impairment, VI, AI or OI, with 
measures of independence, functional and physical decline, low SRH and nursing home 
placement have been previously reported.132,253,289 Combined vision and auditory 
impairments have also been reported to cumulatively decrease health-related quality of 
life148,296 and to increase mortality risk.151,153,291 Evidence on whether correcting these sensory 
impairments with hearing or low vision aids would reduce their negative impact is limited 
with further studies needed.  
 
Our findings highlight some public health concerns for individuals suffering from multiple 
sensory impairments. Specifically, the current imperfect care system inhibits the effective 
delivery of services and rehabilitation to older people with multiple sensory impairments. 
There has been no active screening using case-finding strategies to detect older persons with 
sensory impairment. Further, older persons with these impairments tend to think that sensory 
function loss is part of aging, which are thus likely to be under-reported. By the time affected 
individuals seek services, they are often at a relatively late stage, and may have already been 
socially isolated and have had a substantially reduced quality of life and limitations in daily 
functioning for some period of time. While separate vision and hearing rehabilitation systems 
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currently operate in Australia and the U.S., such systems often fail to service and support 
older people with multiple sensory impairments in a coherent and collaborative manner. The 
bewildering complexity of current systems for the care of older people with two or more 
sensory impairments highlights the need for clearer, and better co-ordinated health policies.  
 
Strengths of our study include its large population-based dataset, with high participation and 
standardized measurements of visual acuity, olfactory and hearing assessments. Among 
limitations, the study sample consisted of a survivor cohort and the data were cross-sectional 
in nature. Our study may also have underestimated the true prevalence of sensory impairment 
as those who did not have a complete collection of sensory data tended to be older and were 
therefore more likely to have multiple sensory impairments. In addition, the small number of 
persons with combined sensory impairment in the two gender subgroups could have led to 
chance findings in the different clustering patterns of these sensory impairments between men 
and women, and limits our ability to detect weak associations that could have been 
significant.   
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Summary 
Visual, olfactory and auditory impairments tend to aggregate mutually and dependently in 
older persons. This implies that once a sensory impairment is detected, screening for other 
concomitant sensory impairment may be warranted. The higher than expected frequency of 
combined sensory impairment implies that the current health care provision may not have 
met the needs of older persons with sensory impairment. It may not have provided 
appropriate, coherent rehabilitation services to these older individuals with multiple sensory 
losses. Our study findings advocate for greater attention from health care providers and health 
policy makers to improve health care services to older persons with multiple sensory 
impairments.
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Chapter Five: Direct and Indirect Effects of Visual 
Impairment on Mortality Risk in Older Persons 
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Abstract 
Purpose: To investigate pathways from visual impairment to increased all-cause mortality 
in older persons. 
 
Methods: The Blue Mountains Eye Study examined 3654 persons aged 49+ years (82.4% 
response) during 1992-1994 and after 5 and 10 years. Australian National Death Index data 
confirmed deaths until 2005. Visual impairment was defined as presenting (PVI), correctable 
(CVI), and non-correctable (NCVI), using better-eye visual acuity. Associations between 
visual impairment and mortality risk were estimated using Cox regression and structural 
equation modelling (SEM).  
 
Results: After13 years, 1273 participants had died. Adjusting for mortality risk markers, 
higher mortality was associated with NCVI (hazard ratio (HR), 1.35, 95% confidence interval 
(CI) 1.04-1.75). This association was stronger for ages <75 years (HR 2.58, CI 1.42-4.69). 
SEM revealed greater effects of NCVI on mortality risk (HR 5.25, CI 1.97-14.01 for baseline 
ages <75), with both direct (HR 2.16, CI 1.11-4.23) and indirect effects (HR 2.43, CI 1.17-
5.03). Of mortality risk markers examined, only disability in walking demonstrated a 
significant indirect pathway for the link between visual impairment and mortality.  
 
Conclusions: Visual impairment predicted mortality by both direct and indirect pathways, 
particularly for persons with NCVI aged <75. Disability in walking, which can substantially 
influence general health, represented a major indirect pathway.
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Background   
Visual impairment has consistently been associated with a higher risk of dying.56-58,60,61,64 
Visual impairment is also reportedly associated with many factors also linked to increased 
mortality. These include unintentional injury109,110, reduced walking speed,109,110 
depression,50,58,110 lower body mass index,67,111 increased risk of falls,109,297 SRH,20 self-
reported difficulty in physical activity,110 systemic inflammation,106,111 cardiovascular 
disease,110,111 dementia113 and cancer84,114. Correction for these “confounders” has been found 
to attenuate the association between visual impairment and mortality, but the mechanisms 
behind the association between visual impairment and mortality remain to be determined.   
 
Due to the complex interactions of other mortality risk factors with visual impairment, 
correcting for these covariates using traditional regression techniques could underestimate the 
total effect of visual impairment on mortality.115 For example, persons with visual 
impairment may be more likely to use walking aids because of an increased risk or fear of 
falling. If true, then adjustment for the use of walking aids, an independent marker of 
mortality, would underestimate the effect of visual impairment. This covariate is an 
intermediate variable, a variable that lies on the causal pathway between visual impairment 
and mortality.298 Simple adjustment for such variables in a traditional statistical model is not 
appropriate.    
 
Structural equation modelling (SEM) is a modern statistical method that permits modelling of 
complex relationships that are difficult to estimate using traditional regression techniques.252 
SEM facilitates the examination and quantification of direct pathways, plus indirect pathways 
via intermediate variables. Estimates for such variables can be summated to determine the 
total indirect effect of the variable of interest on the outcome. Adding the indirect and direct 
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effects then estimates the total effect of the variable of interest on the outcome. To our 
knowledge, only one study has utilized SEM to examine the associations between visual 
impairment and mortality.299 This large population survey relied on self- or proxy-reporting 
of visual impairment and co-morbidities. The authors reported that in addition to a direct 
effect on mortality, visual impairment increased mortality risk indirectly through intermediate 
variables, SRH and disability.299 To confirm the findings by Christ et al,299 we aimed, in an 
older Australian population-based cohort, to examine association between visual impairment, 
mortality risk markers and the 13-year risk of mortality, using a SEM approach   
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Methods 
Medical and smoking histories were determined by interviewer-administered questionnaire at 
baseline (Methods, Chapter 2). To identify and confirm persons who died after the baseline 
examination, demographic information including surname, first and second names, gender 
and date of birth of the 3654 participants were cross-matched with Australian National Death 
Index (NDI) data for deaths, to the end of 2005.300 A probabilistic record linkage package 
was used, adopting a multiple pass procedure in which both data sets were grouped based on 
different characteristics (e.g., date of birth, name, sex) each time. Matches were divided into 
exact and non-exact. All non-exact matched records were examined manually and accepted if 
there was only one non-exact matched characteristic that was not critical. Information 
provided by family members during follow-up was also included if the participant was 
reported to have died on or before December 2005. 
 
Statistical analyses were performed using SAS software v9.13 (SAS Institute, Cary, NC) and 
Mplus.250 Simple statistics included Student t tests for comparing means and chi-square tests 
for comparing proportions. Cox regression models were used to estimate hazard ratios (HR) 
and 95% confidence intervals (CI). Multivariable-adjusted models included variables found 
significantly associated with mortality after age adjustment. These were previous history of 
acute myocardial infarction (AMI), stroke, angina and hypertension, current smoking, low 
body mass index (BMI), cancer, diabetes, walking disability, home ownership, tertiary 
qualification and SRH. Additional stratified analyses were conducted by age-group (age <75 
years vs.. 75+ years) to assess whether the impact from visual impairment was stronger on 
premature mortality of the relatively younger age group at baseline (<75 years). A p value of 
less than 0.05 was considered statistically significant. 
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Structural equation modelling pathway analysis252 was used to model the relationship 
between visual impairment, survival and co-variables found significantly associated with 
mortality by Cox regression. The SEM was fit using the MPlus250 statistical package with 
maximum likelihood and Monte Carlo integration methods. Standard errors were calculated 
using the delta method and hazard rates obtained from the coefficients by exponentiation. The 
co-variables used in the model were previous history of acute myocardial infarction (AMI), 
stroke, angina and hypertension, current smoking, low body mass index (BMI), cancer, 
diabetes, walking disability, home ownership, tertiary qualification and SRH. The multiple 
potential pathways to mortality are shown in Figure 5.1. Each variable was adjusted for age 
and gender. Models were simplified by removing indirect pathways for individual co 
variables that were not significant at the p value level of 0.1.
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4  Figure 5.1 Path model of the SEM for the relationship between non-correctable visual impairment, risk markers and all-cause mortality in all 
ages showing hazard rates and 95% confidence intervals (Total Indirect 1.68 (1.21-2.33)). 
Visual 
impairment 
Poor Self-Rated 
Health** 
Disability in 
Walking 
 
Body Mass 
Index 
Other 
Covariates* 
Mortality 
Disability in Walking 
via Self-Rated Health 
1.10 (1.01-1.19) 
BMI 
1.21 (0.99-1.48) 
Direct 
1.35 (1.04-1.75) 
Disability in Walking  
1.39 (1.07-1.80) 
 
Not Significant 
Covariates are corrected for age, gender 
*Other covariates include the mortality risk markers angina, myocardial infarction stroke, cancer, hypertension, smoking, diabetes, 
home ownership, tertiary education and self-rated health  
** There was no significant relationship between visual impairment and self-rated health independent of walking disability 
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Results 
Study Population 
As of 31/12/2005, 1273 BMES participants had died. Table 5.1 shows the distribution of known 
mortality risk markers in persons with and without visual impairment. Compared to those with 
normal vision, participants with non-correctable visual impairment at baseline were more likely to 
be female, older (age ≥75 years) and underweight. Persons with correctable visual impairment were 
more likely to be older (age ≥75 years), but there was no difference in the proportions of women or 
persons with low body mass index. They were more likely to have a self-reported history of angina, 
myocardial infarction, stroke, cancer, low SRH and an observed difficulty in walking or use of 
walking aids. They were less likely to have tertiary education or to own their home. There were no 
significant differences in the proportions of current smokers or history of hypertension or diabetes 
between the groups with and without visual impairment. 
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Visual impairment   
Characteristics 
None 
(n=3224) 
 Correctable 
(n=269) 
Non 
Correctable 
(n=130) 
 P value 
Sex 
Men 
Women 
n(%) 
1412 (43.8%) 
1812 (56.2%) 
 n(%) 
119 (44.2%) 
150 (55.8%) 
n(%) 
38 (29.2%) 
92 (70.8%) 
 0.004 
Age, years 
<75 
≥75 
 
2743 (85.1%) 
481 (14.9%) 
  
155 (57.6%) 
114 (42.4%) 
 
27 (20.8%) 
103 (79.2%) 
 <0.001 
Smokinga 
Never 
Past 
Current 
 
1492 (48.4%) 
1122 (36.4%) 
471 (15.3%) 
  
128 (49.6%) 
88 (31.3%) 
42 (16.3%) 
 
67 (59.8%) 
35 (34.1%) 
10 (8.9%) 
 
0.13 
 
Body mass indexb 
Underweight 
Normal 
Overweight 
Obese 
 
168 (5.3%) 
1183 (37.6%) 
1250 (39.7%) 
549 (17.4%) 
  
18 (6.9%) 
110 (42.3%) 
97 (37.3%) 
35 (13.5%) 
 
19 (17.9%) 
45 (42.5%) 
24 (22.6%) 
18 (17.0%) 
 
<0.001 
 
 
Hypertensiona, b 
      None 
      Stage I  
      Stage II 
 
926 (28.9%) 
843 (26.3%) 
1437 (44.8%) 
  
69 (25.7%) 
65 (24.2%) 
135 (50.2%) 
 
30 (24.4%) 
34 (27.6%) 
59 (48.0%) 
 
0.41 
 
Diabetesa 244 (7.6%)  23 (8.6%) 13 (10.0%)  0.52 
Stroke a 150 (4.7%)  23 (8.6%) 16 (12.7%)  <0.001 
Angina a 366 (11.4%)  54 (20.1%) 25 (20.0%)  <0.001 
Myocardial infarction  a 275 (8.6%)  34 (12.7%) 21 (16.8%)  <0.001 
Cancera 260 (8.1%)  27 (10.0%) 19 (14.6%)  0.02 
Walking Disabilityb 173 (5.4%)    41 (15.2%)   44 (33.8%)  <0.001 
Home Ownershipa 2807 (89.3%)  219 (83.9%) 103 (83.1%)  0.004 
Higher Educationa 1810 (59.7%)  116 (47.2%) 48 (41.7%)  <0.001 
Fair or Poor Self-Rated 
Healtha 
766 (24.1%)  83 (31.4%) 
 
47 (38.8%) 
 
 
<0.001 
 
aSelf-reported bExaminer assessed 
17  Table 5.1 Prevalence of mortality risk markers in participants of the Blue Mountains Eye 
Study 10-year follow-up examination by visual impairment. 
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Association between Visual Impairment and Mortality 
Table 5.2 shows all-cause mortality rates and mortality risk after age and sex adjustment, 
which were higher in persons with visual impairment compared to those with normal vision. 
This difference was greater in persons younger than 75 years compared to those aged ≥75 
years at baseline. Persons aged <75 years with visual impairment were at greater risk of (for 
PVI: Hazard Ratio (HR), 1.69, 95 % confidence interval (CI) 1.32-2.17; for CVI: HR 1.60, CI 
1.23-2.09; for NCVI: HR 2.58, CI 1.42-4.69). The associations for all ages combined 
remained either significant or marginally significant after multivariable adjustment (Table 2), 
although were substantially attenuated in magnitude (for PVI: HR 1.29, CI 1.09-1.52; for 
CVI: HR 1.26, CI 1.04-1.53; for NCVI: HR 1.35, CI 1.04-1.75). In persons aged <75 years, 
only PVI and NCVI were statistically associated with mortality, while for those age 
≥75years, only PVI was significantly associated with mortality, after multivariable 
adjustment.
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Age Mortality rate Age and Sex Adjusted Multi-variable Adjusted* 
 No VI 
n of deaths/ 
n at risk 
VI 
n of deaths/ 
n at risk 
Hazard Ratio 
(CI) 
p 
value 
Hazard Ratio 
(CI) 
p 
value 
Presenting Visual Impairment 
All 995/3224 273/399 1.49 (1.29-1.73) <0.001 1.29 (1.09-1.52) 0.003 
<75 595/2680 72/170 1.69 (1.32-2.17) <0.001 1.42 (1.07-1.87) 0.015 
≥75 400/544 201/229 1.39 (1.17-1.67) <0.001 1.24 (1.01-1.53) 0.042 
Correctable Visual Impairment 
All 
 
995/3224 163/269 1.47 (1.24-1.74) <0.001 1.26 (1.04-1.53) 0.017 
<75 
 
595/2680 61/147 1.60 (1.23-2.09) <0.001 1.33 (0.99-1.80) 0.061 
≥75 400/544 102/122 1.36 (1.09-1.70) 0.006  1.20 (0.94-1.55) 0.15 
Non-correctable Visual Impairment 
All 
 
995/3224 110/130 1.56 (1.25-1.94) <0.001 1.35 (1.04-1.75) 0.024 
<75 
 
595/2680 11/23 2.58 (1.42-4.69) 0.002 2.16 (1.11-4.23) 0.024 
≥75 
 
400/544 99/107 1.45 (1.15-1.83) 0.002 1.30 (0.97-1.73) 0.08 
* Covariates include the mortality risk markers angina, myocardial infarction stroke, cancer, 
hypertension, walking disability, low body mass index, smoking, diabetes, home ownership, 
tertiary education corrected for age, gender and visual impairment 
 
 
18  Table 5.2 The association of visual impairment (VI) and all-cause mortality assessed 
using Cox regression by visual impairment category and expressed as hazard ratios with 95% 
confidence intervals (CI): reference group is persons without any visual impairment.  
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Structural Equation Modeling (SEM) pathway analysis confirmed that visual impairment 
influenced mortality by both direct and indirect pathways. Table 5.3 shows the hazard ratios 
and 95% confidence intervals using this model. The pattern was similar to the Cox regression 
models, except that the hazard ratios were higher when estimated using SEM. 
 
296 
 
Age Total Direct Indirect* 
 Hazard Ratio 
(CI) 
p 
value 
Hazard Ratio 
(CI) 
p 
value 
Hazard Ratio 
(CI) 
p 
value 
Presenting Visual Impairment 
All 1.80 (1.38-2.35) <0.001 1.29 (1.09-1.52) 0.0028 1.40 (1.13-1.73) 0.0019 
<75 2.14 1.39-3.28) <0.001 1.42 (1.07-1.87) 0.0150 1.51 (1.07-2.12) 0.0179 
≥75 1.46 (1.04-2.05) 0.030 1.24 (1.01-1.53) 0.0416 1.18 (0.90-1.54) 0.2438 
Correctable Visual Impairment 
All 1.60 1.18-2.17) 0.002 1.26 (1.04-1.53) 0.0174 1.27 (1.00-1.61) 0.0501 
<75 1.81 (1.15-2.85) 0.011 1.33 (0.99-1.80) 0.0607 1.36 (0.95-1.93) 0.0891 
≥75 1.34 (0.89-2.03) 0.16 1.20 (0.94-1.55) 0.1462 1.12 (0.80-1.55) 0.5126 
Non-correctable Visual Impairment 
All 2.27 (1.50-3.43) <0.001 1.35 (1.04-1.75) 0.024 1.68 (1.21-2.33) 0.002 
<75 5.25 (1.97-
14.01) 
<0.001 2.16 (1.11-4.23) 0.024 2.43 (1.17-5.03) 0.017 
≥75 1.63 (1.03-2.59) 0.039 1.30 (0.97-1.73) 0.08 1.25 (0.87-1.81) 0.22 
* Covariates include walking disability, low body mass index 
  
19  Table 5.3 The association of visual impairment (VI) and all-cause mortality assessed 
using structural equation modelling by visual impairment category and expressed as hazard 
ratios (HR) with 95% confidence intervals (CI): reference group is persons without any visual 
impairment. 
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Of the risk markers investigated by SEM, only disability in walking represented a significant 
indirect pathway from visual impairment to mortality. Table 5.4 lists the hazards ratios and 
95% confidence intervals for the indirect effects of disability in walking on mortality. Figures 
5.1, 5.2 and 5.3 illustrate the detailed pathways that could explain the associations found 
between visual impairment and mortality. There was a significant indirect pathway from 
visual impairment to mortality via disability in walking, through poorer SRH, to mortality 
(Table 5.4, Figures 5.1, 5.2, 5.3). An indirect pathway through lower body mass index (BMI) 
bordered on significance for NCVI in all age groups (HR 1.21, CI 0.99-1.48, p=0.06) but was 
not significant for other forms of visual impairment or after age stratification (data not 
shown). There was no indirect pathway through any other mortality risk markers: e.g. past 
history of angina, acute myocardial infarction, stroke, hypertension, diabetes, cancer or 
smoking. There were also no indirect pathways from visual impairment to mortality through 
lower home ownership or education levels. There was no indirect pathway from visual 
impairment to mortality through poorer SRH that was independent of disability in walking.
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Age 
Total Indirect Effect Disability in Walking 
Pathway 
Disability in Walking via 
Poor Self-rated Health 
Pathway 
 Hazard Ratio 
(CI) 
p  
value 
Hazard Ratio 
(CI) 
p 
value 
Hazard Ratio 
(CI) 
p 
value 
Presenting Visual Impairment 
All 1.29 (1.09-1.53) 0.004 1.20 (1.05-1.37) 0.006 1.07 (1.01-1.14) 0.01 
<75 1.35 (1.01-1.80) 0.041 1.22 (0.99-1.51) 0.07 1.11 (0.99-1.24) 0.07 
≥75 1.18 (0.95-1.47) 0.12 1.14 (0.96-1.34) 0.14 1.04 (0.98-1.11) 0.19 
Correctable Visual Impairment 
All 1.24 (1.03-1.51) 0.025 1.17 (1.02-1.35) 0.030 1.06 (1.00-1.13) 0.04 
<75 1.27 (0.94-1.71) 0.11 1.08 (0.97-1.21) 0.14 1.17 (0.95-1.44) 0.14 
≥75 1.19 (0.92-1.53) 0.19 1.14 (0.94-1.38) 0.20 1.04 (0.97-1.12) 0.23 
Non-Correctable Visual Impairment 
All 1.39 (1.07-1.80) 0.013 1.27 (1.04-1.54) 0.017 1.10 (1.01-1.19) 0.03 
<75 1.82 (0.99-3.34) 0.05 1.23 (0.98-1.54) 0.08 1.48 (0.95-2.31) 0.08 
≥75 1.18 (0.88-1.57) 0.26 1.13 (0.91-1.41) 0.27 1.04 (0.97-1.12) 0.29 
 
 
 
20  Table 5.4 Total indirect effects of visual impairment to all-cause mortality using 
structural equation modelling pathway analysis expressed as hazard ratios (HR) with 95% 
confidence intervals (CI) stratified by pathway: reference group is persons without any visual 
impairment. 
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5  Figure 5.2 Path model of the SEM for the relationship between presenting visual impairment, risk markers and all-cause mortality in all ages 
showing hazard rates and 95% confidence intervals (Total Indirect 1.40 (1.13-1.73)). 
Covariates are corrected for age and gender  
*Other covariates include the mortality risk markers angina, myocardial infarction stroke, cancer, hypertension, smoking, diabetes, 
home ownership, tertiary education and self-rated health**.  
** There was no significant relationship between visual impairment and self-rated health independent of walking disability 
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6  Figure 5.3 Path model of the SEM for the relationship between correctable visual impairment, risk markers and all-cause mortality in all ages 
showing hazard rates and 95% confidence intervals (Total Indirect 1.27 (1.00-1.61)). 
Covariates are corrected for age and gender  
*Other covariates include the mortality risk markers angina, myocardial infarction stroke, cancer, hypertension, smoking, diabetes, 
home ownership, tertiary education and self-rated health**.  
** There was no significant relationship between visual impairment and self-rated health independent of walking disability 
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Discussion 
In agreement with previous reports,56-58,60,61,64 we observed that the presence of visual 
impairment predicted mortality in older persons. Using Cox regression models, PVI predicted 
mortality independent of age, sex and the presence of known mortality risk markers. Using 
SEM analysis, we confirmed that visual impairment increased mortality via both direct and 
indirect pathways. The relationship between visual impairment and mortality was strongest 
for NCVI among persons with baseline ages <75 years. 
 
Compared with estimates from SEM, Cox regression appears to underestimate the effect of 
visual impairment on mortality by over-correcting for intermediate variables that were 
associated with both visual impairment and mortality. To determine which indirect effects 
were important in predicting mortality for visually impaired persons, we modelled each 
covariate as a pathway to mortality (Table 5.4). Of the mortality risk markers we assessed, 
only disability in walking represented a significant indirect pathway. For this association, two 
possible pathways were identified, one pathway involved only disability in walking; the 
second also involved an effect through low SRH (Table 5.4, Figure 5.1). Because of reduced 
power through fewer events, we were unable to differentiate indirect effects via age. The age-
related trend for mortality, however, suggests that in persons younger than 75 years at 
baseline, the pathway through SRH may be more important than the pathway directly from 
disability in walking to mortality (Table 5.4). 
 
Weaker associations were consistently found in persons aged 75+ years at baseline, and are 
not unexpected. Many studies have reported no associations between visual impairment and 
mortality after correcting for covariates in older populations or in analyses that included all 
ages in one model.57,67,110 Similar findings are reported for cardiovascular risk factors where 
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risk factors lose their predictive power after ages of 80+ years.57,301-303 One explanation is a 
ceiling effect, where mortality risk is already high in persons aged 75+ years because of 
multiple mortality risk factors so that there is a limit to the additional contribution from visual 
impairment to mortality. Another explanation is "selective survival", that is persons 
genetically predisposed to die from causes related to visual impairment will do so at a 
relatively younger age, leaving those without this predisposition to survive into very old age.  
 
We found that CVI also increased mortality risk via both direct and indirect pathways. 
Although the direct effect of CVI on mortality risk seems counterintuitive, it is important to 
recognize that the association may occur in both directions. The SEM model provides 
information on the magnitude of the association but not its direction. There are several 
mechanisms that could explain the associations we found between visual impairment and 
mortality. Persons with various disabilities in walking may be less likely to see a doctor 
regularly, or to have prescriptions for critical medications filled. They may be more socially 
isolated, have a poorer and relatively unvaried diet and may be less able to seek urgent help 
when needed. They may also be less likely to exercise regularly, leading to lower 
cardiorespiratory reserve and greater risk of death during the stress of illness. Disabilities in 
walking are also associated with increasing risk of falls and fractures (e.g. hip fractures),45 
which may lead to an increased risk of death.  
 
For the direct pathway, there are probably many unidentified covariates that were not 
accounted for. One example is poor diet, which is associated with AMD,304-306 cataract,307,308 
and with cancer,309,310 diabetes,311,312 and cardiovascular disease.309,310,313 We found some 
evidence of an indirect association through lower BMI to mortality for non-correctable visual 
impairment, which may support this speculation.  
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The direct pathway may also be explained by some systemic processes that are common to 
both visual impairment and mortality, such as chronic inflammation. For example, the CFH 
Y402H polymorphism is associated with ARMD101-104 and cardiovascular death independent 
of cardiovascular risk factors.105,106 Possession of this polymorphism is a biologically 
plausible cause for excess cardiovascular mortality in persons with VI due to ARMD after 
adjustment for cardiovascular risk factors. 
 
To our knowledge, only one other study has used SEM to examine the pathways from visual 
impairment to mortality. In agreement with their findings, this study reported a small but 
significant indirect effect through disability.299 In contrast to our results, however, these 
authors reported that SRH was a significant indirect pathway that was independent of 
disability in walking. Other notable differences from this earlier study were that the indirect 
pathways had a lower magnitude than the direct pathway and the hazard ratios were much 
lower in comparison to those estimated from our study sample. There were two main 
differences between this earlier study and ours that may explain this disagreement. First, 
while the earlier study was comparable to ours in many ways, there was no objective measure 
of VA. Visual function was assessed by self and proxy reporting of visual impairment by 
asking whether each person was blind or had difficulty seeing from one or both eyes. This 
could have introduced bias as persons with lower SRH and/or disability might have been 
more likely to overestimate visual impairment and vice versa. Second, the earlier study 
included persons aged 18+ years in comparison to 49+ years in our study.  
 
The strengths of our study include its large population based dataset, with high participation 
and long follow-up period, standardized VA assessment, use of Australian National Death 
Index mortality and causes of death data, and detailed data on the health and functional status 
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of participants. Limitations include the possibility that not all potential mortality markers 
were included in the model, such as exercise, diet and nutrition variables. Also, the relatively 
low number of persons with visual impairment after age stratification limits our ability to 
detect weak associations that could be significant. Limitations of structural equation 
modelling include the assumption that relationships between variables in the model are linear 
and that the directions of the arrows in the path model are assumed but cannot be proven. 
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Summary  
This study reaffirms that visual impairment is associated with an increased risk of all-cause 
mortality. Analysis using SEM suggests both direct and indirect pathways for this 
relationship. Disability in walking may represent an important indirect pathway to mortality 
for persons with visual impairment, and adjusting for this factor in statistical analysis may 
over-adjust for the indirect effect of visual impairment on mortality risk. It is important to 
recognize that the impact of visual impairment on mortality may in fact be greater than that 
reported from previous studies that have used traditional statistical models. 
 
 
  
306 
 
Chapter Six: Direct and Indirect Effects of Hearing 
Impairment on Mortality Risk in Older Persons 
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Abstract 
Purpose: To assess whether hearing loss predicts an increased risk of mortality. 
 
Methods: The Blue Mountains Hearing Study (BMHS) examined 2956 persons aged 49+ 
years (75.5% response) during 1997-2000. The Australian National Death Index was used to 
identify deaths until 2005. Hearing loss was defined as the pure-tone average (0.5-4kHz) of 
air-conduction hearing thresholds >25 decibels hearing level (dB HL) in the better ear. 
Associations between hearing loss and mortality risk were estimated using Cox regression 
and structural equation modelling (SEM). 
 
Results: After 5 years, 403 participants had died. Using Cox regression, hearing loss was 
associated with increased risk of both cardiovascular (hazard ratio (HR) 1.36, 95% 
confidence interval (CI) 1.08-1.84) and all-cause mortality (HR 1.39, CI 1.11-1.79) after 
adjustment for age and sex, but not after multivariable adjustment. Structural equation 
modelling pathway analysis, however, revealed a higher all-cause mortality risk (HR 2.58, CI 
1.64-4.05) in persons with hearing loss, which was mediated by two variables: cognitive 
impairment (HR 1.45, CI 1.08-1.94) and disability in walking (HR 1.63, CI 1.24-2.15). These 
variables increased mortality both directly and indirectly through effects on self-rated health. 
Adjusting for these co-variables in Cox regression underestimated the impact of hearing loss 
on mortality. 
 
Conclusions: Hearing loss was associated with increased all-cause mortality, via three 
mediating variables: disability in walking, cognitive impairment and SRH. It is important to 
recognise that persons with combined disabilities are at increased risk of cardiovascular and 
all-cause mortality. 
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Background   
Hearing impairment increases with age and was the third most frequent chronic condition 
reported by elderly persons in the 2002 United States National Health Interview Survey,277 
affecting between 35% and 45% of persons aged 50+ years.121,278,314,315 This common 
disability is independently associated with many mortality risk markers including stroke163, 
ischemic heart disease164, diabetes165,166 and smoking.167 Hearing impairment is also 
associated with increased functional, physical and psychosocial impairment,316,317 poorer 
health related quality of life,128 increased risk of institutionalization,160 increased risk of 
falls,318 cognitive impairment,161 increased risk of car accidents162 and a poorer understanding 
of one’s health and its treatment.319 In addition, occupational noise exposure is reported to be 
associated with a significant increased risk of CVD and death due to AMI.158,159  
 
Despite these associations, the link between hearing impairment and mortality is 
inconsistently reported, with most studies finding the association to become non-significant 
after multivariable adjustment.151-153,156,157 Consistent with these reports,151-153,156,157 There are 
no reports that assess potential pathways between hearing impairment and mortality. Better 
understanding of this association may help guide mortality lowering interventions in persons 
with hearing loss. 
 
Prospective studies suggest that hearing impairment increases the mortality risk associated 
with visual impairment.151,153,291,320 However, the association with mortality independent of 
visual impairment is lost after adjustment for co-morbidities and self-reported health 
status.151,152,156,291 The association with mortality has been attributed to the effect of hearing 
loss on contextual variables such as self-rated health (SRH), mood, functional status and 
social relationships.151,152,156,291 This was based on the finding that the association was lost 
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after adjustment for these variables. To our knowledge there have been no reports using 
structural equation modelling to identify mediating variables between hearing impairment 
and mortality. 
 
We aimed, using structural equation modelling in an older Australian population-based 
cohort, to confirm firstly, that no direct link existed between hearing impairment and 
mortality and secondly, to determine whether indirect associations existed through mediating 
variables associated with increased mortality risk.  
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Methods 
The Blue Mountains Hearing Study (BMHS) is a population-based survey of age-related 
hearing loss in a representative older Australian community. The BMHS invited participants 
who attended the second cross-sectional survey of the Blue Mountains Eye Study (BMES 2). 
Persons who moved into the study area or study age group, identified from a repeat door-to 
door census in 1999, were also invited to participate. Of the original 3654 participants, 575 
(15.7%) died before the 5-yr follow-up eye examinations commenced, whereas 383 subjects 
(10.5%) moved from the study area. This left 2696 subjects still living in the region and 
eligible to participate. Of these, 2015 (74.7%) agreed to take part in hearing examinations, 
whereas 681 (25.3%) refused. At the time of participating, the mean age of hearing study 
subjects was 69.8 years, and there were 1156 women and 859 men. The BMHS was 
conducted during 1997 to 2000. Medical, alcohol and smoking histories were determined by 
interviewer-administered questionnaire (Methods, Chapter 2).  
 
To identify and confirm persons who died after the baseline examination, demographic 
information including surname, first and second names, gender and date of birth of the 2965 
participants were cross-matched with Australian National Death Index (NDI) data for deaths, 
to the end of 2005.  
 
Statistical analyses were performed using SAS software v9.13 (SAS Institute, Cary, NC) and 
Mplus.250 Simple statistics included student t tests for comparing means and chi-square tests 
for comparing proportions. Cox regression models were used to estimate hazard ratios (HR) 
and 95% confidence intervals (CI). Multivariable-adjusted models included variables found 
significantly associated with mortality after age adjustment. These were previous history of 
acute myocardial infarction (AMI), stroke, angina and hypertension, current smoking, BMI, 
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cancer, diabetes, walking disability, high serum urate, alcohol consumption, cognitive 
impairment, depression and SRH. A p value of less than 0.05 was considered statistically 
significant. 
 
Structural equation modelling (SEM) pathway analysis252 was used to model the relationship 
between hearing impairment, mortality and co variables found to be significantly associated 
with mortality by Cox regression. Co variables used in the model were previous history of 
acute myocardial infarction (AMI), stroke, angina and hypertension, current smoking, BMI, 
cancer, diabetes, walking disability, high serum urate, alcohol consumption >1 unit per day, 
cognitive impairment, depression and SRH. For this model, the cardiovascular risk factors 
acute myocardial infarction (AMI), stroke, angina and hypertension were modelled as latent 
variables. Each mediating variable was adjusted for age, gender and hearing loss. The 
multiple potential pathways to mortality are shown in Figure 6.1.
312 
 
7  Figure 6.1 Path model of the structural equation model for the relationship between hearing loss, risk markers and mortality. 
Hearing 
loss 
Poor Self-
Rated 
 
Significant 
co-variates** 
Other co-
variates* 
Mortality 
Covariates are corrected for age and gender  
* Other covariates were smoking, alcohol intake, home ownership, low body mass index (<20 kg/m2), previous history of diagnosed 
angina, acute myocardial infarction, fair or poor self-reported health, high serum urate. 
** Significant co-variates were disability in walking and cognitive impairment.  
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Results 
Study population 
As of 31/12/2005, 403 BMHS participants with detailed cause of death data available had 
died. Table 6.1 shows the distribution of significant mortality risk markers in persons with 
and without hearing loss. Compared to those with normal hearing, participants with hearing 
loss at baseline were more likely to be male, older, cognitively impaired, diabetic or 
underweight. They were more likely to have a self-reported history of angina, myocardial 
infarction, stroke, low SRH, an observed difficulty in walking or use of walking aids and 
reported lower alcohol consumption. There were no significant differences in the proportions 
of current smokers or persons with a history of cancer between the groups with and without 
hearing loss. 
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Mortality Risk Marker 
All Subjects  
n (%) 
(n=2815) 
Hearing Impairment n (%) 
p valued 
No b n (%) 
n=1886 
Yes c n (%) 
n=929 
Male 1218 (43.3) 750 (39.8) 468 (50.4) <0.001 
Age Mean (SD) 66.6 (9.3) 63.5 (8.0) 73 (8.4) <0.001 
Current Smoker 267 (9.6) 188 (10.0) 79 (8.6) 0.22 
Body Mass Index e <20 74 (2.6) 36 (1.9) 38 (4.1) <0.001 
Body Mass Index e 20-30 2023 (72.4) 1343(71.6) 680 (74.2)  
Body Mass Index e >30 696 (24.9) 497 (26.5) 199 (21.7)  
Alcohol >1 unit/day 2160 (76.7) 1480 (78.3) 680 (73.2) 0.002 
Diabetes 289 (11.0) 163 (9.3) 126 (14.3) <0.001 
Stroke 119 (4.2) 55 (2.9) 64 (6.9) <0.001 
Angina 291 (10.3) 144 (7.6) 147 (15.8) <0.001 
Previous Myocardial Infarction 210 (7.5) 114 (6.0) 96 (10.3) <0.001 
History of Cancer 314 (11.2) 208 (11.0) 106 (11.4) 0.76 
Disability in Walking 194 (6.9) 58 (3.1) 136 (14.6) <0.001 
Cognitive Impairment 79 (2.9) 21 (1.2) 58 (6.5) <0.001 
Self-Rated Health 
Fair-Poor 
536 (19.1) 319 (17.0) 217 (23.4) <0.001 
a Excludes subjects with hearing loss from birth, otosclerosis or conductive hearing loss. 
b ≤25 decibel hearing loss 
c >25 decibel hearing loss 
d For comparison between normal hearing and hearing impaired 
e Body Mass Index calculated in standard international units of kg/m2 
21  Table 6.1 Prevalence of mortality risk markers in participants of the Blue Mountains 
Hearing Study by hearing impairment.a 
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Association between hearing loss and mortality 
Table 6.2 shows age and sex adjusted as well as multivariable adjusted cardiovascular and 
all-cause mortality rates, stratified by severity of hearing loss, expressed as hazard ratios 
(HR) with 95% confidence intervals (CI). After age and sex adjustment, cardiovascular (CV) 
and all cause (AC) mortality was higher in persons with any hearing loss compared to those 
with normal hearing (for CV: HR 1.36, CI 1.00-1.84; for AC: HR 1.39, CI 1.11-1.75). There 
was no difference in the association with mortality between any, mild or moderate-severe 
hearing loss. There was no statistically significant association between hearing loss and 
cardiovascular or all-cause mortality, however, after multivariable adjustment using Cox 
regression (Table 6.2). There was no significant association between other  causes of death 
(including cancer, cerebrovascular, respiratory, renal, liver, gastrointestinal, injury, 
neurological, diabetes and other) and hearing impairment (data not shown). 
 
316 
 
Cause of Mortality 
Any hearing loss 
(n=929) 
Mild hearing loss 
(n=635) 
Moderate-severe hearing loss 
(n=294) 
Deaths HR (CI) p Deaths HR (CI) p Deaths HR (CI) p 
Age and Sex Adjusted 
Cardiovascular 144 1.36 (1.00-1.84) 0.048 89 1.44 (1.04-1.90) 0.027 55 1.22 (0.83-1.78) 0.31 
All-cause  245 1.39 (1.11-1.75) 0.004 146 1.39 (1.09-1.77) 0.009 99 1.41 (1.06-1.88) 0.018 
Multivariable Adjusted c 
Cardiovascular 122 1.06 (0.76-1.48) 0.73 75 1.18 (0.83-1.68) 0.35 47 0.85 (0.55-1.31) 0.46 
All-cause 208 1.12 (0.88-1.44) 0.36 125 1.16 (0.89-1.51) 0.27 83 1.04 (0.76-1.44) 0.80 
a Excludes subjects with hearing loss from birth, or with otosclerosis or other causes of conductive hearing loss. 
b >25 decibel hearing loss 
c Adjusted for age, sex, smoking, alcohol, home ownership, low body mass index (<20 kg/m2), previous history of diagnosed angina, acute 
myocardial infarction, walking disability, cognitive impairment (mini mental state examination <24), fair or poor self-reported health, high 
serum urate.
22  Table 6.2 Association between the severity of hearing loss a and mortality by cause after co-variable adjustment in the Blue Mountains 
Hearing Study using Cox regression, expressed as hazard ratio (HR) with 95% confidence intervals (CI): the Reference group is persons without 
hearing lossb (n=1886). 
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Table 6.3 shows the association between hearing loss and mortality using SEM pathway 
analysis. In contrast to the Cox multivariable adjusted model, SEM identified a significant 
association between hearing impairment and mortality after adjusting for confounders. This 
occurred only via indirect links to mortality through the mediating variables of disability in 
walking and cognitive impairment. The pathways from disability in walking and cognitive 
impairment to mortality occurred both directly and indirectly, via a third mediating variable, 
SRH. Figure 6.2 shows the path model with hazard rates and 95% confidence intervals. 
However, there was no significant link between mortality and SRH that was independent of 
disability in walking or cognitive impairment. Other co-variables including smoking, alcohol 
intake, home ownership, low BMI (<20 kg/m2), prior history of diagnosed angina or acute 
myocardial infarction, hypertension or high serum urate, were found not to be associated with 
either hearing loss or mortality.
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Pathway Hazard Ratio (CI) p value 
Total 2.58 (1.64-4.05) <0.001 
Direct 1.09 (0.84-1.41) 0.51 
Indirect 2.37 (1.58-3.54) <0.001 
Covariates of Indirect Pathway 
Disability in Walking 1.63 (1.24-2.15) <0.001 
Cognitive Impairment 1.45 (1.08-1.94) 0.014 
Direct Through Covariate to Survival 
Disability in Walking 1.37 (1.11-1.68) 0.003 
Cognitive Impairment 1.25 (1.00-1.57) 0.05 
Through Covariate via Poor Health to Survival 
Disability in Walking 1.19 (1.05-1.37) 0.009 
Cognitive Impairment 1.16 (1.01-1.32) 0.034 
a Excludes subjects with hearing loss from birth, otosclerosis or conductive hearing loss 
b >25 decibel hearing loss 
23  Table 6.3 The association of hearing loss a and all-cause mortality assessed using 
structural equation modelling and expressed as hazard ratios with 95% confidence intervals 
(CI) stratified by pathway: reference group is persons with normal hearingb. 
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Covariates are corrected for age and gender  
* Other covariates include smoking, alcohol intake, home ownership, low body mass index (<20 kg/m2), previous history of diagnosed angina, 
acute myocardial infarction, fair or poor self-reported health, high serum urate.
 
8  Figure 6.2 Detailed path model showing estimated hazard rates and 95% confidence intervals for the relationships between hearing loss, risk 
markers and all-cause mortality (Total indirect effect 2.37 (1.58-3.54)).  
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Discussion 
Consistent with previous reports using Cox regression, we observed that hearing loss 
predicted mortality after adjustment for age and sex, but the association became non-
significant after adjusting for other co-variables associated with mortality in the study 
population (mortality risk markers).151,152,156,291 Using structural SEM pathway analysis we 
found no direct pathway between hearing loss and mortality but identified disability in 
walking and cognitive impairment as mediating variables for the increased mortality risk 
associated with hearing loss. These variables acted both directly on mortality and via a third 
mediating variable, SRH. 
 
While previous studies concluded that the association between hearing loss and mortality was 
likely to be mediated by contextual variables such as SRH and functional status,151,152,156,291 
these conclusions were based on findings that the association was lost after adjustment for 
these variables. In a further advancement in this field, our study using SEM has now 
documented that disability in walking and SRH are two mediating factors likely to account 
for the link between hearing impairment and mortality. To our knowledge, this is the first 
report to suggest that cognitive impairment may be a mediating variable between hearing loss 
and mortality. 
 
Our proposed model is supported by previous work. Studies suggest that both functional and 
physical decline as well as cognitive impairment 321-323 are associated with low SRH. 
Functional and physical impairment, cognitive impairment and low SRH are each 
independently associated with increased mortality.156,324-326 In keeping with these findings, 
our study showed that disability in walking and cognitive impairment are associated with an 
increased mortality risk, both directly and indirectly via SRH. Associations between hearing 
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loss and measures of functional and physical decline have also been reported 
previously.47,132,133,289,296,318,327,328 Mechanisms that could explain the association of hearing 
loss with disability in walking include increased fear of falling, infirmity due to declining 
physical and social activities associated with hearing loss, reflecting a decreased ability to 
seek professional help for hearing impairment319 and impaired balance from accompanying 
decreased vestibular function.318 
 
Associations between hearing loss and cognitive impairment have also been reported.289,329-
332 These may be explained by sensory underload (lack of intellectual stimulation reducing 
cognitive ability),329,333 attentional demands of sensory measurement (measurement of 
hearing loss is sensitive to negative age differences in cognitive processes such as sustained 
attention and discrimination),329 or some common cause (hearing loss and cognitive function 
are both measures of the physiological architecture of the brain).331 These reports support our 
finding that associations exist between hearing loss and cognitive impairment. Our study adds 
a new dimension to these associations and extends the hearing loss-cognitive impairment 
association to mortality risk by identifying pathways from hearing loss to mortality through 
cognitive impairment and disability in walking.  
 
Our finding that hearing loss increased the odds of cardiovascular death but not other causes 
may be explained by the pathways through disability in walking and cognitive impairment. 
Affected persons are more socially isolated and may be less likely to see their doctor 
regularly, or to have prescriptions for preventive medications filled. They may also have a 
poorer understanding of their own health issues and its treatments.319 They may have 
relatively poorer diets and be less able to seek urgent help when needed. They may also be 
less likely or unable to exercise regularly, leading to lower cardiorespiratory reserve and 
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greater risk of cardiovascular death. Other causes of death may either be less susceptible to 
these associations, or because of fewer events, we may have had insufficient statistical power 
to detect associations. 
 
Our results also suggest that severity of hearing impairment may not be so important in 
predicting mortality risk. This is significant as persons with mild hearing loss may not report 
it or the loss may go unnoticed by treating clinicians, particularly if they have cognitive or 
functional impairment. This makes identification of at risk groups more difficult. It also 
raises the possibility of some unidentified common mechanism leading to an increased risk of 
hearing loss, cognitive and functional impairments and mortality. 
 
The strengths of our study include its large population based dataset, with high participation 
and long follow-up period, standardized hearing assessment, use of Australian National 
Death Index mortality and causes of death data, and detailed data on the health and functional 
status of participants. Limitations include the possibility that not all potential pathways were 
included in the model, such as the variables, exercise, and diet and nutrition variables. 
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Summary 
This study supports the contention that hearing loss is associated with an increased risk of 
mortality through mediating variables, including disability in walking and SRH and identifies 
cognitive impairment as a further mediating variable between hearing loss and mortality risk. 
We could not, however, document a gradient effect from the severity levels of hearing loss on 
mortality risk. It is important for clinicians to recognise that persons with this combination of 
disabilities are at increased risk cardiovascular and all-cause mortality so they can implement 
strategies that may reduce mortality risk.
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Chapter Seven: Implications of the Findings of this Thesis 
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This thesis provides prevalence data in a representative population based cohort of older 
Australians for VI, AI and OI. To our knowledge, this study is the first population based 
cohort study to document the prevalence of concurrent VI, AI and OI and is the first to 
document the prevalence of OI in a representative Australian population cohort.  
 
We observed a high prevalence of PVI (11%), AI (43%) and OI (27.0%) in this cohort of 
Australians aged 60 years and over. Based on these data and the 2006 Australian census, we 
estimate that among Australians aged 60 years or older, 354,000 have VI, 1,383,000 have AI 
and 868,000 have OI. 
 
Only two other large-population based studies have assessed the prevalence of olfactory 
impairment. The EHLS reported a prevalence of 24.5% rate for persons aged 43-86 years.168 
The Skövde study reported prevalence of 32.9% in persons aged 53 years or older.170 After 
age and sex standardising our BMES prevalence to the EHLS,168 we observed a slightly 
lower prevalence of olfactory impairment of 24.3% (22.4-26.3) in our study compared with 
29.8% (27.8-31.9) in the EHLS (for participants aged >60 years). 
 
This thesis supports the reported significant age-associated increases in the prevalence of VI, 
AI and OI.1,3-5,8,116,119,121,124,168,170,253,268,269,273 We found the prevalence of VI, AI and OI to 
increase significantly with increasing age.  
 
This thesis supports reported gender biases for VI, AI and OI.1,3,5,116,119,121,124,168,173,273 
13,170,253,268,269 We found auditory and olfactory impairments were more frequent in men and 
visual impairment more frequent in women. 
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To our knowledge, we are the first to examine the clustering patterns of VI, AI and OI. We 
observed that the prevalence of two or more sensory impairments in older persons was higher 
than the predicted prevalence if these impairments were assumed to have occurred randomly 
and independently. This suggests common mechanisms may underlie VI, AI and OI.  
 
We observed different clustering patterns between men and women. This finding suggests 
mechanisms and/or exposures (e.g. workplace or environmental exposures, smoking status, 
genetic, hormonal or other sex differences) underlying these sensory deficits may differ 
between men and women. 
 
This thesis supports previous reports of increased mortality risk in persons with 
VI.56,57,59,62,64,65,67,70 We observed that the presence of visual impairment predicted mortality 
in older persons using Cox regression. 
 
This thesis supports previous reports that hearing loss is associated with increased mortality 
after adjustment for age and sex, but not after adjustment for co-variables associated with 
mortality in the study population.151-153,156,291  
 
Using SEM pathway analysis, we confirmed that PVI, CVI and NCVI increased mortality via 
both direct and indirect pathways. Based on our estimates from SEM, Cox regression 
underestimates the association of visual impairment with mortality by over-correcting for 
intermediate variables associated with both visual impairment and mortality. Visual 
impairment was reported to be independently associated with many of the confounding 
variables associated with mortality and corrected for in previous studies.20,50,67,84,106,109-114 
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 When modelling these associations, it must be considered that due to complex interactions 
between other mortality risk factors and visual impairment, correcting for these covariates 
may underestimate the association between visual impairment and mortality.115 
 
To our knowledge, only one other study has used SEM to examine the pathways from visual 
impairment to mortality.299 This study reported a small but significant indirect effect through 
disability. We identified disability in walking as a potential mediating variable for the 
association between VI and mortality. Two possible pathways were identified, one involved 
only disability in walking; the second also involved an effect through low SRH. We found 
evidence of an indirect association through lower BMI to mortality for non-correctable visual 
impairment.  
 
To our knowledge, ours is the first study to examine the association between hearing 
impairment and mortality risk using SEM pathway analysis. We found no direct pathway 
between hearing loss and mortality but identified indirect pathways via two mediating 
variables: disability in walking and cognitive impairment. These variables acted both directly 
on mortality and via a third mediating variable, SRH.  
 
To our knowledge, ours is the first to document that disability in walking and SRH are two 
mediating factors likely to account for the link between hearing impairment and mortality. 
Previous studies concluded the association between hearing loss and mortality was likely 
mediated by contextual variables such as SRH and functional status.151,152,156,291 These reports 
support our findings. 
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To our knowledge, ours is the first report to suggest cognitive impairment may be a 
mediating variable between hearing loss and mortality. Associations between hearing loss 
and cognitive impairment have been reported previously.289,329-332 These reports support our 
finding that associations exist between hearing loss and cognitive impairment.  
 
Our finding that disability in walking is a mediating variable between VI, AI and mortality 
has important implications for the care of older persons. Affected persons are reportedly more 
socially isolated27,29,31,33,37,41,42,125-129,131,132 and may be less likely to see their doctor regularly, 
or to have prescriptions for preventive medications filled. They may have relatively poorer 
diets and be less able to seek urgent help when needed. They may also be less likely or 
unable to exercise regularly,43,46 leading to lower cardiorespiratory reserve and greater risk of 
illness and death. It is important for clinicians to recognise this combination of disabilities 
may increase morbidity and mortality so treatment strategies are formulated and implemented 
early. 
 
Our data support an essential role for olfactory function in maintaining a healthy nutritional 
status and body weight. Our finding that participants with moderate olfactory impairment 
were twice as likely to be underweight (BMI <20 kg/m2) than those without impaired 
olfaction has important implications for the care of older persons. Ours is the first 
community-based study to demonstrate that older people with mild renal impairment are 
significantly more likely to have moderate (but not mild) olfactory impairment. It is 
important for clinicians to recognise that persons with renal impairment are at higher risk of 
OI and that persons with OI may be at increased risk of nutritional deficiencies so they can 
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implement strategies that may reduce this risk. Several smaller studies demonstrated similar 
findings.263,270,271  
 
This thesis provides additional data to support the link between impaired olfaction and 
neurodegenerative disorders, including cognitive impairment and 
PD.175,201,205,207,209,210,216,217,219,257,272 After multivariable adjustment, BMES participants with 
marked cognitive impairment had approximately 3-fold higher odds of mild and 
approximately 6-fold higher odds of moderate OI. Participants with a diagnosis of Parkinson 
disease had a 10- and 16-fold higher risk of having mild and moderate olfactory impairment, 
respectively.  
 
This thesis supports a previous population studies168,170,173,175,177 that self-reported OI was an 
unreliable indicator of measured olfactory decline. Of those with olfactory deficit, 67.8% did 
not report a loss of smell function. Of participants that did report smell deficit, 40.5% had no 
measurable loss. 
 
While not examined in this study, it is important to consider that presence of all three sensory 
impairments may increase the burden of shared adverse health outcomes on affected 
individuals and their families and carers. Combined vision and auditory impairments have 
been reported to cumulatively decrease health-related quality of life148,296 and to increase 
mortality risk.151,153,291 Associations of each impairment, VI, AI or OI, with measures of 
independence, functional and physical decline, low SRH and nursing home placement have 
been previously reported.20-23,27,29,31,33,37,41,42,125-129,131,132,160,173,177,182,184-187,253,289 Evidence on 
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whether correcting these sensory impairments with hearing or low vision aids would reduce 
their negative impact is limited with further studies needed.  
 
Our findings highlight several public health concerns for individuals suffering from multiple 
sensory impairments. Specifically, the current imperfect care system inhibits the effective 
delivery of services and rehabilitation to older people with multiple sensory impairments. 
Visual, olfactory and auditory impairments tend to aggregate mutually and dependently in 
this cohort of older Australians. This implies that once a sensory impairment is detected, 
screening for other concomitant sensory impairment may be warranted. The higher than 
expected frequency of combined sensory impairment implies that current health care 
provision may not meet the needs of older persons with sensory impairment. Self-report is an 
inaccurate measure of sensory impairment in older persons so they are likely to be under-
reported.117,119,168,170,173,175,177 There has been no active screening using case-finding strategies 
to detect older persons with sensory impairment. By the time affected individuals are 
identified they may already be socially isolated and have substantially reduced quality of life 
and limitations in daily functioning.  
 
Separate vision and hearing rehabilitation systems currently operating in Australia and the 
U.S. fail to service and support older people with multiple sensory impairments in a coherent 
and collaborative manner. The bewildering complexity of current systems for the care of 
older people with two or more sensory impairments highlights the need for clearer, and better 
co-ordinated health policies. Our study findings advocate for greater attention from health 
care providers and health policy makers to improve health care services to older persons with 
sensory impairments. 
331 
 
 
 
The strengths of our study include its large population-based dataset with high participation 
rate; the use of standardised measurements of vision, olfaction and hearing; the use of 
Australian National Death Index mortality and cause of death data; and detailed data on the 
health and functional status of participants.  
 
The limitations of our study design include the study sample being a survivor cohort and the 
data being cross-sectional in nature. Our study may underestimate the prevalence of sensory 
impairment as those who did not have complete sensory data tended to be older and therefore 
more likely to have individual or multiple sensory impairments. In addition, the small number 
of persons with combined sensory impairment in the two gender subgroups could have led to 
chance findings in the different clustering patterns of these sensory impairments between men 
and women, and limits our ability to detect weak associations that could have been 
significant.  
 
The SDOIT tests a limited number of “common” stimulants, possibly resulting in under-
detection of deficits. In addition, the SDOIT assesses odour identification but not threshold. It 
is, however, substantially more reliable than self-reported methods. This simple and quick 
test may be useful in screening older persons at risk of neurodegenerative disease and 
malnutrition. The presence of nasal polyps, known to reduce olfactory function, was not 
assessed in our study. This may have led to an underestimation of the associations with other 
comorbid conditions. 
 
The limitations of the SEM include the possibility that not all potential pathways were 
included, such as the variables, exercise, diet and nutrition. 
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Chapter Eight: Summary 
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Visual, auditory and olfactory impairments were frequent in this representative older 
Australian population. We estimate that among Australians aged 60 years or older, 354,000 
have visual impairment, 1,383,000 have auditory impairment and 868,000 have olfactory 
impairment. The prevalence of VI, AI and OI increased with increasing age in both sexes. 
The prevalence of AI and OI was higher in males. The prevalence of VI was higher in 
females.  
 
Visual, auditory and olfactory impairments aggregated mutually and dependently. If one 
sensory impairment is detected, screening for other concomitant sensory impairment seems 
warranted. Common mechanisms may underlie these disabilities and their associated 
morbidities and mortality. Separate hearing and vision services may not adequately support 
older persons with multiple impairments. 
 
Our data support an essential role for olfactory function in maintaining a healthy nutritional 
status and body weight and provide additional support to the link between impaired olfaction 
and neurodegenerative disorders, including cognitive impairment and Parkinson disease. 
Olfactory assessment may be a simple to administer, useful clinical tool, in older persons. 
 
This data reaffirms that visual impairment is associated with an increased risk of all-cause 
mortality and suggests the impact of visual impairment on mortality may be greater than that 
reported by previous studies using traditional statistical models. Analysis using SEM suggests 
both direct and indirect pathways for this relationship. Disability in walking may represent an 
important indirect pathway to mortality, both directly and via SRH, for persons with visual 
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impairment. Adjustment for these mediating variables in statistical analysis may over-adjust 
for the association between visual impairment and mortality risk. 
 
This study supports the contention that hearing loss is associated with an increased risk of 
mortality through mediating variables, including disability in walking and SRH and identifies 
cognitive impairment as another mediating variable between hearing loss and mortality risk. 
 
Studies of sensory impairment using self-report do not correlate have poor correlation with 
objective measures of sensory impairment overall. Importantly, self-reported sensory 
impairment is associated with higher risk of morbidity compared to objectively measured 
impairment. This may lead to overestimation of the significance of the associations between 
sensory impairment and morbidity.  It is important for clinicians to recognise this and that 
formal testing is preferred. It is also important that clinicians recognise that persons with this 
combination of disabilities, particularly self-reported sensory impairment with normal 
objective measures of the senses, are at increased risk of social isolation, depression, low 
SRH and QOL, functional difficulties, mobility problems, falls, fractures and mortality so 
they may implement strategies that reduce these risks. 
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Chapter Nine: Future Studies 
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Over 50% of participants with OI had normal BMI and no neurodegenerative disease. 
Longitudinal studies in this cohort to assess the incidence of neurodegenerative disease in 
persons with and without OI will provide useful data regarding the sensitivity and specify of 
this simple test in predicting neurodegenerative disease risk in a representative population of 
older adults. 
 
Olfactory impairment was associated with low BMI in this cohort. Longitudinal studies in 
this cohort assessing whether persons with normal BMI and OI are at increased risk of 
subsequent low BMI are needed. If OI predicts subsequent weight loss then this simple test 
may allow early nutritional intervention in persons at risk. 
 
The significant inverse association between hypertension, total cholesterol and measured 
olfactory impairment, may be confounded by premature death in participants with these co-
morbidities, by medications used to control these risk factors, or some shared mechanistic 
pathway. The associations warrant further investigation given the previously reported 
relationship between blood pressure, cholesterol and the incidence of cognitive decline. 
 
Associations between VI, AI or OI individually and of VI and AI combined and measures of 
independence, functional and physical decline, low SRH, nursing home placement and 
mortality have been previously reported. Evidence if possession of all 3 sensory impairments 
further increases the observed negative impacts and whether correcting sensory impairments 
reduces significantly these negative associations is limited. Longitudinal studies are needed to 
address this question. 
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Our study found VI, AI and OI clustered dependently and that AI and VI were associated 
with increased mortality risk indirectly via disability in walking. Studies examining the 
clustering behaviour of these sensory impairments with disability in walking in this cohort 
would add weight to our findings. If disability in walking did dependently cluster with these 
sensory impairments then underlying biological mechanisms could be postulated and 
investigated.  
 
Whether sensory impairments are independent risk factors for mortality remains unknown. 
One of the difficulties in objectively scrutinising the literature is that study populations 
significantly differ and co-variables adjusted for are not standardised. Biologically plausible 
mechanisms need to be postulated and investigated to help elucidate this question. Such 
research may identify potential drug targets to reduce morbidity and mortality. The CFH 
Y402H polymorphism has been reported associated with ARMD, CVD and hearing 
impairment suggesting a biologically plausible explanation for the association between VI 
and HI and mortality, particularly cardiovascular mortality after adjustment for 
cardiovascular risk factors in ARMD. Studies examining the associations and clustering 
behaviour between CFH Y402H polymorphism and VI, HI, OI, walking disability and low 
SRH in this cohort would help determine whether this polymorphism has potential as one 
biological explanation for the dependent clustering characteristics of these sensory 
impairments and their direct and indirect associations with morbidity and mortality.  
 
Overall the literature suggests glaucoma is not associated with increased mortality, all though 
one study did report a significant association. Glaucoma is underdiagnosed in the community 
and one large study found significant associations with mortality when combining baseline 
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IOP >21mmHg and diagnosed glaucoma as the at risk group. Neither elevated IOP nor 
glaucoma predicted mortality in this study. Studies that have assessed only baseline 
diagnosed glaucoma may have underestimated an association between IOP and mortality. 
Over adjustment of mediating co-variables is another possible cause for underestimating this 
association and SEM would be useful in this regard. The association of baseline elevated IOP 
and glaucoma with mortality warrants further investigation. That timolol may be associated 
with higher mortality in glaucoma patients also warrants further investigation. 
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Appendix A: Blue Mountains Eye Study Questionnaires 
and Flow Sheets 
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